Trade, Medicines & Human Rights:
Protecting Access to Medicines
in Fiji & the Pacific by Meads, Sarah
  
 
 
 
 
Trade, medicines & human rights: 
protecting access to medicines  
in Fiji & the Pacific  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Meads 
Victoria University of Wellington 
Wellington, New Zealand 
 
Submitted in partial fulfillment of the 
Masters in Development Studies Degree 
 
March, 2008 
 I 
Abstract 
 
 
Restrictive provisions in international trade agreements, particularly trade related intellectual 
property rights (TRIPS), are impeding access to essential medicines in developing countries, 
making medicines unaffordable to poor people.  The extent to which trade restrictions have 
adverse effects on health and economic development in Fiji and the Pacific region may depend 
critically on how Pacific Island Countries cope with the forces of regionalism and the realities 
of joining the global trading system, where there are pressures to make concessions in TRIPS. 
Yet awareness is relatively low.  A central question to be asked here is what underlying factors 
shape how Pacific islanders view trade and access to medicines, notably in the area of trade, 
health, local culture, and human rights and what are the regional and national responses to 
mitigate potential trade impediments. By combining a public health lens with a multi-sector 
review of population health trends, intellectual property rights law, trade policymaking, and 
human rights, this research elaborates multidisciplinary findings that are usually less evident 
because they are conventionally researched and managed on a sector-by-sector basis.  The 
findings suggest human rights are less significant in this debate, with challenges associated 
with small island developing states, local cultural preferences and pressures from regionalism, 
having more of a direct influence.  The combined effect of these factors may be creating a 
unique context that is leading the Pacific region not to deal with these issues as well as some 
other developing countries might.  This paper also discusses the emergence of two new 
challenges for human rights theory; to promote the collective rights of individual countries in 
the ‘new regionalism’, and the relationship with traditional knowledge. 
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Chapter 1: Describing this research 
 
1.0 Introduction 
 
“The best form of leadership in this (access to medicines) debate is coalition leadership”. 
Excerpt from, Ethics and the Pharmaceutical Industry 1  
 
The global campaign on access to medicines grew in the late 1990’s in response to the major 
health crises in developing countries, compounded by HIV/AIDS, where those most in need of 
medicines were the least able to afford them (Mayne, 2002). Obligations in multilateral and 
free trade agreements (FTA), including trade related intellectual property rights (TRIPS), 
pharmaceutical patent examination and pharmaceutical pricing strategies (Danzon and Towse, 
2005), are the aspects of trade that most influence access to medicines in developing countries 
and the structure of the global pharmaceutical industry (Abbott, 2005; Drahos, 2005).   
 
The nub of the campaign centres on how these factors promote private rights over public 
commons (Drahos, 2005; Tansey, 2005; Ulrich, 2005) and restrict development policy space 
in developing countries (Wade, 2005; Chang, 2005).  Opponents contend these block generic 
competition, raise drug prices, and divert R&D investment away from neglected diseases 2 
(Mayne, 2002; Balasubramanian, 2002).  Yet proponents claim the enforcement of strong 
intellectual property rights (IPR) encourages technology and knowledge transfer and 
incentivises research; a globalised IPR system will produce economic growth for all who 
participate (Stiglitz, 2005).   
 
Paradoxically, these supply-side constraints are at odds with the triple burden 3 of diseases 
afflicting developing countries, which is driving up demand for R&D and affordable 
medicines (UNESCAP, 2007), and a growing recognition that health is fundamental to 
accomplishing economic and social development (WHO, 2007a). 
 
                                                 
1
 See reference Santoro and Gorrie, 2005, pp. 258   
2
 See www.WHO.int , for diseases categories: Category I,II (neglected diseases), III (very neglected diseases) 
3
 These include: communicable disease, that disproportionately affect developing countries, non communicable 
diseases and pandemics 
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In this chaos, a variety of independent initiatives are underway that have the potential to 
gradually transform the un-level playing field, so that more medicines reach the poor in 
developing countries.  Thailand’s defiant application of compulsory licences (CL); new global 
solutions to improve R&D and drug supply discussed at the World Health Assembly; a human 
rights committee (ICESCR) urging Costa Rica to review CAFTA under the right to health; 
prizes to replace patents to encourage R&D (Love, 2007); political pressure for he US to back 
out TRIPS-plus from the Peru-US FTA; a call for adoption of human rights norms by drug 
companies (Hunt, 2006; Oxfam, 2007a); inclusion of health in foreign policy with the 
emergence of a new global health diplomacy (WHO, 2007b); and elevation of intellectual 
property rights to the highest level in the World Health Organisation (WHO) structure, are  
some examples. 
 
The neoliberal context of the access to medicines debate 
 
Tensions arise between access to medicines and the global trading system because the latter is 
an axiom of the neoliberal consensus (Hestermeyer, 2007).  Human rights instruments are the 
most comprehensive socioeconomic rights framework outside this system; providing a counter 
balance by placing public goods, such as health, above purely economic growth (Robinson, 
2006).  However this arrangement pits ‘soft law’ against ‘hard law’, which often means 
neoliberalism dominates (Uvin, 2004).   
 
Furthermore, proponents of intellectual property rights enforcement, for example, the US, EU, 
Japan and transnational companies, continue to formulate stronger protections which are 
spread globally through FTAs. This trend is reinforced by the trilateral agreement between the 
three major trading blocs (US, EU and Japan) to harmonise their patent offices and by political 
coercion to join the Patent Cooperation Treaty (PCT)4, that then acts as a ‘patent pipeline’ by 
streamlining patent registration in developing countries (Drahos, 2007). 
 
This research acknowledges that structural and financial limitations place significant 
impediments on access to medicines at a country level, particularly in small island developing 
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states where the logistics and costs of providing a full range of health services to remote 
islands are high.  However, this research is concerned about the gross asymmetry between 
developed and developing countries and how the current systems are not providing stronger 
incentives to make sure medicines reach people in need (Balasubramaniam, 2002).  The 
technology for treating tuberculosis is an example of this. Tuberculosis is a significant 
infectious disease in developing countries, including the Pacific region. However, the 
technology for treating tuberculosis is over 30 years old and growing resistance is diminishing 
its effects.  Despite this, there were only six drugs for treating tuberculosis in clinical 
development in 2006 compared with around four hundred for treating cancer (WHO, 2007a).   
 
What determinants influence access to essential medicines? 
 
The WHO defines essential medicines as those medicines that are necessary to satisfy the 
healthcare needs of the majority of the world’s population and therefore ought to be available 
to all individuals, in adequate dosage, and at affordable prices.  It estimates that approximately 
one third of the world’s population lacks access to essential medicines, with the proportion 
being as high as two thirds in some of the poorest countries in Africa and Asia. 
 
The WHO Essential Medicines List (EML) is a list of medicines to satisfy the majority of 
healthcare needs in developing countries, making it easier for developing countries to procure 
affordable, safe medicines.  Of the 312 medicines on the list in 2006, only sixteen are newer 
patented drugs, including fourteen for the treatment of HIV/AIDS.  No patented drugs for non 
communicable diseases, for example, cancer, diabetes, or for ischemic heart disease, are 
included.  This is despite the fact that non communicable diseases are the leading cause of 
mortality in low-income countries, including in the Pacific region, and that many new drugs 
offer substantial improvements in their treatment. 
 
Some groups argue the EML contains enough varieties of drug, with a few exceptions, to 
satisfy the majority of health needs in developing countries (Mould, 2004) while others are 
pushing for modifications.  Still others argue that developing countries don’t take full 
advantage of the WHO EML at present and therefore shouldn’t need to criticise 
 4 
pharmaceutical companies or to raise compulsory licences that override pharmaceutical 
patents (Lofgren, 2007). 
 
There are multiple determinants influencing access to medicines, globally and in the Pacific.  
Many originate from outside the health sector, highlighting the complex linkages between 
health, poverty, development and trade.  They include: domestic factors, for example, lack of 
adequate finance, limited, or no, domestic manufacturing capacity; market factors, for 
example, undisclosed, differential pricing strategies, and  trade factors, for example Bilateral 
Investment Treaties (BITS)5.  Some of the adverse effects of the internal domestic factors are 
compounded in the Pacific region because of the cost and logistics of delivering a full range of 
services to isolated, remote islands with limited infrastructure and resources.  The particular 
focus of this research is on the implications of external trade factors and on private property 
rights that are legally enforced through TRIPS agreements.  
 
1.2 Anticipating the need for this research 
 
Most advocacy for access to medicines is centred on HIV/AIDS (Maynes, 2002).  However, 
with the exception of Papua New Guinea (PNG), where HIV/AIDS is an epidemic 
(Tukuitonga, 2006)6, the incidence is relatively low in most other Pacific Island Countries 
(PICs).  HIV/AIDS therefore does not provide the same catalyst for advocacy for access to 
medicines as in other countries. Alternatively, the region is experiencing the double burden of 
disease with non communicable diseases (NCDs) now accounting for most deaths, and poor 
health indicators contributing to the poverty trap and to political and human insecurity 
(Tukuitonga, 2006).   
 
Unlike some neighbouring emerging economies, such as Thailand, where access to medicines 
                                                 
5
 BITS have been signed with a number of PICs.  BITS may mean use of public health safeguards eg. those in 
TRIPS flexibilities could be expropriation and so require compensation from the host government to the investor 
from the other country in an international tribunal.  They are not enforceable through trade sanctions.  Some are 
listed on http://www.unctadxl.org/templates/DocSearch779.aspx and www.paclii.org referred to in a conference 
presentation by Ms Sanya Reid Smith, Third World Network, Regional High Level Consultation on HIV and  the 
Law April 2007, Auckland NZ on file with the author. 
6
 Though there is an increasing trend in Fiji. 
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has a high public profile (because of HIV/AIDS) and health and human rights advocacy is 
well organised, in the PICs, and in Fiji, the profile appears to be comparatively low, and the 
topic has not generally featured on the trade or health agenda.7  
 
Research to gain insights into how Pacific islanders view trade and access to medicines, which 
is the topic of this research, and the reasons for the lack of priority it is accorded, is vital; 
especially as the regional trade landscape is about to change with the EU EPA. This research 
uses a public health sector perspective, as distinct from a trade sector perspective, to evaluate 
the factors influencing people’s views and the impact of trade and TRIPS on access to 
medicines.  
 
Furthermore, to my knowledge a comprehensive overview, and the relationship between, the 
four systems (population health trends and services, intellectual property rights law, the 
process of trade policymaking, and human rights) has not been documented in one paper 
before.  These four separate, but interrelated, systems have a profound impact on access to 
medicines in developing countries and the structure of the global pharmaceutical industry.  
This multi-system approach I will apply, may provide a new tool for policymakers and 
development practitioners working in the trade and health sector, where conventionally these 
issues are managed in isolation, using a sector by sector approach. 
 
The main focus of this research will be on Fiji, which is set within the broader Pacific context.  
As small island economies, Fiji and other PICs face economic and geographic barriers that 
make them dependent on foreign trade and investment that is secured through trade 
agreements with developed countries.  Fiji’s trade policymaking is dominated by issues 
relating to regionalism (Crocombe, 2005), neoliberalism (Slatter, 2006), the re-negotiation of 
major trade agreements, such as EU- EPA and PACER (which may be triggered under 
Cotonou), the Sugar Protocol with the EU and expansion of multilateral agreements under 
WTO into services, intellectual property rights and investment.  
                                                 
7
 An exception appears to be the substantial knowledge of the Chief Pharmacist, and senior staff of Fiji 
Pharmaceutical Services and a staff member of the PIFS. The Chief Pharmacist has provided a point of reference 
for some other PICs that have sought assistance to understand the trade issues relating to medicines in their own 
countries 
 6 
 
Another factor of importance in this thesis is that in December 2007, Fiji and Papua New 
Guinea, under external pressures from the EU, had agreed to sign individual agreements with 
the EU instead of continuing to negotiate a regional economic partnership with all 14 PICs.  
Earlier versions of the EU draft agreement offered to African and Caribbean regions included 
TRIPS-plus provisions (CIEL, 2007), which were opposed by the international development 
community (Correa, 2007). In September 2007 the EU had signaled that IPR issues would be 
negotiated with the PICs in 2008 if a regional economic partnership agreement was signed by 
the 14 PICs by the December 2007 deadline.  It is not yet clear, when the EU intends to 
negotiate IPR issues with Fiji and PNG.  
 
Fiji’s existing national IPR law, inherited from its colonial past, does not contain all of the 
WTO TRIPS safeguards.  A more development-friendly version, that removes these 
inflexibilities, was recommended to the Fijian Government in 2003 by an expert 
commissioned by the WHO.  Although the benefits of doing this were acknowledged at the 
time, the law has not yet been re-drafted by the Attorney Generals Office. The reason for this 
delay is unclear. Progress has been further halted following the 2006 coup. Furthermore, Fiji is 
not a member of Patent Cooperation Treaty (PCT), yet in 2007 the Fijian Patent Office already 
had over one hundred and twenty pharmaceutical patents registered. Information about what 
drugs and companies these were for is not readily available.   
While the empirical evidence isn’t any where as stark as for HIV/AIDS (that galvanised the 
access to medicines debate in other developing countries) there is nevertheless one example in 
Fiji of a drug (the antipsychotic, Olanzapine), patented in 1998, that is in high demand because 
of its low side effects.  Fiji is required to patent Olanzapine to comply with WTO obligations.  
However if, for example, Fiji was to sign a trade agreement with the EU that contained 
TRIPS-plus, this 20 year monopoly could be extended by another five, or even 20, years. This 
extension would mean these drugs would continue to cost the Fijian Government more than if 
it had declared its public good priorities (Shaffer, 2005) and refused to sign away WTO TRIPS 
safeguards. 
 
Furthermore, although not directly caused by trade impediments, drug stock-outs in hospitals 
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and clinics are not infrequent (Bailey, 2004). Whereas a specified range of generic medicines 
are publicly funded and freely available to the Fijian public through hospitals and clinics, 
when this happens the public are expected to pay full price at a private pharmacy.  Anecdotal 
evidence suggests many people often miss out on these essential medicines because they 
cannot afford them.  The price sensitivity reinforces a two-tier health system and social 
inequality (Marmot and Wilkinson, 1999). Empirical studies on the affordability of drugs in 
Fiji and the PICs are very limited, but again would be valuable.  
 
This combination of these and other factors suggests there is a growing urgency to commence 
developing national and regional strategic and policy responses to assess and mitigate any 
future trade restrictions and the effects of these on access to medicines. In a worst case 
scenario, TRIPS inflexibilities may be signed away by trade negotiators, with little attention to 
their health costs.  Once integrated into national legislation, these obligations might sit, like a 
‘trojan horse’, to be triggered at a later stage when the Ministry of Health or private 
pharmacies may wish to import a particular drug and are restricted from using safeguards, 
such as parallel importation.  
 
There is an immediate need to begin raising the general levels of awareness and to commence 
the internalisation of policies in the trade and health sector, in order to limit any potential 
impact on health development in the future. 
 
1.3 Aim and objectives 
 
Aim 
 
The primary aim of this research is: 
 
To evaluate whether current trade obligations, such as Trade Related Aspects of Intellectual 
Property (TRIPS), impede access to essential, affordable medicines in Fiji and to suggest 
national and regional responses, including human rights instruments, which might address this 
by putting a public health perspective into trade and property rights.  
 8 
 
Objectives 
 
The primary objectives are: 
 
1. To assess any reported trade-related restrictions on access to essential medicines in Fiji, 
including any potential impacts of future regional trade agreements. 
 
2. To assess whether trade related impacts on access to medicines is on the agenda in the 
public or civil society sector in Fiji and, if not, to determine why, and what, factors would 
trigger PICs adopting this focus. 
 
3. To identify which stakeholders have a role in putting a public health perspective into trade 
and intellectual property law and whether the impact of trade obligations on access to 
medicines is factored into trade negotiations.  
  
4. To evaluate whether trade-related impacts on access to medicines are taken into 
consideration in    regional integration initiatives identified under the Pacific Plan; in 
particular, the review of collective medicines procurement and regulation, and regional 
integration of intellectual property rights.  
 
5. To assess the general scope, for using human rights instruments to protect access to 
medicines in Fiji. 
 
6. Based on the analyses, suggest national and regional responses that are culturally and 
politically appropriate, to mitigate trade-related factors from impacting on access to essential 
medicines.  Such responses might include human rights instruments (along with a range of 
other strategic, policy and advocacy initiatives) designed to mainstream a public health 
perspective into all aspects of international trade that impact on access to medicines.  This will 
include: (i) the analysis of international trade agreements (in particular TRIPS and Bilateral 
Investment Treaties (BITS), (ii) drafting of national intellectual property law, and (iii) the 
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examination of pharmaceutical patents.     
 
These primary objectives are underpinned by a secondary objective, which is: 
 
7. To describe how four seemingly, separate systems work, and interrelate, in Fiji and the 
Pacific region, so that a cross sector analysis may be undertaken under the primary objectives.  
These are:  
 
(i) Pacific population health trends and public health services, including national 
medicines policy and procurement and how global schemes for treating 
communicable diseases eg. Global Fund, UNICEF, function alongside national 
procurement; 
(ii) intellectual property law, including pharmaceutical patent law and examination;  
(iii) the process of trade policymaking, the capacity for trade and health advocacy and 
the key multilateral and free trade agreements, including the potential impact of 
proposed agreements currently under negotiation, such as EU EPA; 
(iv) the application of human rights instruments, in particular the right to health (and to 
access to medicines).  
 
1.4 Epistemology 
 
Epistemology, or the theory of knowledge, is the branch of philosophy which is concerned 
with the nature and scope of knowledge.  A description of the various epistemologies 
associated with different worldviews and of the considerable academic debate about each of 
these is not included in this research.  Instead, I identify the epistemology that best describes 
my research position and how this has influenced the methodology. 
 
The epistemology used in this research can broadly be classified as Critical Realism; a blend 
of Realism and Critical Theory.  My approach is Realist in that I accept that a real world exists 
outside, and independently, of our senses and perceptions.  It also seeks to find out how 
something happens (causal mechanisms) and how extensive a phenomenon it is (empirical 
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regulatory) in order to influence its root causes (Kitchin and Tate, 2000).  Realism considers 
these root causes stem from people’s knowledge rather than simply experiences (the latter is 
associated with Pragmatism, another epistemology).   
 
The Critical Theory that accompanies this Realism is associated with reformulations of 
Marxism (Johnston et.al., 2000) which considers the purpose of social research is to enable 
people to act on their findings to improve society, a process referred to as emancipation.  
Unlike classical Marxism however, Critical Theorists have a broader view of interactions 
between individuals and society than as just a means of capital production (exchange of labour 
for a wage); taking into account other dynamic, social factors into its research (Johnston et.al., 
2000).        
 
Building on the different types of science is the recognition of different types of research.  For 
example, it is possible to select a position along the continuum between descriptive and 
explanatory, or value-free and action- based.  It is important to identify positionality because 
individuals do not conduct research in a vacuum (Murray and Overton, 2003).   
 
My positionality is best described as ‘action-based’ research instead of ‘value-free’ research, 
and as ‘problem solving’ as opposed to ‘exploratory’, and as ‘market-oriented’ and ‘applied’ 
rather than as ‘pure’ and ‘academic’. This is illustrated by the research methodology, which 
seeks to comprehensively describe four systems that impact on access to medicines, the 
potential impact this may have on the health and wellbeing of individuals, and how this may 
inform local responses to mitigate any impediments.  This approach is also consistent with the 
purpose of Critical Theory which seeks to describe processes and relations and to 
communicate these so that people may act upon them to improve society (Murray and 
Overton, 2003).   
 
1.5 Research lens 
 
This research uses a public health sector perspective, as distinct from a trade sector 
perspective, to evaluate the impact of trade and TRIPS on access to medicines. This approach 
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is underpinned by two fundamental principles.  First, the concept of using trade (and of using 
TRIPS) as a means to promote sustainable social, economic and environmental development, 
rather than to prioritise economic and financial growth regardless of the social costs (Winters, 
2005), and secondly, the principle that trade policy is not central, but is complementary, to 
alternative domestic, heterodox, institutional innovations (Rodrik, 2001).  
 
Furthermore, it is important to clarify that I am not using human rights theory as a ‘lens’ to 
evaluate IPR and access to medicines, but as a perspective. As stated above, my aim is to 
elaborate whether aspects of trade and IPR currently impede access to essential medicines in 
Fiji and to suggest national and regional responses to help mitigate these.  A human rights 
perspective is considered here as one response, along with a range of other strategic, policy 
and advocacy responses, which might address this by putting a public health perspective into 
trade and property rights. My research therefore includes a detailed description of human 
rights theory to set the context for discussing the existing institutions and challenges facing 
human rights in Fiji and the Pacific region.  
 
I could have selected other development discourse, besides human rights, as a perspective to 
research and promote equitable access to essential medicines.  Some alternative discourses 
include: gender equality, pro-poor development, and studies in social inequality.  For example, 
a gender equality approach would challenge schemes which provide contraception to young 
boys but deny access to young girls, with the stated rationale that access might prompt girls to 
be sexually active (Youth Research, 1997). These are however not covered in this thesis.   
 
A human rights perspective was preferred for this research because it is the only discourse 
with a comprehensive, globalised, legal, political and philosophical framework (Gruskin et al, 
2005).  At the international level, it is also the ‘closest thing the international community has 
to a common resource of values that might be used to guide issues of access to property and 
knowledge’ (Drahos, 2005, pp.16). Such a ‘common source’ may not be an appropriate 
descriptor in the Pacific region, where reports have noted tension exists between human rights 
and customary rights (PIFS/NZHRC, 2006). As a result of these tensions, the potential to use 
human rights to advocate for access to medicines is explored after discussing how Pacific 
 12 
communities view human rights.  
 
1.6 Methodology and field research design 
 
1.6.1 Methodology 
 
This methodology primarily uses qualitative research, combined with some quantitative 
research.  This choice of methodology reflects my chosen epistemology, Critical Realism, 
discussed in Section 2.1 
 
Several research theorists advocate that, rather than exclusively using one method, quantitative 
and qualitative may be effectively mixed to complement each other; leading to a richer 
research result (Murray and Overton, 2003; Brockington and Sullivan, 2003).  My emphasis 
on qualitative data and anecdotal evidence is also partly due to a lack of quantifiable data 
relating to this topic.  The statistical data would have been useful to better understand the 
impact on the health of people, for example, the affordability of medicines for poor people 
when there are stock-outs of government procured drugs, the estimated cost of patented 
medicines versus generic versions if patent extensions were approved, the social and economic 
costs caused by ill health when people cannot afford drugs, or the efficacy of free medicines 
and whether diseases persists despite being medicated.  Further research is recommended in 
instances where I considered quantifiable data would have been useful.  
  
The methodology consisted of a two main steps.  First, an extensive literature review of the 
trade, access to medicines and human rights issues at a global, regional and national level.  
This step set the context and guided the second step which was to conduct field research.  The 
field research involved a series of semi-structured interviews with twenty two participants 
from a range of trade and health-related government ministries, non government organisations 
(NGOs) and UN agencies in Fiji and New Zealand.  This second step explored the questions 
set out in the literature review. Both steps are elaborated below.  
 
The literature review commenced by compiling information on the global evolution of Trade 
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Related Intellectual Property Rights (TRIPS) in multinational, regional and bilateral trade 
agreements.  This included empirical evidence and the arguments raised by opponents and 
proponents about the impact of intellectual property rights on access to medicines in 
developing countries. The literature relating to international human rights theory, in particular 
‘human rights and access to medicines’ was then reviewed.  This included the complex 
challenges associated with the application of human rights instruments, the interface with 
other world systems, for example the World Trade Order, and case studies that exemplify the 
application of human rights to successfully improve access to medicines. The review then 
focused on the Pacific region and examined the literature relating to the regional population 
health status and description of health services and the mechanism for trade policymaking.  
The potential for trade-related provisions, such as TRIPS, in proposed regional trade 
agreements (for example, EU EPA) and a description of human rights mechanisms and 
challenges was also included.  
 
Finally, the literature review was narrowed down to a national level in Fiji.  Here the review 
scoped out the capacity for trade policymaking and advocacy, the content and status of Fiji’s 
national patent law and a description of the national human rights mechanisms.  The literature 
describing the national pharmaceutical policy, medicines procurement and medicines 
regulation in Fiji was also researched, taking note of any regional integration initiatives that 
may impact on medicines. 
 
1.6.2 Field research design  
 
In-country interviews were conducted in Suva, Fiji, over a two week period from 8 – 21 
October 2007.  Suva was selected because of the concentration of Fiji Government Ministries, 
UN agencies and domestic and regional NGOs.  It is also the head quarters for the Fiji 
Pharmaceutical Services, the bulk procurement and regulatory agency for medicines in Fiji.  
Findings were that the Chief Pharmacist responsible for this agency has been proactive in 
raising awareness about safeguarding access to medicines, particularly in regard to national 
IPR law, and is acknowledged amongst other PICs as having acquired substantial knowledge 
on this subject.   
 14 
The majority of interviews were conducted on a face-to-face, individual basis, using a set of 
thematic questions to prompt discussion (refer to Appendix 1 for an example of interview 
themes). 8 The four interviews conducted in New Zealand were completed in early November 
2007.   
 
A representative sample of organisations were selected from a cross section of the Fijian 
Government, Council of Regional Organisations in the Pacific (CROP), UN agencies, and 
domestic and regional NGOs using four criteria.  Organisations selected to be included in this 
research qualified if they were directly involved in any of the following:  
(i) the procurement or prescribing of medicines in the public health sector – and 
therefore are directly involved in measuring the impact of the safety, affordability 
and access of Fijian citizens to medicines;  
(ii) critiquing or drafting of national IPR law and pharmaceutical patent examination;  
(iii) policy or advocacy for health development, trade or human rights and health; 
(iv) trade negotiations or providing technical assistance to the Pacific Island Forum 
Secretariat on trade, intellectual property rights and/or health issues. 
 
Around half of the interviewees were contacted using telephone and email and meetings were 
scheduled in advance of my trip to Suva. Generally I did not experience difficulty arranging 
further interviews once I was in the country as the topic was of great interest to most people.  
The remaining interviews were arranged as referrals from existing interviewees, or by making 
further telephone calls.   
 
Twenty two participants were interviewed from pre-selected organisations, including the 
following organisations in Fiji:  
(i) Fiji Pharmaceutical Services,  under the Fijian Ministry of Health, responsible for 
Fiji’s public medicines procurement (2); 
(ii) Fijian Government Patent Office located within the Company's Registration Office 
(1); 
                                                 
8
 One international participant was interviewed by telephone and one meeting included two participants at the 
same time.  
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(iii) Pacific Island Forum Secretariat, trade section. The Secretariat is responsible for 
providing technical support on trade and economics to the Pacific Island Forum 
Leaders (1); 
(iv) health-related UN agencies: WHO (West Pacific Regional Office), UNAIDS, 
UNICEF, UNDP (Pacific Centre), UNFPA (6); 
(v) regional and national NGO’s involved in trade and health advocacy to varying 
degrees: PANG, PCRC, ECREA, FSPI and PCC (5); 
(vi) Pacific Regional Rights Resource Team; a project of the UNDP Pacific Centre (1)  
(vii) CROP agency: Fiji School of Medicine (1); 
(viii) senior pharmacist from a Pacific Island agency involved in health development (1). 
 
In New Zealand, prior to, and following on from my trip to Fiji: 
(ix) PHARMAC NZ, the NZ agency responsible for procurement of all government 
funded pharmaceuticals (2); 
(x) New Zealand Ministry of Pacific Islands Affairs, the Ministry responsible for 
researching, designing and advising the New Zealand Government on policies that 
enhance the economic and social wellbeing of the Pacific Island community living 
in New Zealand (1); 
(xi) NZ Human Rights Commission, involved in supporting PICs to establish 
appropriate human rights instruments aligned with local custom (1). 
 
When I commenced designing this field research methodology I had intended to travel from 
Suva to Noumea, New Caledonia, to interview key people within the Secretariat of the Pacific 
Community (SPC).  SPC is one of the Council of Regional Organisations in the Pacific 
(CROP).  The Secretariat is responsible for implementing many of the Pacific Plan health 
objectives and undertakes other health-related work, such as public health surveillance, 
laboratory, communicable disease control, healthy pacific lifestyle, HIV/AIDS projects, and 
Global Fund to fight AIDS, Tuberculosis and Malaria under its Public Health Program. 
 
However, when I approached a senior manager within the organisation they commented it 
wouldn’t be worth my while and declined to be telephone interviewed, stating the Public 
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Health Program ‘was not involved in trade issues’.9  I did however conduct a telephone 
interview with an SPC staff member who agreed to provide personal comments and not to 
answer on behalf of SPC. These comments are discussed under the findings in Chapter 5 
alongside my views on what I perceive as an opportunity for regional level agencies, PIFS and 
SPC, together with WHO, to play a significant role in promoting a public health perspective in 
trade policymaking and to raise awareness of the potential impediments of trade on access to 
medicines in Fiji and other PICs.   
 
A critique of this research methodology, including the absence of interview participants from 
SPC, and any limitations this may have on gathering and interpreting information, is covered 
in Section 1.6.4.  This critique is taken into account in my key findings and recommended 
responses in Chapter 5.  
 
1.6.3 Human ethics approval 
 
Human Ethics Committee (HEC) approval was gained from Victoria University of Wellington 
prior to any interviews taking place and every attempt was made to maintain confidentiality 
where this was requested. 
 
Prior to each interview all participants were made aware of the ‘Information Sheet’, explaining 
the reason for my research, and ‘HEC Participant Form’ (see Appendix 2 for both forms).  
Participants were given an opportunity to complete this form either prior to the interview, or 
after, at completion of the interview.  Some participants elected to retain the form and to 
determine how they would fill it out once they had read a draft copy of the thesis which I gave 
a verbal undertaking I would send to them, prior to the final version being submitted.  Others 
did not consider there was any need to sign HEC forms as the information they were providing 
was general in nature. The same procedure was followed with the single interview conducted 
by telephone.  In this case, the forms were exchanged by email prior to the interview.  By 
undertaking these steps I have fulfilled the University’s ethics policies.  
 
                                                 
9
 Personal email correspondence 
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Scheyvens and Storey note that ethical considerations in field work should extend beyond 
obtaining ethics consent to also take the potential effects of the research, and researcher, on 
the participants into consideration (Scheyvens and Storey, 2003).  Since my interview 
participants didn’t appear to be particularly marginalised or vulnerable people, and appeared 
to be familiar with participating in an interview, this consideration was relatively less 
complex.  However, trade and health issues are particularly political in nature and the Fijian 
community is relatively small and closely networked.  Because of this I was aware of the need 
for diplomacy in articulating some of the research findings and for respecting the integrity of 
those interviewed.  
 
To that end I undertook to send a draft version of the thesis to interviewees which enabled 
them to see the information and quotations they provided in the context of the thesis and to 
modify these if required. In addition, I asked if the participants had any ethics approval 
criterion particular to their organisation or association that I needed to complete prior to the 
interview.  No participants indicated that prior ethics approval by their organisation was 
necessary. 
 
1.6.4 Methodology critique 
 
Limitations of this methodology primarily related to assuming a representative sample of 
stakeholder organisations when not all organisations were available to be interviewed, 
portraying the views of an individual as if they represent the views of their organisation, over-
reliance on qualitative data versus quantitative data, limited comparison with other PICs to 
assess how recommended responses may be translated to a regional level, and my own ability 
to interpret correctly participant’s views and realities without misrepresenting their response. 
  
The number of stakeholder organisations that I managed to interview is perhaps the major 
limiting factor.  Several key interviews were not possible for a variety of reasons.  These 
included: meeting arrangements disrupted because my trip coincided with the 38th Forum 
Leaders Conference in Tonga and the Civil Society Conference which preceded it; key 
individuals working overseas; the Fijian coup which placed additional responsibilities on 
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several Fijian Government Ministries, extending their resources and limiting their time to 
meet.   
 
Some of the key people that I would have liked to interview included: officials from the 
Ministry of Foreign Affairs and External Trade and the Ministry of Health involved in trade 
and health policy; the Solicitor Generals Office involved in drafting national IPR law; hospital 
clinicians and managers who administer medicines paid for by the government; the 
Pharmacists Association commenting on drug efficacy and frequency of stock-outs; the 
Human Rights Commission; other NGOs , for example the World Council of Churches.  
 
As a result there is a danger of an over-reliance on information supplied by the organisations 
interviewed which may have been overly critical or supportive of other stakeholders without 
my being aware. This presented less of a problem where information was factual in nature (for 
example, a description of how medicines are procured, or the status of the draft IPR Bill) than 
when it related to say, a description of the mechanisms, both formal and informal, used to put 
a public health perspective into trade negotiations. 
 
Another limitation arose from interviewing a single individual from each organisation which 
may not represent that organisation’s views. This is less critical because my objective was to 
elaborate processes, mechanisms and mandates around trade and medicines rather than to 
document the views of one organisation about another. 
 
A lack of quantitative data is noted, however this would have helped to underpin the research 
rather than to substantively change the findings.  For example, it would have been useful to 
establish which pharmaceutical firms and what products were registered in the existing 
pharmaceutical patents.  However, this was not feasible because the documents are not yet 
stored electronically  at the Fijian Patent Office making it necessary to make a prior request 
and to manually check each registration.  Furthermore, these are complex documents which 
would require employing someone with specialist expertise to interpret.  For example, the 
records often describe the active chemical agents and process of manufacture, which a 
pharmacist would recognise, rather than a brand name.  
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The limitations described in this section are acknowledged and wherever possible they are 
taken into consideration in the findings and recommendations.  Despite its flaws, the 
methodology did however provide three valuable insights.   
 
First, when I established contact with the Ministry of Health and asked to speak with someone 
involved in trade issues, or I contacted the Ministry of Foreign Affairs and External Trade and 
asked to talk to someone who dealt with health-related issues in trade, I was advised that 
person did not exist.  I did not dismiss these responses because they did not result in an 
interview.  Potentially this might have reflected my approach, not explaining well enough my 
research.  Alternatively, such responses may be an indication that trade and health issues are 
not currently factored into decision making processes, or that they did not see the need to do 
so; warranting further research.  I have factored these responses into my findings in Chapter 5.  
Second, some of the research questions cannot readily be answered at present because of a 
lack of capacity and information on the topic.  Third, individuals had incomplete knowledge of 
the whole system making it critical to cross-reference information from several different 
sources.  This wasn’t always possible within the scope of this project, and so sometimes raised 
more questions than answers. The qualitative nature of this research methodology means that 
this cross-section of organisations and cross-referencing of information is very important.   
 
Finally, where divergent responses were given to my interview questions I attempted to use 
analytical rigour to clarify the issues that were raised.  In the very few cases, when different 
answers were made, I highlighted both sides of the issue and identified the need for 
subsequent research.  This occurred in particular in discussions about the appropriateness of 
using human rights to advocate for trade and access to medicines, exemplifying the tension 
with customary rights in the Pacific region.  
 
1.7 Structure of this dissertation 
 
This thesis researches four seemingly separate, but interrelated, systems that have a profound 
impact on access to medicines in developing countries and the structure of the global 
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pharmaceutical industry.  These are:  
 
1. regional population health trends and public health services, including national 
medicines policy and procurement;  
2. intellectual property rights, including pharmaceutical patent law and examination;  
3. trade policymaking, including trade and health advocacy, and key multilateral and free 
trade agreements, and; 
4. human rights instruments, in particular the right to health (and access to medicines).  
 
These four systems are mutually reinforcing, however, they are generally researched and 
managed in isolation, on a sector by sector basis. This situation continues to exist despite an 
increasing awareness of the benefits of a multi-sector approach to public sector management, 
particularly as the effects of trade liberalisation cut across different sectors (WHO, 2007b). To 
my knowledge, an overview of these four systems in the Pacific region, and an attempt to 
critique across the four systems, has not been undertaken before.  This multi-sector research 
may therefore be useful to policymakers and development practitioners working in any of 
these, or related fields, as it has the benefit of elaborating a wide range of multidisciplinary 
findings that are usually less evident because they are conventionally researched and managed 
in isolation. 
 
This research sequentially describes each of the four systems at a global, regional and national 
level.  After broadly describing the global level, the thesis then explains how these four 
systems work (in principle) in the Pacific region and, more specifically, in Fiji.  This 
reinforces the understanding of how local issues are being shaped by global forces. This 
overview, combined with a brief description of the local cultural, political and economic 
context in Fiji, then provides an insight into the way Pacific communities generally might 
view access to medicines and the political status that access to medicines is accorded 
compared with neighbouring emerging economies, such as Thailand.   
 
A discussion of how these four systems work at a regional level is included because several of 
their components, for example, collective medicines procurement and regionalised patent 
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administration, are identified as areas for regional cooperation under the Pacific Plan.  This 
research therefore sees the Pacific Island Forum Secretariat (PIFS) as a regional stakeholder, 
as it is the agency that provides technical assistance on economic and trade development to the 
Forum Leaders.   
 
This thesis is divided into five chapters as follows: 
 
Chapter 1: Describing this research.  An introduction and outline of the research aim, 
methodology and epistemology are provided in this chapter.  It also discusses how my 
epistemological approach has shaped the methodology and provides a critique of the 
methodologies limitations and how these might influence my findings.  
 
Chapter 2: The global context.  This chapter is designed to place the debates surrounding trade 
and access to medicines and a description of international human rights mechanisms within a 
theoretical and global context before the research is narrowed down further to describe how 
these mechanisms function in the Pacific region and then in Fiji. Human rights theory is 
extensively described, in particular the human right to health, and to access to medicines, 
including challenges and opportunities facing human rights and the interface with the WTO 
global trading order where private property rights are dominant over access to public goods.  
 
Chapter 3: The Pacific context.  Following an introduction to the Pacific context this chapter 
provides an overview of the four interrelated systems that impact on trade and access to 
medicines.  They include a description of population health trends and public health services, 
intellectual property rights and pharmaceutical patent examination, trade policymaking 
mechanisms and key multilateral and free trade agreements, and the application of human 
rights instruments.  The chapter includes a discussion of the potential impact of the proposed 
regional trade agreements with Europe (EU EPA), and with New Zealand and Australia 
(PACER), on access to medicines and how human rights are generally perceived by Pacific 
islanders.  
Chapter 4: The national context.  Here, the research focus is narrowed down to Fiji.  It begins 
with a general introduction to Fiji that sets the socio economic and political context before it 
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focuses on how the same four systems function at a national level.  The information in this 
chapter is mainly drawn from my field research interviews.  Also in this section I pay close 
attention to examining local cultural preferences towards western medicines culture and views 
about human rights.  These attitudes and understanding contribute to how trade and access to 
medicines is perceived in Fiji and at the regional level of the Forum Secretariat. 
 
Chapter 5: Findings and conclusions. This chapter provides an extensive summary of the main 
research findings under each of the five primary research objectives.  These findings, together 
with suggestions from interview participants and personal observations are then used to design 
multi disciplinary responses to help mitigate trade-related factors from restricting access to 
medicines in the future. The need for regional cooperation on health, IPR and trade has been 
acknowledged by the Pacific Forum Leaders under the Pacific Plan.10  The responses are 
summarized in Appendix 5.  Finally, this chapter discusses the significance of this research for 
human rights theory and for the wider academic audience, in particular the emergence of 
human rights mechanisms needing to adapt to promote ‘collective’ national sovereignty within 
economic trading blocs and the relationship at the interface with traditional knowledge. 
 
                                                 
10
 See Strategic Goal 11 in reference PIFS. (2007). Pacific Plan. Available at www.pacificplan.org last accessed 
5/12/07 
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Chapter 2: The global context 
 
2.1 Introduction  
 
This chapter grounds this research in the global context firstly by briefly describing 
development theory and international trading systems that influence access to medicines, and 
secondly, by providing a more detailed description of international human rights theory, and 
of human rights and access to medicines in particular.11   
 
Debates on universal human rights needs to distinguish between legal, political and 
philosophical human rights perspectives.  The practice of shifting seamlessly between these 
perspectives has been criticised as an unfortunate trait within literature and public discourse 
(Evans, 2002).  Evans points out this practice serves to undermine the status of human rights 
to global politics because it opens the possibility of gaining the moral status that ratifying 
international human rights law brings, while simultaneously denying socioeconomic rights 
philosophically and politically.  This research aims to clearly distinguish between these three 
perspectives in the discussion of human rights in the Pacific region (and in Fiji) in order to 
reduce the possibility of misrepresenting the entire human rights framework by selectively 
describing parts of it.    
 
The section on human rights commences with an overview of the international human rights 
framework and summarises some of the complex challenges confronting its application in 
developing countries.  This is particularly relevant to the Pacific region where reports have 
noted human rights are generally regarded with suspicion because of the tension with 
customary rights (PIFS/NZHRC, 2006; NZ Law Commission, 2006).  The focus is then 
narrowed down to one particular aspect of the comprehensive international human rights 
framework; human rights and access to medicines, which is a sub-category of human rights 
                                                 
11
 As explained in Section 1.5, human rights theory is not used as a lens in this research.  I do not intend therefore 
to describe human rights theory comprehensively.  Extensive references and appendices are provided however for 
readers who require in-depth information on a particular aspect of human rights.     
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and health12.  Here I also describe the theoretic and legal interface of human rights and access 
to medicines with two other World Orders. Namely, the global economic (WTO) order, and 
intellectual property rights (WIPO).  Considerable tension exists between human rights and 
these Orders because they represent the dominant neoliberal consensus that is axiomatic of the 
global trading system (Hestermeyer, 2007) which is often given priority over environmental, 
social and cultural rights (Gruskin et al, 2005).   
 
Two case studies are included that illustrate the successful application of a human rights 
instrument to protect the right to essential medicines in developing countries.  For example, 
the national level critique of the Thai-US FTA by the Thai Human Rights Commission 
contributed to its rejection on the basis that it limited the Government’s ability to fulfill the 
Constitutional Right to Health (UNDP, 2006).  Finally I reflect on the main themes in the 
global context that will influence how trade and access to medicines are viewed and to what 
extent health may be mainstreamed into trade policymaking in the Pacific region.  
 
2.2 Trade, TRIPS and access to medicines 
 
“Intellectual property rights are about balancing public goods and private rights.  The 
(Pacific Island) Forum Secretariat has an obligation under its mandate to be the eyes and 
ears for the public (interests) as opposed to the private rights.  Because Pacific Island 
Countries don’t have a huge private sector, and they are not abundant creators of 
technology, or net producers of intellectual property, they are overwhelmingly 
dependent on accessing public goods.  So, intellectual property rights needs to reflect 
this development reality. We need to ensure Pacific Island Countries have access to 
these goods and that they are affordable.  Any indication otherwise, the Forum 
Secretariat would need to flag (to Forum Leaders).” 
Ms Gail Olsson, Trade Consultant, Pacific Island Forum Secretariat, interviewed October 2007 
 
TRIPS are established at the international level by a number of treaties including those 
                                                 
12
 For a comprehensive discussion of different aspects of human rights and health see reference Gruskin, S. et. al. 
(eds) (2005)   
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administered by the World Intellectual Property Organisation (WIPO), which is a specialized 
UN agency, and the WTO.  TRIPS especially had an impact after 2000, when the WTO 
TRIPS Agreement came into force. Under the Agreement, all WTO members are obliged to 
implement a set of minimum principles and rules, including patents and their enforcement.  
These rights include the control of production, sale, use and sometimes importation of 
medicines.  TRIPS therefore give pharmaceutical companies near-global monopolies, allowing 
them to block competition from generic manufacturing companies and to raise the price of 
patented pharmaceuticals (Lofgren, 2007; WHO 2007a). 13  
 
More restrictive TRIPS, called ‘TRIPS-plus’, and trade related provisions are contained in 
bilateral and free trade agreements (FTAs), especially US FTAs.  These include patent 
extension, data exclusivity, linkage evergreening and restrictions on compulsory licensing and 
parallel importation14.  
 
In the past developed countries have set IPR standards to suit their own stage of economic and 
social development and used them to successfully distance themselves from rival economies 
by preventing developing countries from employing these same policies (Drahos and Mayne, 
2002; Wade 2005); a tactic Chang has described as ‘kicking away the ladder’ (Chang, 2005).  
However, the globalisation of IPR means states no longer have discretion in setting their own 
preferred levels.  This globalisation fails to recognise the importance of allowing countries to 
retain national sovereignty to manage the rules that regulate development goals such as health 
(Oxfam, 2007b; WHO, 2007a; UNESCAP, 2007). 
 
The intended outcomes of globalised IPR regime is to improve markets for trading 
information internationally by encouraging invention and technology transfer.  However, it is 
also recognised that the system creates roadblocks in the path of generic medicines, 
competition and the attainment of public goods (Maskus and Reichman, 2005).  In response to 
significant and mounting international concern that property rights are impeding access to 
medicines, various multinational working groups have been established under the WTO, 
                                                 
13
 See reference WHO (2007a) for a comprehensive description of all of the issues 
14
 For a description of these terms see reference WHO (2006a) and visit the health section of the Third World 
Network website at http://www.twnside.org.sg/heal.htm 
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WHO and UN agencies to monitor the impact of TRIPS on public health 15 and to explore new 
models to stimulate investment in R&D and medicines supply for developing countries. For 
example, offering prize money to encourage more research and development into neglected 
diseases instead of awarding patents once a medicine has been discovered. 
 
The WTO TRIPS Agreement includes a number of transition periods for developing countries 
and LDCs 16.  Under the original TRIPS agreement these members had until 1 January 2005 
and 1 January 2006, respectively, to implement patent protection for pharmaceutical products.  
Prior to this, many developing countries only protected patented processes, and not products.  
This enabled countries like India to develop generic drug manufacturing capacity.   
 
Under the Doha Declaration, Least Developed Countries (LDCs) can now delay legislation to 
protect pharmaceutical products until 1 January 2016.  However, if LDCs graduate to being 
developed countries, the extended timeframes no longer apply.  These dates are not beyond 
challenge, for example, under the proposed WTO accession package of 2007, Samoa is under 
considerable pressure to implement TRIPS far earlier than the dates specified under the Doha 
Declaration17. 
 
TRIPS implementation has been debated by two sides 18.  One favours swift compliance and 
limited use of flexibilities using coercive pressures such as trade deals and threats, WTO 
disputes and diplomatic demands, to foster a pro-IP climate. The other advocate for a more 
flexible approach tailored to specific national development priorities by harnessing ideational 
power, such as running access to medicines campaigns (Abbott, 2005).  To win over 
developing country decision-makers, the two groups have been engaging in a research war and 
compete in the area of capacity building (Deere, 2007). 
 
                                                 
15
 Examples include: WTO and Public Health; WHO Commission on Intellectual Property, Innovation and Public 
Health (CIPIH); International Centre on Trade and Sustainable Development (ICTSD) a UN accredited NGO eg. 
UNCTAD-ICTSD joint working group  
16
 Least Developed Countries in the Pacific region include: Solomon Islands, Samoa and Vanuatu.  PNG and Fiji 
already have to comply, Solomon Islands is delayed until 2016, while Tonga’s deadline is 1June 2008 
17
 Personal correspondence with Oxfam New Zealand re. evaluation of the proposed WTO accession package for 
Samoa, July 2007. 
18
 For an excellent overview of trade and access to medicines see reference Abbott, F.M.(2005).  
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2.3 Overview of international human rights law  
 
“Human rights are what reason requires and conscience demands.  They are us and we 
are them.  Human rights are rights that any person has as a human being.  We are all 
human beings; we are all deserving of human rights.  One cannot be true without the 
other.”   
Kofi Annan, Former Secretary General, United Nations 
 
Human rights are legally guaranteed by human rights law.  These laws protect individuals and 
groups against actions that interfere with fundamental freedoms and human dignity (WHO, 
2002). A moral imperative created the impetus for their development during the post-World 
War II settlement. The Universal Declaration of Human Rights was originally envisaged as a 
single instrument.  However, a disagreement 19 resulted in the drafting of two major 
Covenants; exemplifying the cultural relativist debate (Uvin, 2005) discussed in more detail 
below. 
 
The legal instruments which form the foundation of modern international human rights law 20 
include: 
(i) the International  Bill of Human Rights which is the name given to the Universal 
Declaration and the two Covenants, the International Covenant on Economic, Social and 
Cultural Rights (ICESCR)21 and the International Covenant on Civil and Political Rights 
(ICCPR), adopted by the UN General Assembly on 10 Dec 1948.  This Bill is the most 
important international human rights legal instrument, (ii) other UN instruments with 
supervisory bodies, of which there are currently six Conventions, and (iii) other major human 
rights treaties and standard setting by the UN.22 
                                                 
19
 By the time States were prepared to turn the Declaration into binding law, the Cold War had polarised human 
rights into two separate categories. The West argued that civil and political rights had priority and that economic 
and social rights were aspirations while the Eastern bloc argued to the contrary.    
20
 For a detailed description of the 7 main international HR law instruments see reference RRRT/UNDP, (2005).  
21
 For a description of the Committee for ICESCR and others refer to NZ MFAT, (2003). pp. 57.  
22
 HR instruments normally consist of formal treaties and declarations drafted by HR bodies, such as the 
UNCHR, as well as authorized interpretations of these instruments, such as General Comments by Treaty Bodies.  
These are the normal reference documents of HR lawyers.  When these do not exist, or do not adequately cover 
the concerns of the international community, documents by professional organisations and major international 
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These instruments form the bedrock of contemporary international human rights law, not only 
because of their potential worldwide application, but also because of the breadth of the human 
rights contained in each.  ICCPR places an immediate and absolute obligation on states, 
whereas the implementation of rights under ICESCR is both progressive and dependent upon 
the availability of resources.   
 
2.4 Some complex challenges surrounding the application of human 
 rights 
 
There are many complex challenges preventing broad political support for the human rights 
mechanism.  Passing more human rights legislation will not overcome these challenges as they 
represent fundamental differences in values, or blatant disregard by those in charge (Farmer 
and Gastineau, 2005). Some of the main challenges identified from the literature research 
include: cultural relativism and euro-centrism; emergence of third generation rights, for 
example, the responsibility of pharmaceutical companies in the right to health; the status of 
human rights within the neoliberal global economic order, and the need for new 
methodologies and indicators to operationalise the human rights framework. Each of these 
challenges is discussed below.   
 
2.4.1 The ‘ism’s’: cultural relativism and euro-centrism  
 
The separation of the two major Covenants (the ICESCR and ICCPR), combined with the 
West’s almost exclusive focus on the latter, has created a sense that there are two levels of 
human rights, called first and second generation 23. Although they can be categorised in this 
                                                                                                                                                         
conferences and summits are developed.  These do not carry the same legal authority, but are invaluable to 
understanding the normative issues involved in the relationship between health and HR and to elaborating 
policies and programs in this field. 
23
 First generation rights are for civil and political rights which prevent the State from interfering in the day-to-
day lives of citizens. Second generation rights are economic, social and cultural rights that require the State to 
ensure provision of goods and services which contribute to these rights to people at all levels of society.  They are 
not interpreted as being of ‘lesser’ priority.  
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way, the UN has consistently stressed the universality and indivisibility of human rights.24 
 
There has, nevertheless, been ongoing debate as to whether the human rights enunciated in the 
UDHR and core human rights treaties are in fact universal or should instead be culturally 
relative.  The cultural relativists hold that not all states can be, or should be, expected to 
protect human rights to the same degree, due to varying levels of economic, political and legal 
development and differing cultural views on the necessity of freedom (NZ MFAT, 2003). 
 
Related to the cultural relativism debate is the argument over so-called (eastern) Asian versus 
western values, or euro-centrism.  The former focus on duties and discipline rather than on 
rights and entitlements; on community and the common good as opposed to individualism; on 
respect for authority, as opposed to freedom and on hard work and savings, as opposed to 
consumption, and contend that these values are superior to those in the West (Uvin, 2004).   
 
Proponents also argue that the UDHR is essentially a product of western countries and values, 
given the limited UN membership (56 States) at the time of its adoption in 1948 (Uvin, 2004).  
Furthermore, given all state members of the UN are also members of WTO, they see 
developed states as having a duty of international cooperation and assistance in the ICESCR to 
work towards equitable multilateral trading investment and financial systems.  This means that 
states should respond to these rights in all jurisdictions to ensure trade agreements or policy 
will not adversely affect these rights (Hunt, 2005).  
 
The relativism debate is further compounded by the misunderstanding by some groups that 
human rights is a hegemonic, package that can simply be adopted (Uvin, 2004; Farmer and 
Gastineau, 2005).  Increasingly however, it is acknowledged that local customs need to be 
taken into consideration and a human rights ‘blend’ developed, that is owned by local people 
and suited to the cultural setting of each country (PIFS/NZHRC, 2006) 
 
                                                 
24
 The debate on universality and indivisibility continues in international fora, especially when more controversial 
issues are discussed such as gender preferences and reproductive rights. The term means that everyone has rights 
and freedoms set forth in the Declaration, without distinction of any kind, such as race, etc.  Despite general 
acceptance that HR are universal and indivisible, there may be occasions, for example, when it is necessary to 
restrict certain rights for the welfare of society as whole.   
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Eurocentrism and the juxtaposition of custom and human rights are significant to how human 
rights is perceived and applied in the Pacific region. “In the Asia/Pacific region, there is some 
resentment about the concept of human rights.  Some of our leaders are fond of decrying them 
as a western or alien concept at odds with our values.” (NZ Law Commission, 2006, pp.15).  
This is discussed further under Section 3.5. 
 
2.4.2 Third generation rights, extending from state to other duty-holders  
 
In traditional international law only states are subjects of the law.  The duty to promote and 
protect health as a human right is therefore assumed to lie with the state, although the liberal 
expectation is that this duty can only be fulfilled progressively (Gruskin et al, 2005).  
However, given the conditions of globalisation, the changing contexts of the social 
determinants of health are becoming increasingly supra-national, in turn challenging the 
notion of national duty-holders.  Recent additions to human rights legislation have sought to 
bind non state actors as duty-holders, especially transnational corporations.25  
 
Third generation rights, or rights of fraternity or solidarity, represent a more controversial 
category since these require states to cooperate to improve the lives of their entire populations 
for example, the Right to Emergency Assistance and the Right to Development.  The status of 
these rights in international law is not yet clear and poses significant challenge to much 
traditional human rights thinking (Hunt, 2005). 
 
2.4.3 The status of human rights within the world trade order 
 
Human rights interface with other World Orders that determine the behaviour of states and 
third parties, such as transnational corporations.  These include the World Bank and WTO, 
through multilateral and free trade agreements, and WIPO, through private property rights. 
These institutions are dominated by the neoliberal consensus which emphasise the freedom of 
                                                 
25
 One important step in clarifying these responsibilities was taken in the form of Norms adopted in 2003 by the 
UN Sub-Commission on the Promotion and Protection of HR which include reference to economic, social and 
cultural rights.  Another example, is the “Ethical Globalisation Initiative’ which explores with pharmaceutical 
companies what the right to health and corporate responsibility implies, particularly in relation to patents, pricing 
and R&D (Robinson, 2004; Hunt 2005). 
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individual action, non interference in the private sphere of economics, and the right to own 
and dispose of property; a set of principles axiomatic to the ideology of the free market 
(Drahos 2001; Cullet, 2005; Hoen, 2005; Hestermeyer, 2007).    
 
Furthermore, human rights law is also fundamentally different from world trade law. For 
neoliberals, socioeconomic claims are legitimate claims, or aspirations, but these can never be 
legal rights. Such soft law, associated with human rights, versus hard law of the WTO Order, 
and its dominance in determining the behaviour of states, is commented on by Hestermeyer: 
 
“Enforcement of human rights law is further hampered by the fact that, unlike economic 
law, the most common case of a states’s violation of HR law – namely a violation of the 
rights of its own citizens – does not harm other states directly which therefore lack an 
incentive to complain about the violation… It is a recipe for perplexity; while the claim 
of normative superiority of human rights has strong emotional (but far less legal) appeal, 
state behaviour will be largely dominated by the tenets of WTO law.  The question to be 
tackled …is whether there is a way to make human rights law count within the WTO 
system, as it is that system that will determine the behaviour of states”  
Hestermeyer, H. (2007). pp.207 
 
Proponents of human rights contend that the dominance of the neoliberal consensus remains 
the single most important factor hindering the establishment of socioeconomic rights as 
legitimate claims.  They argue that the process of globalisation itself, and of structural 
adjustment programmes (Gruskin et al, 2005) that themselves are guided by neoliberal 
principles, cause the conditions that increasingly threaten health security in all regions of the 
world (Robertson, 2004; Evans, 2003).  For example, the WHO estimates that nearly a quarter 
of disease and injury is connected to environmental degradation and decline attributable to 
globalisation and notes that 90% of malaria deaths are caused by the settlement of people in 
and around rainforests and the construction of large open-water irrigation schemes which 
increase human exposure to disease carrying mosquitoes (WHO, 2006b). 
 
These tensions are perhaps illustrated in the (uncomfortable) role of the UN agencies involved 
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in evaluating and monitoring human rights (Uvin, 2004) when they are also told not to get 
involved in multilateral trade agreements. For example, some UN agencies are expected to 
highlight obstacles that impact on specific human rights treaties, such as violence against 
women, or on progress towards the Millennium Development Goals (MDGs); yet the WTO 
system is often implicated as the major source of restrictions on health development.  
 
2.4.4 Need for new methodologies and indicators   
 
The human rights framework is broad and may be expressed through a wide range of 
mechanisms from a state’s constitution to national case law.  However, a fundamental 
difference between human rights and trade and development theories is expressed in Article 2 
of the Universal Declaration of Human Rights.  The Declaration emphasizes ‘universality’ and 
‘indivisibility’, and the delivery of rights to ‘all’, rather than accepting that on some occasions, 
some people may be disadvantaged in order to provide a net benefit to society.  For example, 
having to decide between investing in a school facility or water sanitation may advantage 
some people, while disadvantaging others, in realising their right to health and the right to 
education.  
 
Human rights practitioners acknowledge there is a need to develop new skills and techniques 
to make this operational;  especially if it is to extend beyond the classic methodologies of 
political naming and shaming and taking test cases in case law, into engaging with policy 
making.  Appropriate human rights indicators and benchmarks are also needed, especially in 
relation to socioeconomic and cultural rights to assist with ‘getting a handle on the slippery 
concept of progressive realisation’ (Hunt, 2005, pp. 58). Integrating human rights into 
development entails empowering poor people, ensuring their participation in decision-making 
processes which concern them, and incorporating accountability mechanisms that improve 
transparency.  These strategies take time to develop and introduce, particularly as developing 
human rights capacity and culture amongst organisations, and society as a whole, is a long 
process (Uvin, 2004). 
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2.5 Human rights to health, the significance to access to medicines 
 
“It is my aspiration that health will finally be seen not as a blessing to be wished for, but 
as a human right to be fought for.” 
Former United Nations Secretary General, Kofi Annan 
 
The right to the highest attainable standard of health (the right to health) was first reflected in 
WHO's Constitution and has been firmly endorsed in a wide range of international and 
regional human rights instruments. 26 The most authoritative interpretation of the right to 
health is outlined in Article 12 of the ICESCR, which has been ratified by approximately 150 
countries (NZ MFAT, 2003). 
 
Since its inception the UN has focused on classic civil and political rights, such as the right to 
a fair trial. However, in 2000, the UN began to address cases of historical neglect when the 
UN Committee on Economic, Social and Cultural Rights, which monitors the Covenant, 
adopted a General Comment (14) on the right to health that further clarified the nature, scope 
and content of the right to health. 
 
The General Comment 14 of ICESCR sets out four criteria by which to evaluate the right to 
health: availability, accessibility (affordability), acceptability (medical ethics) and quality.  
This Comment acknowledged that health promotion goes beyond the health sector and that 
coordinated, multi-sector action is necessary to foster greater equity in health, income and 
social policies.  
 
                                                 
26
 Most HR and health issues are thoroughly covered at the website of the United Nations Commission on HR 
available at www.unchr.ch. Health-related information, including explicit references to HR, is available at the 
website of the WHO (www.who.org).  The Francois-Xavier Bagnoud Center available at 
http://www.hsph.harvard.edu/fxbcenter/international_hhr.htm and Global Lawyers and Physicians for HR have 
collaborated in the preparation of a ‘Perspectives in Health and Human Rights’ Gruskin (eds) (2005) which is  
accompanied by a special website containing links to documents, organisations and other references on health 
and human rights (http://www.glphr.org/resources/appendix.).  The University of Minnesota Human Rights 
Collection also provides a valuable list of documents on bioethics (see 
http://www1.umn.edu/humanrts/links/bioethics.html) 
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The Ottawa Charter 27 provides a common understanding of health promotion internationally 
which reflect the human rights ideology. It was developed at the first International Conference 
on Health Promotion meeting in 1986 as a charter for action to achieve Health for All by the 
year 2000 and beyond.  The Ottawa Charter built on the progress made through the 
Declaration of Primary Health Care at Alma Ata, the World Health Organisation's Targets for 
Health for All document, and debate at the World Health Assembly on moral action for health.  
 
2.5.1 UN Special Rapporteur on Health 
 
The UN Special Rapporteur on Health has a mandate to focus on the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health 28, as reflected in 
article 25 (1) of the Universal Declaration of Human Rights (UDHR), article 12 of the 
International Covenant on Economic, Social and Cultural Rights (ICESCR), article 24 of the 
Convention on the Rights of the Child (CRC) and article 12 of the Convention on the 
Elimination of All Forms of Discrimination against Women (CEDAW), as well as on the right 
to non-discrimination as reflected in article 5 (e) (iv) of the International Convention on the 
Elimination of All Forms of Racial Discrimination (ICERD).  
 
The Special Rapporteur is further mandated to apply a gender perspective and to pay special 
attention to the needs of children in the realization of the right to health. The role also serves 
as a useful political tool to apply pressure to developed countries to remove TRIPS-plus from 
FTAs.  For example, in 2005 a collective of international NGOs wrote to the Special 
Rapporteur citing the impact on the right to health, as interpreted by Article 12 of the 
ICESCR, for an urgent appeal to stop European-FTA member states (Switzerland, Norway, 
Iceland and Liechtenstein) from imposing TRIPS-plus rules in an FTA with Thailand.29  
 
 
 
                                                 
27
 For a description of the Ottawa Charter see WHO/HPR/HEP/95.1 at www.WHO.int 
28
 The current holder is Professor Paul Hunt.   
29
 Personal correspondence with field research interviewee, “Letter to UN Special Rapporteur on the right to 
health regarding the forthcoming EFTA-Thailand negotiations”, 20/6/05. On file with the researcher 
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2.6 Human rights and access to medicines interface with IPR 
 
“We thus find ourselves at a crossroads: health care can be considered a commodity to 
be sold, or it can be considered a basic social right. It cannot comfortably be considered 
both of these at the same time.”  
 Mr Paul Farmer, Director, People’s Health Movement, 2005 
 
During the negotiations of the TRIPS Agreement, developing countries especially voiced 
public health concerns to argue for weaker, or more flexible, patent protection in the 
pharmaceutical sector.  What had been essentially policy-based objections against minimum 
patent standards for pharmaceuticals during the negotiations started to be coined in human 
rights terminology by the UN and NGOs after the TRIPS Agreement came into force in 2000.   
 
Analytically this claim by proponents of human rights is three pronged.  Firstly, it alleges the 
existence of a legal right to access to medicine. Secondly, it asserts that the adoption of patent 
legislation, now mandatory under the TRIPS Agreement, leads to inventors charging higher 
prices because of their ability to patent new drugs, rendering those drugs unaffordable for 
parts of the population. Thirdly, it maintains that this price effect can infringe the right to 
access to medicines, and that this infringement is not justified by other considerations, such as 
the necessity of patents to enable research and development. 
 
Many proponents of TRIPS have replied to this challenge that patents are necessary to 
stimulate research for new medicine (Love, 2007; Oxfam 2007a). 30  Others have added that 
intellectual property too, is protected as a human right (Hestermeyer, 2007; Werhane and 
Gorman, 2005).  
 
In the early 2000’s, the UN human rights system began addressing trade laws and practices in 
relation to human rights law.  For example, the Commission on Human Rights in 2001 
                                                 
30
 One might tolerate the linkage of prices with R&D incentives if the system was more efficient, but globally, 
only 8.5 percent of sales were reinvested in R&D in 2005. Furthermore, only 14 percent of new drug approvals 
are both new and better than older products, and clinical trials for me-too products are about twice as large as for 
innovative drugs. See reference Love (2007) 
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adopted a resolution on access to medication in the context of pandemics such as HIV/AIDS 31 
which reaffirms that, in this context, access is a fundamental element for the progressive 
realization of the right to health.  States are called upon to promote the right to health 
indicators: availability, accessibility and affordability for all, without discrimination for 
treatments, and to adopt legislation, or measures, to safeguard access to pharmaceutical and 
medical technologies, from any limitations by third parties eg. US FTAs. 
 
2.7 Human rights case studies, political and legal challenges  
 
Two case studies (included below) illustrate how human rights may be applied to promote the 
right to health and access to medicines. 32  The first is for a human rights impact assessment of 
an FTA in Thailand, the second is an example of human rights case law in South Africa. 
 
2.7.1 The human rights impact assessment of the Thai-US FTA 
 
Thailand is an example of well organised and multi-sectoral mobilisation of human rights.  In 
1997 Thailand developed an advanced constitution where human rights, in particular, the right 
to health and community rights, figures prominently.  In 2004, the US and Thailand began 
negotiating on a comprehensive bilateral FTA.  The FTA negotiations attracted great concerns 
and opposition, yet the human rights dimensions had not been thoroughly examined.  In 2006, 
the Thailand National Human Rights Commission (NHRC), studied the potential impacts of 
the Thai-US FTA using a sub-committee of eminent experts. This was the first, and only, 
example at national level.   
 
The aim of the NHRC assessment was to inform the Thai people about the implications of the 
Thai-US FTA on their rights, and to generate a public debate for transparency and 
accountability.  The Thai NHRC also provided a clear analysis and policy recommendations to 
the Thai government to ensure that what was being negotiated was consistent with, and 
                                                 
31
 United Nations Commission on HR resolution 2001/33: access to medication in the context of pandemics such 
as HIV/AIDS (E/CN.4.RES.2001.33), available www.unchr.ch 
32
 For a description of a wide range of case studies and mechanisms used to protect HR, health and access to 
medicines see references: Robinson (2004), Gruskin (2005), Rothman (2006)  
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respected, human rights obligations enshrined in the Thai Constitution and international 
conventions to which Thailand is a party.  The health stakes were high because Thailand 
prides itself on its universal health care coverage program and, for example, the inclusion of 
HIV treatment in the 30 baht scheme.  The effect of TRIPS-plus provisions would raise drug 
prices, limiting treatment for the high (800,000) HIV/AIDS population (Oxfam, 2006a).  This 
would also mean there was no going back as HIV-positive people inevitably develop 
resistance to first-generation drugs, the public health services will be morally and legally 
obliged to find new ways to ensure access to second- and third- generation treatments to keep 
these people alive and healthy.  
 
To launch the report 33 and raise public knowledge, the NHRC organised a two day seminar, in 
cooperation with international and national partners, including the UNDP 34, followed by a 
half day expert group discussion with key participants from ASEAN countries to formulate 
regional perspectives.   The work of the group contributed to the rejection of the Thai-USFTA 
on the basis that it was contrary to the enjoyment of several fundamental human rights, 
including the right to health and access to medicines, and that it also challenged Thai 
sovereignty. The Thai government was supported in this work by UN agencies, becoming a 
global model of best practice.35  
 
2.7.2 ‘Right to health’, challenges in case law 
 
Human rights case law is a good illustration of how the right to health can be formally 
introduced into the national justice system so that it ultimately leads to concrete changes in 
government policy and to people’s wellbeing.   
                                                 
33
 Draft translation ‘report on results of examination of HR violations by ad hoc sub-committee to review and 
examine the establishment of Thailand-United States Free Trade Agreement, complainer, issues raised by the 
national HR commission, against the government and agencies of Thailand responsible for Thailand-US FTA 
negotiations, 2006’. Personal source from field research interviewee.  On file with the researcher 
34
 UNDP supported the Thai government to organise reviews of FTAs implications on A2M. In Dec 2005 for 
example, the Thailand National Technical consultation on FTAs and IPR: implications for A2M was co-
organised by MOH departments, Universities, the joint UN program on HIV/AIDS, UNDP and WHO, sponsored 
by UNDP.   
35
 Sourced from ‘Personal notes on the Thai national HR commission seminar on the HR implications of the 
Thai-US FTA’ (Bangkok 18 – 19 Jan 2007) provided by field research interview participant on file with the 
researcher.  Several of the eminent persons included the worlds leading thinkers on TRIPS and A2M (and HR). 
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A majority of the right to health case law relates to access to anti-retroviral treatment.  The 
most commonly described case is the Treatment Action Campaign (TAC) v. Minister of 
Health case in South Africa in 2002; also known as the Nevirapine case (Robinson 2004)  In 
this case, the Constitutional Court of South Africa held that the Constitution, which protects 
the right to access healthcare services, required the government to devise and implement a 
comprehensive and coordinated program to progressively realize the right of pregnant women 
and their newborn children to have access to treatment in order to prevent mother-to-child 
transmission of HIV. 
 
2.8 Conclusion 
 
Some of the main challenges to human rights identified from the literature research include: 
cultural relativism and euro-centrism, the emergence of third generation rights, for example, 
the responsibility of pharmaceutical companies in the right to health, the status of human 
rights within the neoliberal global economic order, and the need for new methodologies and 
indicators to operationalise the human rights framework.   
 
Human rights advocates need to be aware of these challenges when they draw on international 
human rights instruments to initiate change in governance, policy, legislation, and traditional 
and cultural practices in different countries.  I have taken these into consideration in 
evaluating Primary Research Objective 5 which is to assess the general scope for using human 
rights instruments to protect access to medicines in Fiji and in the wider Pacific context.  
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Chapter 3: The Pacific Context 
 
3.1 Introduction 
 
The Pacific region is comprised of 20,000 to 30,000 islands that are grouped into three main 
areas: Micronesia, Melanesia and Polynesia 36.  Approximately 90% of the 8.5 million people 
who live in the region reside in the Melanesian countries: Papua New Guinea (PNG), the 
Solomon Islands and Fiji.   
 
The region’s remoteness from major trading blocs, such as the United States, and the relatively 
small and highly dispersed population, presents major obstacles to achieving economic growth 
either through south-south trade between Pacific countries, or trade with the north. These 
factors contribute to the region’s dependence on preferential foreign trade agreements, 
remittances and international development aid. 
 
Pacific island countries are under pressure from the north to move towards formal regional 
integration, dubbed ‘new regionalism’, in order to engage with the global free trading system 
and adapt to the global security environment.  Recent negotiations with the EU to replace 
existing preferential trade agreements with a reciprocal, regional trade agreement that includes 
conditional aid administered at a regional level, rather than directly to individual countries (as 
it is currently), is a poignant example of this.  Here the EU has dictated the nature, terms and 
configuration of regional integration in ways that cut across organic developments that are 
underway based on south-south cooperation (Kelsey, 2006).   
 
The application of ‘new regionalism’ is problematic in the context of the Pacific.  Not only is 
this due to the lack of competitive or comparative advantage in most sectors, and of the 
prioritisation of economic growth over the development agenda, but because Pacific people do 
                                                 
36
 ‘Melanesian’ countries and territories consist of: Bismarck Archipelago, Fiji, New Caledonia, New Guinea 
(Papua New Guinea mainland and the Indonesian province of Papua), Maluku Islands, Solomon Islands, Torres 
Strait Islands, Vanuatu, Palau Islands.  ‘Polynesia’ includes: American Samoa, Cook Islands, French Polynesia, 
New Zealand, Niue, Pitcairn, Samoa, Tokelau, Tonga, Tuvalu, Wallis and Futuna.  ‘Micronesia’ includes the 
Federated States of Micronesia, Guam, Kiribati, Marshall Islands, Nauru, Northern Mariana Islands, Palau. 
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not view themselves as a ‘region’ in the same sense that is cultivated by Western 
neoliberalism (Thomas, 2004).  For example, Hau’ofa notes that the identity of Pacific 
islanders is associated with a seamless oceanic world where communities based themselves on 
kinship and chieftainship and traversed the oceans for trade, marriage or war (Hau’ofa, 1998).  
Furthermore, the notion of independent countries, rather than of regionalism, was imposed on 
this Pacific identity by the colonial occupation of many Pacific island countries and early 
European cultural mapping (Thomas, 2004). 
 
Concern for the region’s marginalisation in 2004 led the Pacific Eminent Person’s Group to 
develop the Pacific Plan, a framework that represents the first articulation of a new Pacific 
vision of the region and which has been signed off by all Forum Island Leaders. The Plan’s 
concept of regionalism is not as far reaching as the western concept and provides scope for 
Pacific countries to pursue self determination  and to explore their own common identity, the 
‘Pacific Way’, which is different from the neoliberal way; an identity that continues to evolve 
in response to western hegemonic discourse. 
 
An in depth analysis of the implications of regionalism in the Pacific is beyond the scope of 
this thesis. However, this research describes some of the key features of regionalism that are 
shaping how Pacific people view, and respond to, trade impediments to access to medicines; 
which is the topic of this research. 
 
This chapter describes the three separate systems that influence access to medicines in the 
Pacific region (outlined in Section 1.3) and what are some of the factors which influence 
Pacific peoples’ access to medicines.  The Chapter commences with the demand-side; a 
description of population health trends and public health services.  The focus then moves to 
the supply side and elaborates on the regional and national trade policymaking mechanisms in 
the Pacific.  Here, the potential impact of proposed international trade agreements (EU EPA 
and PACER) on access to medicines is discussed, along with the diverse forms of national 
intellectual property rights law that currently exist.  The chapter concludes with a description 
of the architecture of human rights mechanisms in the Pacific region and how human rights 
are perceived by Pacific people. 
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The countries comprising the Pacific region are: the Cook Islands, Federated States of 
Micronesia, French Polynesia, the Fiji Islands, Kiribati, Nauru, New Caledonia, Niue, Palau, 
Papua New Guinea, the Republic of Marshall Islands, Samoa, Solomon Islands, Tonga, 
Tuvalu and Vanuatu. 
 
3.2 Overview of health trends and services in the Pacific   
 
3.2.1 Pacific population health trends  
 
Despite good progress being made in selected health statistics in some PICs, there is 
increasing concern over the variation in health statistics between, and within, countries with 
progress slowing down or reversing in some areas. Furthermore, the MDGs progress report 
showed that some PICs are unlikely to achieve the health-related goals by 2015 without 
significant additional investment in health and related sectors (Tukuitonga, 2006).   
 
The economies of several PICs are static or in decline, and despite substantial external 
development assistance over several decades, indicators are that living standards have either 
deteriorated or only slowly improved.  Health indicators suggest that much more needs to be 
done to improve health in the region and to offset some of the adverse effects of poor 
economic performance, political instability, urbanization and globalisation, and fragile health 
systems.  
 
The region is undergoing a demographic transition in which birth and mortality rates continue 
to decline, although several PICs continue to have high fertility rates. Morbidity and mortality 
patterns are also changing in the region, and notably age-standardised all-cause death rates are 
two to three times higher than in neighbouring developed countries.  Although each country 
exhibits its own health trends, there are some common trends. 
 
As seen in Table 1, non communicable diseases (NCDs) and their common risk factors, 
including unhealthy diet, inactivity and tobacco use, are the leading causes of death, disease 
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and disability in all PICs.  For example, NCDs accounted for 70 - 75% of all deaths in all PICs 
except for PNG where they accounted for 58%.  Pacific overweight and obesity rates are 
among the highest in the world, with seven PICs ranked in the top ten most obese countries in 
2007 (WHO, 2007c). Obesity can slice 2-3% off the gross domestic product (GDP) in indirect 
costs to the economy as a result of poor health and an inability to work. 
 
After NCDs, communicable diseases, maternal, perinatal conditions and nutritional disorders 
are the second largest group of conditions causing death. Generally, this group accounted for 
about 20% of all deaths in most PICs except in Kiribati (27%) and PNG (34%).  Diarrhoeal 
diseases and tuberculosis are the leading infectious diseases causing death. WHO estimates 
that over 4% of the global burden of disease is accounted for by diarrhoeal diseases, mainly 
concentrated in children, and that 88% of this burden is caused by unsafe water supply, 
sanitation and hygiene. Deaths caused by HIV/AIDs were infrequent in all PICs except in 
PNG which is experiencing annual increases in HIV/AIDS of 15-30% (similar in scale to sub-
Saharan Africa in 1992). Left unchecked it could affect 30% of all women by 2010.  
HIV/AIDS is also a rising problem in Fiji.  
 
The proportions of the three major causes of death in each country are depicted in Table1 
below. 
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Table 1: Age standardised death rates per 100,000 and proportion (%) by cause, by 
country. 2002. 
 
Country 
 
All 
Causes 
(Age Std 
Rate)  
NCDs 
(Age Std Rate  
and % of all 
deaths) 
Communicable, 
Maternal, Perinatal, 
Nutrition 
(Age Std Rate and 
% of all deaths) 
Injuries  
(Age Std Rate 
and % of all 
deaths) 
American Samoa Na Na Na Na 
Cook Islands 817 616 (75) 163 (20) 38 (5) 
Fiji 1,065 825 (77)  200 (19) 40 (4) 
Kiribati 1,099 773 ( 70) 303 (28) 22 (2) 
Marshall Islands 1,333 998 (75) 274 (21)  62 (5) 
Micronesia 1,062 782 (74) 242 (23)  39 (4) 
Nauru 1,446 1,136 (79) 178 (12) 132 (9) 
New Caledonia Na Na Na Na 
Niue 856 637 (74) 181 (21) 39 (5) 
Palau 968 744 (77) 186 (19) 39 (4) 
PNG 1,413 815 (58) 494 (35) 104 (7) 
Samoa 1,026 782 (76) 204 (20) 40 (4) 
Solomon Islands 1,092 786 (72) 269 (25) 37 (3) 
Tonga 888 684 (77) 174 (20) 29 (3) 
Tuvalu 1,428 1,046 (73)  314 (22) 69 (5) 
Vanuatu 1,033 772 (75) 223 (22) 38 (4) 
Source: http://www.who.int/healthinfo/bodestimates/en/index.html 
 
 
3.2.2 Pacific health care provision 
 
In the region, health care systems are organised into three levels: community-based 
health/nursing stations (primary care), district or provincial health centres, and central 
hospitals (secondary care).  These systems provide services for the whole country, including 
remote areas and outer islands.  Due to a lack of in-country capacity and facilities most small 
PICs provide a referral system for specialised medical care (tertiary care) to overseas health 
facilities.  These referrals consume up to 20% of total health care expenditure in some 
countries which further depletes budgets allocated to drugs (Tukuitonga, 2006). 
 
As documented, health care systems are generally orientated towards primary health care with 
the bulk of services provided by nurse practitioners and non-physician providers from village 
and district-based facilities.  Reform of health care systems has been undertaken in several 
PICs including Fiji, Samoa,Vanuatu and PNG.  These have focussed on improving policy, 
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planning and management of health services and health care financing arrangements. Reforms 
are ongoing and the impact on health systems and outcomes remains uncertain.  Several PICs 
have decentralised their health systems, which may have inadvertently contributed to the 
problems of providing a basic level of secondary health care. 
 
3.2.3 Pacific health care financing 
 
Governments are the major funders and providers of health services in the Pacific with limited 
private provision in Samoa and Fiji. Under WTO GATS, countries may elect to include 
‘health’ in their set of services nominated for trade liberalization.  This is how foreign health 
insurance can enter local markets.  However, countries may also apply ‘certain conditions’ to 
the liberalization to gradually introduce the transition. Table 2 shows selected health care 
expenditure indicators in some PICs.  The proportion of GDP spent on health care and the per 
capita expenditure varies considerably within the region with high rates of per capita 
expenditure in Pacific Island Territories affiliated with France, USA and NZ (except the Cook 
Islands).   
 
As seen, the three most densely populated PICs (Fiji, PNG and the Solomon Islands) spend 
proportionately lower amounts of GDP on health (3.4%. 3.7% and 4.8% respectively) while 
countries in Micronesia and Polynesia generally spend a higher proportion of GDP on health 
compared with Melanesian countries.    
 
There is no recommended level of national health spending although 5% of GDP is generally 
used as a benchmark level, in particular for primary health care and health system support.  
Table 2 shows at least five PICs are below this level. The recommended per capita health 
spending per year is $35USD (WHO, 2006b) and PNG and the Solomon Islands are below this 
benchmark (refer to Table 2 below).  
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Table 2: Indicators of health expenditure by selected Pacific Island Countries, 2003 
Country/ 
Population 
Per capita 
health 
expenditure 
US$ (2003) 
# 
 
 
Total 
expenditure 
on health 
as % of 
GDP 
General 
Government 
expenditure 
on health as 
% of total 
expenditure 
on health 
Private 
expenditure 
on health as 
% of total 
expenditure 
on health 
General 
government 
expenditure 
on health as 
% of total 
govt. 
expenditure 
External 
resources 
for health 
as % of 
total 
expenditu
re on 
health 
American 
Samoa 
500 na 98.0 2.0 14.0 70.0 
Cook 
Islands 
294 3.8 87.9 12.1 9.6 12.2 
Fiji 
846,090  
104 3.7 61.3 38.7 7.8 13.4 
Kiribati 
99,000 
96 13.1 92.4 7.6 7.8 0.8 
Marshall 
Islands 
255 13.1 96.7 3.3 14.4 16.4 
Micronesia 147 6.4 88.0 12.0 8.8 na* 
Nauru 798 12.3 88.5 11.2 8.8 Na 
New 
Caledonia 
1558€ 9.2 Na na na Na 
Niue 
1,200 
655 9.7 98.4 1.6 9.3 9.2 
Palau 607 9.7 86.7 13.3 15.2 15.8 
PNG 
5.8mill 
23 3.4 88.9 11.1 10.9 28.3 
Samoa 94 5.4 79.0 21.0 20.1 18.9 
Solomon 
Islands 
478,000 
83** 4.8 93.4 6.6 9.4 68.5 
Tonga 102 6.5 85.1 14.9 21.2 30.9 
Tuvalu 142 6.1 83.3 16.7 6.0 70.5 
Vanuatu 
211,000 
54 3.9 73.8 26.2 12.9 25.4 
New 
Zealand 
1618 8.1 78.3 21.7 17.2 0 
Australia 2519 9.5 67.5 32.5 17.7 0 
#WHO Western Pacific Region internet statistical tables. Refer to data for year of collection 
* previous average of 11.8% for the last 4 years 
** $US83 was submitted by the country and referred to the General Government Health Expenditure at internal 
dollar rate. The per capita health expenditure for 2003 was $US28. 
Source: World Health Report 2006 except CHIPS for American Samoa and New Caledonia  
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While the share of GDP spent on health and government expenditure on health as a percentage 
of total health expenditure is comparatively high in some PICs, these indicators do not reveal 
an accurate picture of health spending. This is because unit costs are high in the region due to 
the high cost of transportation and communication which exists in small island developing 
states.  The government is expected to provide the full range of services even though 
throughputs can be extremely low for some specialist services.  As noted also Pacific 
governments are reliant on developed countries for some off-shore treatment, which the 
Pacific government pays for at great cost.   
 
Therefore, even though the share of GDP spent on health is higher in some PICs, this level of 
expenditure may be insufficient to meet the cost of providing basic health care services.  For 
example, Kiribati and the Marshall Islands spend in excess of 13% of GDP on health.  
However the isolation and remoteness of the islands are a factor as they have higher infant 
mortality rates and maternal mortality rates, and lower immunisation coverage in the region.  
Conversely, Fiji and the Cook Islands have better results for the same indicators yet they 
spend less than 4% of GDP on health (WHO, 2006b).  
 
Private expenditure on health is highest in Fiji, Samoa and Vanuatu where the government 
share are also the lowest in the region. For example, government expenditure as a percentage 
of total health expenditure is lowest in Fiji (61%) and Samoa (79%) which corresponds with 
higher private contributions.  In the case of Fiji, 100% of private funds are derived from 
patients paying for their own medicines, a term called ‘out-of-pocket payment’.  In contrast, 
78% of private contributions in Samoa are derived from people making their own payments 
out-of-pocket.  However, health outcomes and health system performance indicators are 
comparable in both countries.   
 
Private expenditure on health is usually made from out-of-pocket expenses as prepaid, and 
insurance, schemes are rare in the region.  Out-of-pocket expenses have increased 
considerably in recent years in the region but detailed information is not available.  User fees 
are reported to be widely used in several PICs mainly for primary care, pharmaceuticals and 
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related services but most hospital services are free. 
 
3.2.4 Regional medicines initiatives 
 
A ‘Regional Strategy for Improving Access to Medicines in the Western Pacific Region 2005-
2010’ has been developed by the PIFS and Pacific Health Ministers, in conjunction with the 
WHO (WHO, 2005), and partly funded and resourced by the European Community.  The 
strategy has eight technical areas of work including: collective procurement, access to 
medicines, trade globalisation and the TRIPS Agreement.  The WHO WPRO office in Suva is 
the lead coordinating agency.   
 
The information gathered from literature research and participant interviews did not indicate 
that the TRIPS agreement and trade issues feature very strongly in this WHO regional 
strategy, which will be discussed further in the findings in Section 5.2.  The SPC is also 
investigating the benefits of collective pharmaceutical procurement for communicable 
diseases under various regional public health programmes.  Larger PICs, such as PNG and 
Solomon Islands, have indicated they are unlikely to benefit from a regional procurement 
approach.   
   
3.3 Overview of key trade agreements and trade policymaking in the 
 Pacific  
 
3.3.1 Trade policymaking mechanisms in the Pacific  
 
Trade policymaking in Fiji is institutionally linked to the Forum Secretariat at a regional level, 
where Fiji is represented by its Prime Minister as a Forum Leader, and at the Forum 
Secretariat by its Minister of Foreign Affairs and External Trade.  Prior to the 2006 coup, Fiji 
used to share an alternating leadership role with Samoa for the Pacific ACP Regional 
Negotiating Team which meets with European Commissioners to resolve political and policy 
matters.  The Forum Trade Ministers are advised by the Trade Experts Advisory Group 
(TEAG) who prepares regional strategic documents.  When TEAG was created, discussions 
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with regional NGOs resulted in the Pacific Concerns Resource Centre (PCRC) providing a 
member from civil society to join in discussions with this advisory group, but information and 
representation at meetings was reported to have been obstructed and there were few resources 
to support this work (Kelsey, 2005). 
 
It is likely that trade agreements that are specific to Fiji, such as the Bilateral Trade Agreement 
being negotiated with New Zealand and China, are formulated at a national level, without 
reference to the Forum Secretariat.  However, it can be assumed that many of the resources 
and key trade personnel involved in these are common to both.  This situation raises issues of 
accountability and sovereignty.  
 
Regional representation, such as the PIFS, in trade negotiations is not uncommon amongst 
small developing economies, for example the Caribbean small island developing states has a 
similar mechanism.  However this mechanism introduces issues that would not exist if trade 
policymaking remained exclusively within the national domain.  These national and regional 
issues need to be thought through and proactively managed. They include: legal and 
sovereignty rights; access to research undertaken by other members of the regional negotiating 
team, which are officially limited (Kelsey, 2005); accountability and the  increasing risk that 
agreements will only be approached from a trade perspective (Kelsey, 2004). 
 
The role of the PIFS is to provide technical assistance on trade and economic issues requested 
by Forum Leaders.  This assistance includes alerting national leaders to trade obligations of 
significance to their economies.  This regional structure draws on the technical expertise and 
support of ten independent agencies, referred to as the Council of Regional Organisations in 
the Pacific (CROP).  These provide technical advice to the PIFS, and to individual PICs that 
lack the capacity, across a range of scientific, social, and cultural areas. The CROPS 
collaborate with UN agencies and foreign aid agencies on numerous regional programmes 
such as the Pandemic Preparedness Programme coordinated by the Secretariat of the Pacific 
Community (SPC) in conjunction with WHO. 
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3.3.2 Impact of international trade agreements on access to medicines in the Pacific 
 
Most PICs are signatory to several, often overlapping, multilateral, regional and bilateral 
agreements.37 These are listed in Appendix 3.  The number and complexity of the various 
trade agreements and official deadlines set for negotiations places significant pressure on the 
governments whose ability to effectively respond is limited by factors such as a lack of 
financial and technical resources, human resources, expertise and analysis.   
 
The proposed regional trade agreement between the EU and 14 PICs (EU EPA) is the most 
current, and relevant to access to medicines, not only because of the potential TRIPS-plus, and 
PCT membership, but because it can trigger PACER.  If PACER is triggered, the PICs could 
be obliged to commence negotiating this trade agreement with Australia and New Zealand and 
to offer similar concessions made in an EU EPA.   
 
The EU’s primary interest is to liberalise trade and to introduce regulatory reform and TRIPS 
(Oxfam, 2006b).  The proposed texts and responses from the EU suggest that the treatment of 
IPR under the EPAs is more likely to converge with the practice of the US, which has TRIPS-
plus provisions in FTAs.  These include obligations with standards of protection beyond those 
required by the WTO TRIPS Agreement and compromise the use of TRIPS flexibilities in the 
Doha Declaration (CIEL, 2007) which are opposed by the international development 
community (Correa, 2007).  If an agreement had been signed with all 14 PICs in 2007, the EU 
had earlier signaled IPR issues would be negotiated in 2008.38  
 
These terms of the EU would apply to all PICs signed up to the EPA, regardless of their 
existing WTO member status.  Patent activity could be expected to increase significantly as a 
result, including pharmaceutical patents, which could impeded access to medicines through 
raising the price of patented drugs and block the importation of cheaper generic versions of 
that drug, even several years after the patent expired. 
 
                                                 
37
 For updates on the trade negotiation processes see www.bilaterals.org.   
38
 For a description of the EU EPA trade negotiations with the PICs and other updates see, for example, the 
website of Oxfam New Zealand (2007)  
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Under special circumstances, such as a national health emergency (where patents are 
restricting access to cheaper medicines) governments in developing countries have the ability 
to use Compulsory Licences (CL).  A CL permits the government to import, or to 
manufacture, medicines that are patented in their country, without the patent owners consent.  
These medicines must be used to respond to public health crises and not sold for commercial 
gain.  TRIPS-plus provisions can either limit the use of compulsory licences, or block generic 
manufacturing using data exclusivity and linkage evergreening provisions.  
 
As this thesis was being written in early December 2007, Fiji and PNG, under pressure from 
the EU, had negotiated individual agreements rather than continuing to negotiate as a regional 
bloc.  A full evaluation of the content of these individual agreements and the economic and 
political significance to the individual countries, and to the region as a whole, was not yet 
published in the public domain when this thesis was being written.  
 
3.4 Overview of intellectual property rights in the Pacific  
 
“It is the responsibility of all of us to raise TRIPS and access to medicines issues, not 
just leave it to one or two specialised health-related agencies” 
Dr Stuart Watson, Pacific Regional Coordinator, UNAIDS, interviewed October 2007 
 
A comprehensive explanation of the key treaties dealing with substantive patent law (which 
includes the Paris Convention and Patent Cooperation Treaty (PCT), and of WTO membership 
status, the main features of national intellectual property law, application in the Pacific of the 
Doha Declaration and the Paragraph 6 Decision and of traditional knowledge model law) is 
included in Appendix 4. Several of the key features of intellectual property rights and of these 
treaties are discussed here because they contribute to how Pacific islanders view trade and 
access to medicines. 
 
Firstly, the PICs are net ‘users’, rather than ‘generators’, of intellectual property rights.  
Secondly, although there is a low membership of international IP treaties, most PICs have 
national patent laws which vary widely and are influenced by factors such as WTO 
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membership activity, donor assistance and colonial-era regimes. Thirdly, PNG, Tonga, Fiji 
and the Solomon Islands have international obligations regarding substantive patent law under 
WIPO and WTO.  By 1 January 2005, Fiji and PNG had to provide patent protection for 
pharmaceutical products.  Being an LDC, the Solomon Islands do not have to comply until 
2016 (and until 2013 to implement other elements), while Tonga, under its WTO accession 
package, has until 1 June 2008.  Fourthly, in some countries, the Patent Office function is 
limited to re-registration of patents already granted in another nominated country, for example 
the United Kingdom, while in others, all patents are registered without scrutiny and their 
validity tested in court if they are ever appealed. Search and examination capacity is limited 
and the IP offices of Tonga, Fiji and PNG has an arrangement with IP Australia to provide 
patent searches and examination (Farquhar, 2005).  Fifthly, the economic and cultural 
preferences for allocating limited resources to further developing the framework for traditional 
knowledge instead of to developing regional policies and strategies for IPR also appear to be 
relevant to this discussion.   
 
PICs continue to face unauthorized use of their traditional knowledge (Mead, 2007) which, in 
the main, conventional IP law fails to protect.  A model law on ‘Traditional Biological 
Knowledge, Innovation and Practices’ was drafted in 2000 by the South Pacific Regional 
Environment Programme (SPREP). This involved considerable national and regional 
discussion.  It will be developed further in 2008 by the PIFS.  However, resource constraints 
mean that any further IPR initiatives are suspended over that same period, in preference for 
resources being allocated to the development of a traditional knowledge framework.  The 
Pacific Plan refers to a regional institution, such as the SPC, developing a regional framework 
for the Pacific cultural identity and for this framework to (ambitiously) force both IPR and 
traditional knowledge to concede to wider development objectives. 
 
Finally, the patent activity is relatively low and the majority of applications are made by 
foreign applicants, many of these patents are in the pharmaceutical categories (Ey, 2005).  
This activity can be expected to rapidly increase if TRIPS obligations, or PCT membership, 
are introduced to more countries in the region.  The literature research and field research 
interviews suggest this could happen as a result of four independent mechanisms: through 
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regional trade agreements that require all countries, not just WTO members, to implement 
TRIPS and/or to join the PCT; when more countries accede to the WTO; if IPR functions were 
integrated and centralized through a regional patent office, making it easier for foreign 
applications to be registered in several countries at once; in the long term if a review of 
collective medicines regulation were to result in joining the Australian TGA (or proposed 
ANZTPA) that already incorporates TRIPS-plus patent obligations inherited under the Aust-
US FTA. 
 
3.4.1 Patent cooperation treaty 
 
The draft EU EPA being negotiated in 2007 signaled a requirement for all PICs to join the 
Patent Cooperation Treaty (PCT). At present only PNG is a member of PCT.  After it joined in 
2003, one information source indicated that PNG had received 940 designations and that it 
appeared to be routinely designated under the PCT by applicants (Drahos, 2007).  If other 
PICs join the Treaty, the current low rate of patent registration in the region is expected to 
escalate dramatically (Ey, 2005).  
 
There are currently only a few PCT offices worldwide capable of examining PCTs, prior to 
filing in individual countries.  The financial investment required to establish these offices and 
the specialised knowledge required to examine the patents are prohibitive for developing, and 
some smaller developed, countries to consider establishing.  For example, New Zealand uses 
IP Australia to file PCTs in this region.  PICs are likely to have no option but to do the same, 
which would be a reasonable solution if they conceded to join PCT.  
 
PCTs are usually examined using a more flexible set of criterion than in individual countries.  
When the patent holder decides to file in individual countries it is up to the national patent 
office in that country to re-examine the patent against its own (usually stricter) patent law to 
determine if it will be accepted.  However, PICs would not have the capacity to examine each 
PCT case, and therefore may end up accepting products that other countries may reject, such 
as pharmaceuticals dumped on them with commercial rights to raise their price.   
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3.5 Overview of human rights mechanisms and challenges in the Pacific 
 
“You cannot look at human rights in the Pacific without looking at custom.  There is a 
perceived conflict between human rights and custom - a cultural relativist approach.  
Advocacy around custom and advocacy around human rights has caused conflict and a 
better quality of advocacy around both is required.  There is a need to walk through the 
issues on a case by case basis rather than parking human rights, or custom, to one side 
and trying to advance one without the other.” 
Ms Joy Liddicoat, Commissioner, NZ Human Rights Commission, interviewed November 2007  
 
This section builds on the background information provided in Chapter 2 and discusses 
existing human rights mechanisms and obstacles to its application in the Pacific region. 
 
3.5.1 Institutions and mechanisms 
 
Regional networks between national human rights mechanisms are encouraged by the UN 
General Assembly and exist throughout the world, with the exception of the Asia-Pacific 
region.  The possibility of including the Pacific in an Asia-Pacific regional human rights 
mechanism has been suggested, but it is recognised that the two areas are so diverse, 
presenting a major obstacle to achieving this.  Other regional networks, such as Africa, 
America and Europe, share a greater degree of cultural and philosophical homogeneity (New 
Zealand Law Commission, 2006).   
 
If there were a regional mechanism it may be preferable to limit it to the Pacific which 
constitutes a distinct region, or possibly start with sub-regional mechanisms covering countries 
that share particular cultural and historical affinities.  This could take the form of including a 
human rights desk at the PIFS for example.  
   
There has been progress in regional human rights dialogue and cooperation in recent years 
through: (i) annual workshops in the Asia Pacific Forum of National Institutions under the 
mandate of the UN Commission, and (ii) a process founded on national institutions and the 
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benchmarks of the Paris Principles.  
 
The Pacific region has the lowest ratification rates worldwide of the core international human 
rights treaties.  There is however, a broad infrastructure for the promotion and protection of 
human rights in the Pacific amongst the existing institutions (PIFS/NZHRC, 2006), albeit 
some of these are in their early infancy.  Human rights mechanisms vary widely amongst the 
PICs.39  They include national constitutions, parliamentary systems, governance structures and 
systems, legal systems (including the judiciary), an active civil society and regional 
mechanisms.  The efficacy and efficiency of these systems are highly contested and Pacific 
leaders have acknowledged, in the Pacific Plan 40, that more work is needed to fine these up.  
Initiatives for the first three years include steps to support regional consolidation of key 
institutions such as audit and ombudsman offices, custom, leadership codes and departments 
of attorney-generals that underpin good governance. 
 
The Law Commission currently notes that Pacific people raise three broad concerns about 
human rights: limitations on progressing them as a result of competing and significant 
demands on limited resources, onerous international treaty body reporting obligations, and 
tensions at the interface between custom and human rights (New Zealand Law Commission, 
2006). 
 
3.5.2 Concerns between custom and human rights 
 
“In the Pacific region there is some resentment about the concept of rights.  Some of our 
leaders are fond of decrying them as western or alien concept at odds with our values.  
Human rights is universal in nature… Interestingly, it is not the downtrodden, the 
oppressed or the marginalized who make the criticism.  It is those of us who are part of 
established power structures that query the applicability of these rights” 
                                                 
39
 For a thorough discussion of existing infrastructure and attitudes to HR refer to NZ Law Commission, 2006 
and visit the UN website www.unchr.ch 
  
40
 In 2004, the PIFS leaders adopted a vision for a ‘region of peace, harmony, security and economic 
prosperity….respected for quality of governance, the sustainable management of resources, the full observance of 
democratic values, and for its defence and promotion of human rights”.. The leaders agreed to give effect to the 
vision through the Pacific Plan, which was endorsed in 2005. 
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Ratu Joni Madraiwiwi, Vice President of Fiji, 2006 41 
 
Strong philosophical differences exist in the Pacific, particularly relating to the interface of 
custom and human rights (PIFS/NZHRC, 2006).  For example, Pacific people view the good 
of the family as paramount rather than individuals; a fundamental difference that reinforces 
the concept of cultural relativism discussed earlier in Section 2.4.1.  Furthermore, in contrast 
to human rights instruments, customary rights are not codified so they cannot be separated 
from the people enacting them.  As a consequence, customary rights, and the many forms of 
traditional courts and accompanying traditional law, are changing as community opinions 
evolve in response to human rights and globalisation.  
 
These differences are highlighted in a recent village banishment case in Samoa where, despite 
a High Court ruling, there remained a wide range of views about a proposed commission of 
inquiry to examine inconsistencies between the application of the Village Fono Act and the 
Constitution of Samoa (PIFS/NZHRC, 2006).  This situation is acknowledged in the Pacific 
Plan where the PIFS has identified the need to consider how best to reconcile traditional 
systems with formal legal systems, including human rights law. 
 
However, the quote by Ratu Joni Madraiwiwi (above) suggests human rights upsets a political 
economy associated with, and advantaged by, custom.  The group of people who are ‘part of 
the established power structures’ are also the potential beneficiaries.  Resistance to human 
rights can therefore originate from a range of sources, including the church, local police and 
provincial council workers, who feel their authority may be threatened.    
 
Conflicts also exist, for example in relation to children’s rights, where there is a general 
misconception that giving women and children rights might undermine patriarchal authority 
and the parent’s respectively.  Human rights education is needed to shift this perception to 
enable people to understand how human rights can be used to improve social, economic and 
cultural rights.  A New Zealand Human Rights Commissioner observed, ‘The thesis of the NZ 
Law Commission Report on custom and human rights in the PICs is that the values that 
                                                 
41
 Custom and HR workshop, Nadi, 1May 2006 in, NZ Law Commission  (2006). Converging Currents. pp. 15 
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underlie custom, and the values that underlie human rights, are shared.  Human rights provide 
a vehicle for custom to be valued and vice versa.’ 42 
 
The NZ Law Commission Report discusses the current approach and role of several state and 
non state actors and makes suggestions for the way forward.  These range from noting that UN 
agencies active in the Pacific 43 have the potential to support PICs to build on customary rights 
and human rights, while long term aid donors such as NZAID, AusAID and ADB, having a 
role in capacity building 44.  Furthermore, civil society organisations, for example NGOs, trade 
unions and churches, that provide welfare and other services and engage in advocacy on 
social, economic and political rights are acknowledged as having a significant role in making 
human rights culturally meaningful and in helping to enhance customary governance by 
harmonising it with human rights principles (Fairbairn-Dunlop, 2002) 45.   
  
Above all, it is acknowledged that Pacific people need to be in control of change in their 
societies and of shaping harmonisation of human rights and custom.  The NZ Law 
Commission Report identified a common accord on fundamental Pacific values and an agreed 
approach to resolving the tension between custom and human rights would be a necessary step 
for achieving such consensus. 
 
The information from this literature research on human rights, together with field research 
interviews provide an understanding of some of the challenges and opportunities for using 
human rights (and any future human rights and customs blend) more extensively than it is 
perhaps currently, to help protect access to medicines in Fiji and the Pacific region.  Key 
findings and responses relating to human rights instruments are discussed in Section 5.2.5 and 
Appendix 5, respectively. 
                                                 
42
 Field research interview participant 
43
 See United Nations Development Programme (2007) and UNCHR Pacific Regional Centre  
http://www.regionalcentrepacific.undp.org.fj, accessed 7/11/07 
44
 For example, NZAID is to work with traditional leaders in Vanuatu in reforming the corrections system.  
Oxfam recently suggested the strengthening of customary dispute resolution systems in the Solomon Islands: 
Oxfam Australia and Oxfam NZ ‘Bridging the gap between State and Society: New directions for the Solomon 
Islands (2006) 26. The reference UK DFID (2004) relates to a briefing paper that considers strategies for 
engagement with non-state justice systems (including customary systems)   
45
  Useful documents on civil society in the Pacific are available in the South Pacific Civil Society Library at 
http://www.vanuatu.usp.ac.fj, last accessed 5/11/07 
 57 
 
3.6 Conclusion 
 
Pacific people are reliant on their national governments to provide health care services and 
medicines.  A significant difference in the level of awareness of trade and access to medicines 
in the Pacific region compared with some other developing countries might be explained by 
relative differences in population size, level of industrialisation, range of primary healthcare 
services and content of international trade agreements and TRIPS provisions.  However, other 
contextual issues that are specific to the Pacific region also appear to be shaping the findings 
in this research.   
 
The Pacific region is comprised of several independent small island developing states, which 
face their own set of development obstacles as a result of diverse ethnicity, geographic 
remoteness, isolation, and poor competitive or comparative advantage.  Furthermore, the 
region is under pressure to enter the global trading system as a regional trading bloc and to 
deepen trade liberalisation while making concessions in areas such as TRIPS provisions that 
subsequently affect the government’s ability to deliver public goods, including access to 
medicines.  
 
The concept of regionalism appears to have a significant influence on how Pacific people view 
trade and access to medicines.  Firstly, this is because Pacific people have not historically 
identified with regionalism, which is by and large an externally imposed concept, raising 
major issues of national sovereignty and prompting the exploration of regional identity in the 
‘Pacific Way’.   
 
Secondly, regional integration initiatives under the Pacific Plan and regional trade negotiations 
with the north are introducing a new layer of mechanisms that have an influential effect.  
Some examples of these include the strength of institutional linkages and policy coherence 
between regional agencies, for example PIFS and SPC, and between regional and national 
stakeholders, for example information sharing and domestic trade representation in regional 
negotiations.  The capacity of the CROPS to deliver strategic policy advice as well as 
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technical assistance to the PIFS and to individual PICs is a further factor while, interestingly, 
the juxtaposition of traditional knowledge and IPR, and how these two systems are perceived 
by Pacific people as instruments to protect access to public goods and to contribute to 
economic development are also significant.    
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Chapter 4: The National Context 
 
4.1 Introduction 
 
Fiji is one of the larger and more developed PICs.  Fiji’s geographic location and 
comparatively better developed infrastructure provide a hub for local islands to develop their 
industry and exports.  The main sources of foreign exchange, which include sugar, agriculture, 
mining, garments and tourism, are currently in general decline.  The cessation of preferential 
trade agreements and the failure to capitalise on the export sector’s temporary market strength 
(Robertson, 2006), ethnic tensions and political instability are some of the reasons for their 
collapse.   
 
With sugar and garment production in decline, Fiji is now more reliant on tourism, an industry 
which is most vulnerable to political instability.  This sector has been pushed into further 
decline by the 2006 coup, the latest in a series of four coups since colonial independence in 
1970, with two coups taking place in 1987 and one in 2000. 
 
With the gradual loss of preferential trade agreements, Fiji (and other PICs) is being pressured 
to sign reciprocal trade agreements with major trading partners in the north. Such agreements 
are modeled on the free market liberalisation of goods and services with far reaching 
provisions that restrict development policy space (Stiglitz, 2005). Changes to a country’s 
intellectual property rights law that restrict the parallel importation of cheaper pharmaceuticals 
is an example of this.  Thus, Fiji is facing the collapse of previous export earning industries, 
such as sugar and textiles, at the same time as being expected to deepen, and expand, its 
current liberalisation process.  Further, these trade agreements are likely to contain provisions 
that impact on national sovereignty and the ability to achieve culturally appropriate, 
sustainable development.   
 
Fiji’s failure to sustain economic growth has been criticised by proponents of free trade who 
attribute this to aid dependence, public sector cronyism and corruption (Chand and Bowna, 
2007; Hughes, 2003). In contrast, opponents of the hegemonic free trade model point out that 
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trade agreements must be development-friendly (Oxfam, 2005; Oxfam, 2006b) and require 
‘good governance’ to bring about the synchronised actions of deepening and diversification of 
economic activity and the construction of social and economic infrastructure to achieve 
sustainable development (Robertson, 2006). 
 
This chapter provides a brief introduction to Fiji and examines the national process for trade 
policymaking and the capacity of public and civil society organisations to deliver trade and 
health advocacy.  This is followed by a description of national medicines procurement process 
and of the main features of the national intellectual property law. Here I also describe how 
pharmaceutical patents are examined.  The final section elaborates on the challenges and 
application of human rights instruments by government, UN agencies and NGOs. I conclude 
by reflecting on the key factors that shape Fijian people’s views of trade and access to 
medicines and compare these with factors in the broader context of the Pacific region.  
Information in this chapter is drawn substantially from my field research interviews.  It is 
noted that many of the processes described do not appear to be as concisely documented in 
primary literature sources. 
 
4.2 Overview of the Republic of Fiji Islands 
 
The Republic of Fiji Islands is located in the South Pacific and comprises 332 islands, 
approximately one third of which are inhabited. The two largest islands, Viti Levu and Vanua 
Levu, contain most of the population of 850,000 (2005) with around 20% residing in the 
capital, Suva (ADB, 2006). 
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Figure 1: Map of Republic of Fiji Islands (source: NZ MFAT, 2006) 
 
Fiji’s population is composed of indigenous Fijians (54%), Indo-Fijians (39%) and other 
ethnicities (7%). The estimated annual population growth rate per annum is 0.99% (1990-
2005), the fertility rate is 3.3 children per woman, infant mortality is 18 per 1000 (2002) 
(UNDP, 2005) and more than 90% of adults can read and write.  In 2003 life expectancy at 
birth was 67.8 years.  The World Bank classifies Fiji as a lower middle-income country and 
the estimated Gross Domestic Product per capita in 2004 was FJD3384 ($1,952.40USD) 
(ADB, 2006).  Estimates are around  25% (1:4) of households live below the poverty line due 
to uneven distribution of income. An additional one third of all households are highly 
vulnerable to poverty as a result of the flatness of the income distribution.  The incidence of 
poverty is equally as high amongst the Indo-Fijian population, although this tends to get 
overlooked. In the Human Development Index Fiji was ranked 92 out of 177 in 2003 (UNDP, 
2005).  
 
Economy and international trade 
 
As noted, Fiji’s economy is primarily based on sugar, agriculture, mining, garments and 
tourism.  Tourism is Fiji’s largest source of foreign exchange which, together with 
distribution, transport and communications, contributes to approximately 20 percent of GDP 
(NZ MFAT, 2006).  Political instability has contributed to a decline in tourism in recent years.  
It is important also to emphasise that the garment industry and sugar exports have also 
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declined after the gradual phasing out of preferential trade agreements.  For example, the sugar 
industry thrived because of preferential trade with Europe under the Sugar Protocol (that 
guaranteed up to three times the then world prices for at most 70 per cent of its production), 
while the export-oriented textile industry grew under preferential export conditions in 
Australasia after 1980 and later in the United States and Europe (Robertson, 2006).  
 
Fiji acceded to the GATT in 1993, becoming a member of the WTO in 1996.  It accords at 
least Most Favoured Nation (MFN) tariff status to all its trading partners.  In common with 
most PICs, Fiji is also signatory to several overlapping regional and bilateral agreements. 
These agreements, and the regional mechanisms for trade policymaking, are discussed in 
Section 3.3.  
 
The proposed EU EPA currently has the most relevance to protecting access to essential 
medicines because it is likely to contain reciprocal trade arrangements, TRIPS provisions and 
obligations that restrict health development policy space. In early December 2007, under 
considerable pressure from the EU, Fiji and PNG, whose economies are most reliant on trade 
with the EU, broke away from the regional group of 14 PICs to sign individual agreements.  
An anaylsis of the content and of the economic and political implications of this tactic by the 
two countries had not yet been prepared as this thesis was being written.   
 
Political environment  
 
Since gaining independence from Britain in 1970, Fiji has experienced four coups as a result 
of many factors, some of which relate to the underlying ethnic tension, policy that favours 
indigenous Fijians and government corruption. Amongst other factors, the political and civil 
instability have contributed to the decline of the Fijian economy, placed limitations and 
conditions on the flow of development aid and constrained long term, cohesive planning and 
management in the public and private sector.   
 
Following the first seventeen years of independence, in 1987, a coalition of the Fiji Labour 
Party and the National Federation Party came to power under Dr Timoci Bavandra. A month 
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later, it was overthrown by the first of two military coups led by Lt. Col. Rabuka. Fiji was 
declared a republic following a second coup in October 1987. A new constitution was adopted 
in 1990 which favoured indigenous Fijian control of Fiji. Heavy Indian emigration, 
particularly of the middle to high income bracket, followed the coup. The 1997 Constitution 
contained a range of new provisions to encourage multi-ethnic government.  
 
In May 2000, George Speight overthrew the Labour Party-led elected government of Prime 
Minister Mahendra Chaudhry, taking the Cabinet hostage and surrendering after a 56-day 
standoff.  He was sentenced to death for treason (later commuted to a life sentence) in 2002. 
The military installed Laisenia Qarase to lead an interim government. Qarase was elected 
Prime Minister in 2001.  The constitution requires any party receiving more than 10% of seats 
be offered Cabinet posts, but Qarase refused to do this. During his term, Qarase ruled in 
coalition with the Conservative Alliance.  Their actions appeared to support the attempted 
coup in 2000.  The two parties merged just before the 2006 elections.  
 
In September 2005, Qarase appointed Ratu Naiqama Lalabalavu, his former Lands Minister 
convicted for involvement in the May 2000 coup, to head the transport and shipping portfolio. 
A central plank of Qarase’s Party campaign was the Reconciliation, Tolerance and Unity Bill 
which would pardon supporters of the 2000 coup, including Speight, and erase the criminal 
records of those convicted. This was strongly rejected by opposition parties, including human 
rights groups and the military. The strong public reaction pushed Qarase to amend the amnesty 
provision of the Bill and delayed parliamentary debate until 2006.  
 
The ruling SDL Party won the election in May 2006, enabling the incumbent Prime Minister, 
Qarase, to remain. Chaudry, who heads the Labour Party, decided to remain outside 
government.  Citing corruption in the government, Commodore Josaia Voreqe (Frank) 
Bainimarama, Commander of the Republic of Fiji Military Forces, staged a military take over 
on December 5, 2006, placing senior military officials in Government agencies and 
systematically taking in people for interrogation who spoke out against his take over. 
 
Following the 2006 coup, the Commonwealth of Nations suspended Fiji's membership and  
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several major foreign countries withdrew aid; this included the postponement of EU 
development aid for restructuring the declining sugar industry.  Political instability remains a 
major contributing factor in the decline of the economy, and in turn to a decline in government 
revenue used for expenditure on public goods, such as healthcare.   
 
4.3 Trade policymaking, medicines procurement, IPR and human rights 
 in Fiji 
 
4.3.1 Trade policymaking in Fiji 
 
“There is no point in discussing health related trade issues unless the importance of this 
is conveyed to the trade sector and to Forum Leaders.  Any safeguards in national 
strategies and policies may be undermined by trade negotiators signing an agreement 
under political pressure.”  
Comment by a senior health official in Fiji, interviewed October 2007   
 
Trade policymaking in Fiji, and the PICs in general, needs to be understood within the context 
of the introduction of the neoliberal agenda by external advisors in the late 1980’s.  In the 
absence of an alternative economic paradigm, it set the direction and pace of trade policy and 
economic reform and its core values (based on open access and global integration) introduced 
the concept of economic regionalism which is intrinsic to all of the major trade agreements 
Fiji is engaged with today (Slatter, 2006). 
 
Slatter considered this neoliberal thinking was conveyed to Pacific Island Leaders through the 
South Pacific Forum (Slatter, 2006), which subsequently became the Pacific Island Forum 
Secretariat (PIFS). Established in 1991 to investigate free trade among the Forum Island 
Countries, since 1997 it has become pivotal in coordinating negotiations under PICTA, 
PACER, and Cotonou, and recently set up an EU funded WTO Office in Geneva (Kelsey, 
2005).  The Forum Economic Minister’s meetings encourage input from World Bank, IMF 
and ADB representatives.   Traditionally the PIFS has had an exclusive economic focus. This 
has changed recently to include a human development mandate with the support of a number 
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of UN agencies and CROPS, including SPC. This change is relevant to this research because 
government policy on social spending, access to medicines and the right to health are 
essentially socioeconomic and cultural issues that would be expected to be promoted within 
this neoliberal agenda.  There is a tension between human rights and health within the 
dominant neoliberal, global economic order.  This is covered in Section 2.4.3.  
 
The Ministry of Foreign Affairs and External Trade is the key agency involved in trade 
policymaking.  Fiji’s national trade policymaking mechanism is institutionally and legally 
linked with trade policymaking at the regional level at the Forum Secretariat.   A description 
of trade policymaking at a regional level is included in Section 3.3.1.  This situation introduces 
sovereignty and inter-agency management issues that impact on the Fijian Government’s 
capacity for trade policymaking.   
  
At a domestic level, the process of trade policymaking faces internal challenges.  These relate 
to issues of connectivity. Views are that trade policy needs to be better linked with industrial 
policy to ensure investment is more broadly articulated throughout the economy (Robertson, 
2006), improved public sector governance,  better coordination of expenditure on social 
services, and pressure by CSOs to implement formal mechanisms for trade dialogue and 
deeper analysis of various trade options (Oxfam, 2006a). 
 
4.3.2 The capacity for trade and health advocacy in Fiji 
 
“We espouse the Pacific way as being ‘consultative’ but we do not acknowledge our 
Pacific values include revenge.  It is up to leaders of the various organisations to create a 
culture of ‘collaboration’, and for NGOs to fulfill the role of advocating for improving 
the interface between different sectors and structures (to improve our trade 
policymaking).” 
Ms Tupoe Vere, Director, Pacific Concerns Research Centre (PCRC), interviewed October 2007 
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Background 
 
In response to the global trade agenda and development of transnational coalitions, civil 
society organisations (CSOs) are challenging governments to have more active involvement in 
trade policymaking and dialogue.  These challenges are placing significant demands on 
governments, particularly with its uneasy mix of traditional economic and social issues (Ostry, 
2002).  This trend is accompanied by the emergence of new, and stronger, civil society actors, 
supported by international NGOs, to play significant roles, especially in consultation 
mechanisms for trade negotiations and in building capacity amongst domestic CSOs to 
pressure governments for increased consultation and transparency (Stairs, 2000).  For 
example, Oxfam New Zealand provides trade advocacy assistance to the Pacific Network on 
Globalisation (PANG), a regional NGO based in Suva.   
 
This trend is seen in Fiji where CSOs are demanding greater involvement in the EU EPA trade 
dialogue, where the asymmetry in bargaining power is illustrated by the PICs combined GDP 
being 1,400 times smaller than the 25 EU countries (Oxfam, 2006b). 
 
The most descriptive documented account of the trade negotiations and civil society 
consultation under PICTA and EPA has been written by Kelsey (see Kelsey, 2004; Kelsey, 
2005).  Kelsey’s description of ‘obstruction’ to involvement by civil society was reinforced by 
a Trade Workshop facilitated by Oxfam New Zealand in June 2006 which attracted 
representatives from around 60 CSOs.  The Press Release for this meeting stated, “The lack of 
meaningful consultation and transparency on the EPA is a concern. It seems that it is only 
government trade officials and their counterparts in the Pacific Island Forum Secretariat who 
have knowledge on the EPA and what it offers.  The regional CSO group is fearful that the 
EPA trade negotiations are being carried out purely on the basis of theoretical economic 
analysis” (Oxfam 2006c). 
 
In Fiji the various groups representing civil society are mostly based in Suva, with outreach 
programmes to the rural regions. Many of the CSOs requesting to be involved in trade 
dialogue are already involved in social and environmental policy issues and some are 
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receiving assistance by external agencies, such as the Asia Development Bank (ADB, 2006) to 
develop capacity to engage in development. This phenomenon illustrates how civil society has 
traditionally been associated with activism around development issues rather then trade.  
Furthermore, as these CSOs develop capacity for engaging in social and environmental issues 
there is the likelihood that these skills can be transferred to trade related issues, the primary 
constraint being limited resources and finance.   
 
In 2005, the PIFS introduced two formal mechanisms to engage with CSOs. This was a highly 
significant step. The first is through a collective communiqué prepared by regional CSOs at a 
meeting held prior to the annual meeting of the Pacific Forum Leaders.  The second is an 
official PIFS accreditation system that enables accredited CSOs to attend Working Party and 
CROP meetings as observers. PCRC is the only accredited CSO at this stage, with four others 
due to apply in 2008.  Although the process has been slow, the mechanism offers considerable 
potential to elevate CSO input into trade policymaking in the future. 
 
Current situation 
 
With the exception of the World Council of Churches and PANG, it was found that few CSOs 
provide advocacy on trade in Fiji.  This low number is not a reflection of how they rank trade 
compared with other issues.  Often it is because trade is considered too complex (and IPR 
even more so) by CSOs who are challenged by resource constraints and more immediate local 
advocacy issues; an observation reinforced by the Director of PCRC:  
 
“I attended a national workshop on trade and IPR.  One reason why I think there has 
been a lack of focus on IPR by NGOs is it’s overly complicated. That is also the reason 
why few NGOs tackle trade advocacy. I can remember thinking ‘how do I surface 
through this beast?’ I think that is the reason why there were no further discussions on it 
amongst NGOs. As a consequence, the focus has shifted to developing traditional 
knowledge (frameworks) amongst NGOs and not on IPR…also traditional knowledge 
comes onto the community’s agenda more directly and NGO’s need to respond to that.”  
Ms Tupoe Vere, Director, Pacific Concerns Resource Centre (PCRC), interviewed October 2007 
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In contrast, there are several NGO’s and UN agencies providing health advocacy, for example 
FSPI, ECREA, UNAIDS and UNFPA.  However, apart from some specialised areas of health, 
for example tobacco and alcohol, the type of advocacy excludes trade-related factors that 
impact on medicines; which might be a missed opportunity.  A description of national and 
regional NGOs involved in human rights advocacy is included under Section 4.5. 
 
While it is the role of  health-related UN agencies, in particular, WHO, UNICEF, UNDP, 
UNDP Pacific Regional Office and UNAIDS, to provide leadership and assistance on WTO 
and public health issues, these agencies face considerable political pressure, that arise from 
advocating for universal health rights, without being seen to interfere with national 
sovereignty in multilateral and regional trade agreements.   
 
A sector based approach to formulating health and trade advocacy and policymaking presents 
a further challenge to the work of these advocacy agents.  The need for bridging different 
sectors is acknowledged by the Director of PCRC: 
 
“Most of the agencies are very sectoral.  There is a need for bridging across sectors on 
some of these issues.  For example, the Forum Secretariat plays a lead technical advisory 
role on trade negotiations, SPC and WHO provide technical advice on health; they need 
greater 'bridging' between them.  This isn’t only limited to government and inter-
governmental agencies it is also reflected in our own regional NGO structures and roles.  
The structures and mechanisms the government have put in place for NGOs to engage 
with them, including the way the Pacific Plan is structured, often reflects this sectoral 
approach and so the NGOs structure themselves around this too.” 
Ms Tupoe Vere, Director, Pacific Concerns Research Centre (PCRC), interviewed October 2007 
 
These factors of: political tensions for UN agencies, low capacity of CSOs and sector based 
approaches to trade policymaking are a disadvantage to raising awareness on access to 
medicines.   
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4.3.3 National medicines procurement in Fiji 
 
“A critical issue in the Pacific is the absence of a (Western) culture of healthcare.  
People go to their pastor or traditional healer and leave it until their health has 
significantly declined before seeking hospital or medicinal care.  By then, the immune 
system has already been severely compromised.”    
Dr Stuart Watson, Pacific Regional Coordinator, UNAIDS, interviewed October 2007 
 
Fiji’s Essential Medicines List, was adapted from the WHO EML and currently lists around 
430 drugs.  These are available free from government health centres and hospitals but do not 
include medicines (or infrastructure) for most non communicable diseases, such as statins, 
chemotherapy and dialysis.  Drug stock-outs in hospitals and medical centres are not 
uncommon (Bailey, 2004).  When this occurs people are expected to pay full price for drugs at 
a private pharmacy.  
 
There are no foreign multinational or local manufacturing companies in the Pacific region.  
This situation creates a dependency on foreign countries for all medicines which are imported 
directly from wholesalers or manufacturers by the public and private sectors. The Fiji 
Pharmaceutical Services (FPS) funds, procures, stores, registers, and distributes all 
government drugs; relying on re-registration from the source to regulate drug quality. 
Occasionally drugs are sent to the Australian Therapeutic Goods Agency (Aust TGA) for 
quality testing and regulation, but this is expensive.  
 
Fiji’s middle income development status and efficient pharmaceutical procurement agency 
means that Fiji does not qualify for as much financial aid for health as some other PICs.  
Global schemes such as UNICEF, UNFPA, GAVI and the Global Fund, provide financial 
loans or full to partial financing of medicines for treating most communicable diseases, and 
provide varying levels of assistance for their procurement and distribution.     
 
Fiji Pharmaceutical Services operates within a fixed budget which has increased marginally 
over the last four years to partially accommodate formal requests for additional medicines. 
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Requests for budget increases to allow for increased patient numbers or additional medicines 
are submitted to the Ministry of Health by the National Drug and Therapy Committee, which 
is comprised of clinicians, pharmacists, and community representatives. These requests are 
often declined, or meet with mixed success because of the Governments’ limited public health 
budget.    
 
Here I use the metaphor of a ‘generics bubble’ to describe the current public medicines 
procurement scheme.  In this case, trade related impediments acting on newer medicines 
technology would exist outside the bubble, with the focus of the generics only procurement 
policy being within the bubble.  As a consequence Fiji’s limited health resources appear to be 
directed to internal determinants and improving things they believe they can control, such as 
efficient forecasting and distribution, rather than on protecting WTO safeguards and IPR law. 
For example, the Fijian government does not currently have to use parallel importation 
because of the generics only policy. 
 
Interview participants were asked, from a public health perspective, what would puncture the 
‘generics bubble’? Their responses included: (i) local clinicians and civil society lobbying the 
Government for a ‘wishlist’ of medicines not currently procured, for example, patented 
medicines such as statins which are designed to lower the risk of vascular events, new diabetic 
treatments, chemotherapy and dialysis, (ii) the Fiji Pharmaceutical Services goal is to achieve 
the health-related MDGs by 2011. Reaching this point, or the international deadline in 2015, 
could trigger pressure for greater access to patented medicines if the health goals haven’t been 
met, (iii) increased resistance to first generation medicines so that second generation patented 
versions are needed, (iv) increased demand for second generation antiretroviral drugs for the 
treatment of HIV/AIDS in the Pacific region, (v) an external factor, such as a pandemic, and 
(vi) withdrawal of global aid funding for medicines, placing greater financial burden on local 
governments.   
 
Availability, affordability and efficacy of medicines 
 
Despite being better off economically than some PICs, availability of medicines in Fiji is a 
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problem because of drug ‘stock-outs’: 
 
“Frequently, there are media reports about lack of medicines in the public sector (in 
Fiji)… Although an Essential Drug List (EDL) is in place, no absolute commitment has 
been given by the Ministry of Health on guaranteed availability of those medicines to 
the public. Anecdotal reports from health service staff indicate that the medicines supply 
situation in hospitals and in health centres is worsening.  The problem has reached such 
a low point (in 2004), that a committee of enquiry into medicine supply has been 
established by the government.”    
Dr M Bailey, Assoc. Prof. Pharmacy, Fiji School of Medicines, Sept 2004.46 
 
One local clinician commented, ‘A local saying in hospitals is the ‘O.O.S- Syndrome’, which 
means ‘Out-Of-Stock Syndrome’.  This can cause rapid deterioration of a patients health if, for 
example, a staphylococcus infection is left untreated for 24 hours’.  Rather than a trade-related 
or affordability issue, the problem was considered to be the responsibility of Fiji 
Pharmaceutical Services to fix factors such as consumption, prescribing, quantification, and 
ordering and wastage.  To address the stock out problem, the National Drugs and Therapy 
Committee devised the ‘Vital Medicines List’, a subset of the Fiji EML.  This lists drugs that 
should never, ever have stock outs.  
 
In turn, stock-outs create an access issue because of a lack of affordability: 
 
“You see lines of settlement people queuing at outpatients for medications and they will 
be told the hospital has run out, go to the pharmacy.  But these cost money at the 
pharmacy, so people go without.  Who is accountable for the fact the drugs are not there 
for people? Whose role is it to audit and to advocate?” 
Mr Semeti Qulowasa, Field Coordinator, Economic Justice, ECREA, interviewed October 2007  
 
An analysis of the price of drugs in the Pacific region is beyond the scope of this thesis.  
However, further research to determine the extent that price and affordability prevent access, 
                                                 
46
 See reference Bailey (2004).  
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and for which drug groups, would be valuable. Although the results may not be extrapolated to 
other PICs, a study undertaken in 2004 by the Fiji School of Medicine (Bailey, 2004) suggests 
that both the public and private sector procurement of drugs in Fiji compared very favourably 
with international comparator prices and that this was affordable to the waged population. 
However the results stopped short of predicting what this would be for the unwaged. 
  
Given that around 25% of Fijian households living below the poverty line due to uneven 
distribution of income, and an additional one third of all households being highly vulnerable to 
poverty as a result of the flatness of the income distribution (ADB, 2006); clearly for a large 
percentage of the population even essential drugs would be unaffordable during medicine 
stock-outs.  This situation, where medicines are sometimes only available to those who can 
afford them begins to establish a two-tier health system which in turn reinforces social 
inequality (Marmot and Wilkinson, 1999). 
 
Price regulation of pharmaceutical products is a tool that has been used by many developed 
countries to control the price of essential medicines and is a tool used in Fiji.  Out of 135 
countries covered in the World Drug Survey in 1999, over 40% had no measures in place to 
regulate medicine prices, whereas almost 80% of high-income countries and 50% of middle-
income countries practiced some kind of price regulation (WHO, 2004). The Fijian 
Government controls drug prices through the Fiji Prices and Income Board which sets, and 
effectively limits, percentage mark-ups at wholesale and retail level.  
 
As a result Fijian citizens are probably better off for the range of free drugs they have access 
to compared with some other PICs. At the same time, there was early evidence of individuals 
and CSOs starting to question the efficacy of some drugs to produce intended results. This is 
illustrated by the Field Coordinator of ECREA working with Fijian settlement people: 
 
“The quality of the drugs people access are sometimes under-par, but people who can 
afford them, get better drugs through the private sector; reinforcing social inequality.  
For example, I was helping a man in the settlements, he was inhaling on the asthmatic 
drugs given to him by the hospital and he was still wheezing.  I went to the pharmacy 
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and bought a $7 inhaler.  He puffed on it and immediately improved.  I took the hospital 
one back and they told me that's what they issue. It cost $1.90.  It makes me start to 
think the qualities of the drugs that are free are inferior to those in the private system.  
So although you can say we have access, the quality may not help people's health 
improve.  This man could not afford to pay for the pharmacy version.”  
Mr Semeti Qulowasa, Field Coordinator, Economic Justice, ECREA, interviewed October 2007 
 
The quality and efficacy of the medicines that are provided could raise a further access issue 
for many Fijian people if they are unable to afford more efficacious medicines. The efficacy of 
publicly procured medicines would warrant further research and must be on the agenda of the 
WHO and the National Drugs and Therapy Committee, or a regional organisation such as 
SPC. Linking the efficacy of medicines into the access to medicines and trade discussions at 
some point would be valuable, especially if new patented technology offered significant 
improvements in treating some diseases than current generic versions on the Fijian EML.  
 
The private provision of health services and medicines for those who can afford them, or have 
health insurance, is known to reinforce social inequality in health (Marmot and Wilkinson, 
1999).  A two-tier health system may be further reinforced by physicians who advise their 
clients who can afford it, to go to private suppliers to purchase better versions of the medicines 
supplied free by the Government, for example broader spectrum penicillin.  A review of the 
impact of privatisation of health services on access to medicines and on health development in 
developing countries warrants further research.   
 
4.4 National intellectual property law in Fiji 
 
Fiji is working towards WTO TRIPS compliance.  Fiji’s current national IPR law contains 
some inconsistencies between the Act and the TRIPS Agreement with regard to substantive 
requirements. At the same time, the Act does not provide for the flexibilities and safeguards 
allowed by the WTO TRIPS Agreement, notably the exception to exclusive rights (such as 
parallel importation and the ‘Bolar’ exception) and compulsory licenses (Correa, 2003).  This 
was discovered when the WHO funded a review of the national IPR law in 2003.  The 
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researcher, Dr Carlos Correa, recommended these were removed as soon as possible (Correa, 
2003). A draft IPR Bill is pending completion in the Attorney Generals’ Office where its slow 
progress appears to have come to a halt since the 2006 coup.   
 
A full description of the process of pharmaceutical patent examination and registration and 
whether there is any current evidence of trade related impediments impacting on Fiji’s public 
medicines procurement scheme is covered in detail under Section 5.2.1.  Of particular interest 
here is that some PICs use IP Australia to examine some pharmaceutical patents which could 
mean they use examination criterion that is appropriate for Australia, and this is unlikely to 
reflect the development needs of poorer countries, such as the PICs.  
 
The sequence of events describing the lead up to the IPR law review, and ongoing initiatives 
to establish formal and informal stakeholder meetings after this event, is relevant to this 
research because this core group of individuals and organisations are showing interest in 
access to medicines and have realized the significance of trade and IPR law on future access; 
although no ongoing agreement to continue meeting is yet in place.   
  
In1999 the Chief Pharmacist of the Ministry of Health first noticed a pharmaceutical patent for 
Olanzapine had been registered, and this stimulated his own research into WHO policies, 
WTO and TRIPS.  This coincided with a paradigm shift at the WHO when the international 
pharmaceutical company, Cipla, publicly shared drug pricing information for HIV/AIDS for 
the first time.  At that point the WHO shifted its policy on access to essential medicines from 
the ‘majority’, to ‘priority’, diseases to receive essential medicines. In 1999/2000 Fiji started 
to develop an HIV/AIDS policy which, amongst others tasks, included a review of the national 
IPR law.  In 2003, WHO brought in the legal consultant, Dr Correa, through its South to South 
collaboration who suggested re-drafting current patent law.  The IPR review process brought 
together pharmacists, lawyers and different Ministries, for example, agriculture, finance, 
foreign affairs and external trade, for discussions.   
 
In June 2006, Third World Network (based in Asia) in collaboration with WHO WPRO 
organised a workshop in the Pacific on TRIPS and public health.  This was attended by over 
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40 legal and health officials from seven countries and representatives from the UNDP, 
Commonwealth Secretariat, MSF, and the PIFS.   
 
Shortly afterwards, FPS proposed a national follow-on workshop, with funding (hosting) from 
WHO, to which officials from the Ministry of Justice, Commerce, Prime Minster’s Office, 
Ministry of Health, PIFS, civil society,  patent office, and regional directors of the clinicians 
were all invited.  The meetings were not attended by the private sector for example, the 
association representing private pharmacists, which was later acknowledged as an oversight.  
 
A third meeting, organised and facilitated by the Forum Secretariat, invited stakeholders to an 
informal discussion to get their views about IPR (amongst other issues) and to identify 
common issues of concern. Not all stakeholders were invited to this general session however.  
Currently there are no formal mechanisms in place to continue meeting over these issues on a 
regular basis.  However, the FPS Chief Pharmacist is keen to ensure an IPR meeting of all 
stakeholders is held every two years; the next being 2008. 
 
4.5 Application of human rights instruments in Fiji 
 
Fiji’s national constitution includes the Fijian Bill of Rights whose overall emphasis is on civil 
and political rights, rather than socioeconomic and cultural rights.  Like most Asia Pacific 
countries, Fiji has not yet ratified ICESCR, but has signed up to CEDAW and CRC. 47 The Fiji 
Human Rights Commission, established in 1997, temporarily had its accreditation revoked by 
the UN Human Rights Commission in early 2007 following political disputes over the coup.  
 
The application of human rights instruments vary widely among the Fijian state and non state 
agencies and generally emphasise civil rights, for example non discrimination of community 
testing and education of people with a disease, rather than socioeconomic and cultural rights.  
Such an emphasis on civil rights is likely to reflect local cultural and political values and 
historical colonial ties (This is discussed in more detail under Sections 2.4 and 3.5).   
                                                 
47
 ‘CEDAW’ is the Convention on Elimination of Discrimination Against Women; ‘CRC’ is the Convention on 
the Rights of the Child  
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At the present time, there was no evidence in my research that any agencies are applying 
human rights to specifically advocate for access to medicines. Where human rights are linked 
to health, for example with UNDP, UNAIDS and RRRT programmes and policies, the 
emphasis is predominantly on civil rights. Two examples of this include the regional strategies 
and policy documents prepared by the UN agencies UNAIDS and WHO. The Regional 
HIV/AIDS Strategy, which has been signed off by all 14 PICs, and the Regional policy 
document relating to the preventative management of non communicable diseases developed 
by WHO, in conjunction with other stakeholders, not yet fully signed off, are prominent 
regional frameworks for coordinating public health programmes however both strategies do 
not include the right to access medicines. Several of the UN agency participants that I 
interviewed raised these two strategies as examples of a missed opportunity to include access 
to medicines, mainly because they had been unaware of the need.  
 
There also appears to be a lack of awareness of the need for trade and access to medicines 
advocacy amongst CSOs.  The Training Coordinator from the Pacific Regional Rights 
Resource Team (RRRT) specifically commented on this: 
 
“Our use of human rights and rights-based approach do not currently specifically 
address access to medicines however this is something that the community paralegals 
could address at the  community level.  Our health advocacy mainly relates to civil 
rights and non-discrimination.  For example, a senior official in the Ministry of Health 
once described the victim of a sexual assault who contacted HIV. This creates problems 
in a small community as it enabled people in her community to identify who she was. 
This breech of confidentiality and privacy could lead to social stigmatisation. Our 
partner organisations in Fiji highlighted this concern.  We could extend into this area 
however if the need was identified. RRRT could also work at the meso and macro level 
with the Ministers of Trade on building capacity on how they could use international  
human rights law to decline TRIPS-plus in trade agreements by falling back on the fact 
they have signed these international Human Rights Conventions.” 
Ms Gina Houng Lee, Training Coordinator, RRRT, interviewed October 2007  
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The Pacific Regional Rights Resource Team (RRRT) is a project of the UNDP Pacific Centre 
and specialises in providing training, advocacy, technical support and policy advice on human 
rights to the Pacific Island states and non government organisation partners.48  RRRT receives 
primary funding from the New Zealand Aid and International Development Agency.  It works 
simultaneously at the community level, where they educate and support rights-holders to claim 
their rights, and at the government level, where they strengthen the accountability of duty-
bearers towards their human rights obligations.  They also target the meso-level (senior civil 
servants, access to justice agencies, legal profession and law graduates) through training and 
technical advice. They also publish a Pacific Human Rights Law case digest.49  RRRT 
Training Coordinator emphasised this approach was a deliberate strategy on their part in order 
to get the human rights message across: 
 
“Sometimes the human rights language is perceived as confrontational or in conflict 
with the way things are being done.  So we try to promote awareness through the macro- 
level, and filter it downwards, and through the grass roots and meso-level, and push it 
upwards”. 
Ms Gina Houng Lee, Training Coordinator, RRRT, interviewed October 2007   
 
In contrast to RRRT, the human rights approaches and strategies of the national NGO, 
ECREA, focuses on empowering people who live in the settlements to advance social change. 
In this instance human rights are not fully integrated into their work processes but they are 
applied to increase the political status of a message once a community’s needs have been 
evaluated.  Using a human rights platform to successfully facilitate dialogue between 
government and squatter settlements is an illustration of this.  This also reflects how NGOs 
have adapted human rights tools to deal with resistance by communities they work with, as 
expressed by the Field Coordinator at ECREA:  
 
“We have a culture of silence in this country – people don’t question leaders or 
leadership but just accept their word.  They look to the chief system and faith system for 
                                                 
48
 RRRT website available at http://www.rrrt.org accessed 5/10/07 
49
 RRRT website available at http://www.rrrt.org accessed 5/10/07 
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answers.  We need to empower people to question how good that leadership is for 
improving the people and how involved that leader gets in trying to bring this about. 
Although they are suspicious of them, human rights is one, useful tool to help bring this 
about”. 
Mr Semeti Qulowasa, Field Coordinator, Economic Justice, ECREA, interviewed October 2007 
 
The significance of the role of NGOs is further reinforced by the views of the New Zealand 
Law Commission: 
 
“We believe that CSOs have a significant role to play in making human rights culturally 
meaningful for Pacific communities and in helping to enhance customary governance by 
harmonizing it with human rights principles.” 
 NZ Law Commission, 2006. pp.234 
 
In response to the question, “Could human rights, which have successfully been used to 
galvanize the HIV/AIDS campaign, be extended to protect other drugs such as diabetes 
treatments?”  An expert in public health development in the Pacific, who is also a Pacific 
Islander, responded: 
 
“No, I explored the possibility some years ago.  It’s been associated with HIV and the 
nature of HIV is the pandemic.  Chronic non communicable diseases are associated with 
other forms of prevention such as trade in food stuffs, tobacco, alcohol, drugs and fatty 
foods. Besides which, Pacific Islanders are suspicious of human rights.  They see it as a 
means for the West to promote things like, an end to violence against women, and do not 
associate it with helping them to access better health”  50   
 
In contrast, another Pacific person who is a senior academic specialising in social and 
economic development in PICs observed: 
 
 
                                                 
50
 Field research interview participant 
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“As a rights language, the right to health (through the right to medicine) would have 
more acceptance, than, say civil rights, because it is less confrontational to customary 
rights and to  traditional forms of decision making.  Traditional decision making is 
normally the domain of men in the Pacific.  The new generation of human rights 
strategies, such as the right to education, the right to health, and the right to housing, is 
therefore less likely to upset a power balance, and consequently has significant potential 
to bring about improvements in health”. 51 
 
These two responses illustrate the diverse perspectives about human rights and health held by 
different stakeholders.  In this case, the responses further reinforce how contentious and 
challenging the application of human rights can be, even if it is blended with local custom in 
the Pacific region.  These views are possibly commonly held by other people in the global 
context and are not just unique to Pacific people, particularly as the human right to access 
medicines and to health is an emerging right.   
 
4.6 Conclusion 
 
Several interrelated factors associated with trade, health and the local culture, and to much less 
of an extent, human rights, appear to shape how Fijian people view trade and access to 
medicines.  Most factors are not entirely unique to Fiji and are generally applicable to other 
PICs to varying levels depending on, amongst other factors, their WTO status.  The views of 
some domestic and foreign workers employed in international development organisations, 
such as the UN agencies, also appear to be shaped by some of the same factors even when 
they have strong international affiliations and an established profile in access to medicines 
campaigning in other developing countries, for example the WHO and UNDP assisting the 
Thai Government to undertake a human rights impact assessment of the proposed Thai-US 
FTA.  
 
In the trade sector these factors are directly related to the expansion and deepening of trade 
liberalisation and regionalism.  For example, the national trade policymaking mechanism in 
                                                 
51
 Comment made in general discussion with the researcher in November 2007 
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Fiji is institutionally connected with the regional trade policymaking mechanism at the Forum 
Secretariat.  The strength and alignment of these linkages and who they receive assistance 
from has a bearing on domestic perspectives on trade and access to medicines.  This is 
compounded by a sector by sector approach towards trade and health policymaking, instead of 
a multi sector approach, that compromises coherency.  
 
In the health sector, the concept I have referred to as the ‘generics bubble’ appears to direct 
key stakeholders to focus exclusively on internal determinants of access to medicines, rather 
than including  the external environment to protect WTO safeguards and to push for stronger 
institutional linkages between the health and trade sector.   
 
The conflict between human rights and local custom presents a major challenge to how useful 
local people might view human rights as a tool to help protect the right to access to medicines.  
These challenges also appear to contribute to the low capacity for human rights advocacy 
amongst national and regional CSOs.  The current emphasis on political and civil rights is 
likely to be less relevant to the aim of protecting the right to access to medicines than 
socioeconomic and cultural rights. In the Pacific setting therefore, a shift in philosophical 
thinking from civil rights to socioeconomic and cultural rights might be required before 
existing, or new, human rights mechanisms can accommodate the right to access medicines in 
their strategies and programmes.  Moreover, a cultural preference for traditional herbal 
medicines rather than a health culture based on western medicines appears to reduce 
awareness of medicines availability and affordability at both the grass roots and amongst some 
government officials.   
 
Finally, some of these factors may not be unique to Fiji and the Pacific region. Hypothetically, 
other regions comprised of SIDS, such as the Caribbean, may share some of the same factors, 
for example issues associated with regionalism, cultural preferences, and health trends, and 
therefore share similar views on trade and access to medicines.  This would be interesting 
further research, particularly if the findings suggested that different regions comprised of 
SIDS would benefit from information sharing on trade and access to medicines and the 
development of creative solutions, such as collective compulsory licensing. 
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Chapter 5: Findings and Conclusion  
 
5.1 Introduction 
 
Key findings are presented in this chapter under each of the five primary research objectives 
(the objectives were earlier listed in Section 1.3).   I conclude this chapter by reflecting on 
how this research informs human rights theory and contributes knowledge to the wider 
academic audience.  As noted, limitations to the research methodology include: assuming a 
representative sample of stakeholder organisations, accurate recording of participant’s views 
and realities, and the potential over-reliance on qualitative data.  I have attempted to minimise 
these factors by cross referencing interviewees, structuring interviews to allow for information 
exchange at the end of interview questions and acknowledging that quantitative data would 
have helped to underpin my findings rather than changing them substantively.   
 
Finally, the findings from this chapter, together with suggestions made by interview 
participants and personal observations, were used to compile a range of multidisciplinary 
responses to help mitigate trade restrictions on access to medicines at the national and regional 
level.  These suggested responses are summarised in Appendix 5. The need for regional 
cooperation on health, IPR and trade has been acknowledged by the PIFS and is implicit in the 
Pacific Plan. The suggested responses also assist with the mainstreaming of health into trade 
policy to enable any adverse effects on the health sector to be considered in trade negotiations 
and regional institutional design.   
 
5.2 Key research findings 
 
5.2.1 Do trade-related restrictions exist currently, or in future, proposed trade 
 agreements? 
 
The findings in this section relate to research objective one which is “to assess any reported 
restrictions on access to essential medicines in Fiji introduced by trade-related factors and the 
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potential impact of future, proposed trade agreements”. 
 
Four main findings that relate to Fiji emerged from this research objective.  Firstly, with the 
exception of one patented product, an antipsychotic drug called ‘Olanzapine’, there was no 
evidence of TRIPS provisions, or of pharmaceutical patent rights, posing a major obstacle to 
the public procurement of medicines by the Fijian government.  The Ministry of Health’s 
policy of only purchasing generic drugs is the primary reason for this finding.  These drugs are 
from the Fijian Essential Medicines List, which generally lists older, generic medicines 
adapted from the WHO EML. This generics only policy might be a major factor contributing 
to the comparatively low profile of trade and access to medicines in Fiji and the Pacific region 
compared with some other developing countries; which is the main finding under objective 
two.   
 
Olanzapine is one of over one hundred and twenty pharmaceutical patents that are currently 
registered with the Fijian Patent Office, double the number recorded in 2003. Which drugs and 
companies these are for is not a simple exercise to determine because patents are not 
electronically available and require specialized skills to interpret, that are not readily available 
in the PICs.  Identifying these would warrant further investigation as it would enable the Fijian 
government to consider alternative options to ensure affordability or to anticipate increases in 
the pharmaceutical budget.  
 
The second main finding relates to the current practice of out-sourcing the examination of 
some pharmaceutical patents to a developed country, such as Australia, because of the limited 
search and examination capacity. Currently Fiji either re-registers pharmaceutical patents from 
the United Kingdom or has them examined by IP Australia, at the patent holder’s expense.   
 
As discussed in Chapter 2, IPR standards used to be set by developing countries to meet their 
development needs (Wade, 2005; Chang, 2005). With globalisation, IPR systems are 
becoming more homogenous and countries are no longer able to set their own levels.  This 
could mean that IP Australia examines a medicine patent using criterion that is appropriate for 
their own country, but is unlikely to reflect the development needs of poorer PICs (Correa, 
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2007; Drahos, 2007), such as Fiji and other PICs.  The granting of pharmaceutical patents by 
patent offices for essentially what appear to be trivial steps in the innovation process is a real 
concern and one that may be valid in this situation. This means Fiji has no discretion over 
whether these criterion are set at a level to suit their own development needs unless it 
establishes a monitoring mechanism and raises a pre-grant challenge.  This may result in a 
higher acceptance rate of applications, setting a legal precedent that may be inappropriate for 
the country’s development agenda.   
 
Furthermore, the Australian examination is likely to have incorporated stronger, TRIPS-plus, 
provisions, such as the interpretation of the requirement of an ‘inventive step’.  These 
provisions were introduced to Australia in the free trade agreement with the United States; 
which is a further reason to monitor new registrations in Fiji.   
 
A three month pre-approval period enables patents to be challenged in Fiji, however there is 
no formal, external monitoring of patent examinations at present, so none are being 
challenged.  Here, the Brazilian model of patent monitoring is a good example of a 
preventative measure.  The model uses a panel of experts to review patent registrations, 
applying a framework that links patentability criteria for drugs to the goal of welfare-
enhancing innovation in the health sector.  The process also avoids the high costs of 
attempting to remove patents after they are granted.  Another mechanism, the ‘transparency 
register’, requires pharmaceutical companies to disclose information requested by the 
developing country which is set depending on the level of risk pharmaceutical patents pose.  
These may include ownership, licensing, and full disclosure of patents surrounding the 
targeted technology (Drahos, 2007). 
 
The Chief Pharmacist is keen to establish pharmaceutical patent monitoring which would 
enable public health experts in the Ministry of Health to scrutinise registered patents, and 
allow time to oppose the registration during the three month pre-grant period, on such grounds 
as affordability. 
 
Unlike many developed countries that use a range of institutional and bureaucratic procedures 
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to deter patent holders from registering a patent, for example translation into a local dialect 
and high filing fees, these barriers are very low in Fiji. For example, the cost of filing one 
patent is $50FJD.52  This is relevant to the PICs because the region is not a net producer of 
intellectual property.  Consequently, it is not in the national interest to encourage patent 
registration which will result in higher prices as well as weakening the transfer of technology.  
Here, Fiji could consider appropriate mechanisms to provide additional barriers to patent 
registration. 
 
The third finding relates to the existing national IPR law which needs to be modified to 
introduce WTO safeguards, but there appears to be a lack of impetus for this, particularly 
following the 2006 coup.  A review in 2003, sponsored by WHO under a HIV/AIDS policy 
review, found the Fijian national IPR law did not contain all WTO TRIPS safeguards. The 
reviewer, Dr Carlos Correa, recommended re-drafting the law.  In the short term, forming a 
loose coalition of health-related stakeholders may help to re-stimulate its progress. 
 
The likelihood that future proposed trade agreements will contain TRIPS-plus provisions is the 
fourth finding. It is important to clarify at this stage that the patent for Olanzapine meets, and 
does not exceed, the WTO TRIPS agreement that Fiji, as a WTO member, is obliged to 
comply with.  From a development perspective however, concern would be raised if Fiji was 
forced to sign TRIPS-plus provisions in future trade agreements that gave additional rights to 
patent holders, most of whom are foreign.  For example, in 2005 Thailand estimated the 
effects of a five and ten year extended market exclusivity on the cost of 60 core drugs being 
proposed in a Thai-US FTA which added $66 million USD for one additional year of 
extension to $5 billion USD for 10 years of extension53, contributing to the rejection of these 
provisions. 
 
As discussed under Section 3.3.2, under pressure from the EU to sign a regional Pacific EPA, 
in early December 2007, Fiji and PNG splintered off from the other 12 PICs to sign individual 
agreements, potentially leaving TRIPS to be negotiated during 2008. A comprehensive 
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 March 2008 exchange rate of $1FJD = 0.67 USD 
53
 In, Personal notes on the Thai National Human Rights Commission seminar on the Human Rights implications 
of the Thai-US FTA, Bangkok 18 – 19 Jan, 2007, supplied by interview participant, on file with the researcher 
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analysis of the implications this will have on the local economy and the Pacific region as a 
whole is beyond the scope of this thesis.  Earlier EU draft agreements were expected to 
include TRIPS-plus provisions which were opposed by the international development 
community.  Even though only two countries signed an agreement, it may still trigger PACER 
negotiations and require all PICs that are party to PACER to offer the same conditions to New 
Zealand and Australia.   
 
5.2.2 Is trade and access to medicines on, or off, the agenda? 
 
 
Research objective two is “to assess whether trade related impacts on access to medicines is 
on the agenda in the public or civil society sector in Fiji and, if not, to determine why, and 
what, factors would trigger this”.  
 
Under this objective I broadly contrasted the awareness level of trade and access to medicines 
amongst PICs with other developing countries, such as Indonesia.  I then searched for 
evidence of how this awareness had registered, both at a formal level, for example in meeting 
agendas and policy documents, and informally, such as discussions with interview participants 
and articles by academic commentators. Reasons for my findings are then discussed. 
 
In the Pacific region as a whole the profile of trade and access to medicines is generally low 
compared with some other developing countries and the emphasis appears to be on putting in 
place internal factors, such as financial and structural limitations, to improve affordability and 
availability of medicines.  Furthermore, awareness appeared to be very low in some key 
regional stakeholder organisations identified under objective three.   
 
This is in contrast to some Asian countries where external trade factors pose major obstacles 
to access to medicines and awareness levels are much higher.  This is brought about by a 
combination of factors, such as a high HIV/AIDS levels, their economic development being 
such that they no longer qualify for as much aid to access essential drugs, large population 
size, and trade provisions that enables stronger IP enforcement.  Such factors make the market 
more lucrative for pharmaceutical companies to file and enforce pharmaceutical patents  
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At the regional level in the Pacific, access to medicines did not appear to have been explicitly 
or consistently raised on the agendas or in the policy documents of the key regional 
stakeholders.  These regional stakeholders include the PIFS, health-related UN agencies 
(including WHO), SPC, regional NGOs and associations. For example, an opportunity had 
been missed to include access to medicines in regional strategies developed for HIV/AIDS and 
non communicable diseases when they were first drafted 54.  These strategies are signed off by 
the Forum Leaders and developed into national policy documents for individual PICs to 
implement.  In addition, there did not appear to be any academic commentators on this subject 
at the University of the South Pacific where development issues are usually given a high 
profile.  
 
In contrast, awareness levels were slightly higher at an informal level in the Pacific, but this 
was inconsistent and only amongst some organisations, for example, senior employees at Fiji 
Pharmaceutical Services, the Government’s medicines procurement agency.  It is conceivable 
that other Ministry of Health officials are aware of trade and access to medicines, but the 
Ministry was not included in participant interviews owing to unavailability for interviews.  I 
was advised, for example, that trade and access to medicines is not included in the Ministry of 
Health strategic plan or on the 2007 agenda of meetings the Ministry has initiated with the 
Ministry of Foreign Affairs and External Trade. 
 
In Section 4.3.3, I used the metaphor of a ‘generics bubble’ to describe how Fiji’s existing 
public medicines procurement scheme, which is similar in many ways to other PICs, appears 
to condition national and regional stakeholders to focus on internal determinants of access to 
medicines rather than keeping external trade determinants under closer surveillance.      
 
The relatively low rate of HIV/AIDS in Fiji and the Pacific is another reason for the finding 
that trade and access to medicines has a comparatively low profile. Whereas the HIV/AIDS 
pandemic has galvanised the access to medicines debate in other developing countries, such as 
South Africa, despite the pandemic levels reported in PNG, this debate has not been sparked in 
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 Comments made by field research interview participants  
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the Pacific region. Of significance here is that the region is entirely dependent on aid for all 
HIV/AIDS treatment, provided by organisations such as UNAIDS and the Global Fund.  
Amongst other factors, such as denial that the disease exists, the foreign aid spent on 
HIV/AIDS relieves local governments from this financial burden.  Easing the burden can 
inadvertently lead to these constraints not being translated into national trade and health policy 
or an awareness of the need to protect access to medicines in future international trade 
negotiations. 
 
The linkages between dependence on aid assistance for health and awareness of how trade 
provisions can impede access to medicines is relevant to all PICs because they all receive 
foreign assistance, to varying levels, for treating communicable diseases such as HIV/AIDS, 
malaria and tuberculosis, and for pandemics preparedness such as SARS.   
 
A different set of factors, that are unique to non communicable diseases, appears to be acting 
on the profile of access to medicines in this sector.  Although non communicable diseases now 
account for 70 - 75% of all deaths in the Pacific region, they are generally treated with 
preventative, rather than curative, care.  Preventative care promotes changes in lifestyle rather 
than daily drug treatment. A combination of these two regimes is extensively used in Western 
countries where governments can afford to pay for higher priced patented drugs or have these 
subsidised by private health insurance schemes.  This is not an option in most developing 
countries because they are unaffordable.  This difference in affordability and in medical 
philosophy means that expensive medicines associated with chronic diseases such as 
hypertension, cancer, diabetes and renal failure, are not part of the existing public healthcare 
system in the Pacific region.  In contrast, the profile of trade and access to medicines has been 
elevated in other more economically advanced developing countries, such as Thailand, 
because these governments have begun to provide more comprehensive public healthcare 
services. 
 
Other factors contribute to the low profile of trade and access to medicines amongst 
stakeholders that mainly work with non communicable diseases.  These include: less visible 
physical signs of disease compared with HIV/AIDS; smaller and more fragmented lobby 
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groups compared with HIV/AIDS that are sometimes misinformed about the mechanisms they 
should use to advocate for changes in health and medicines policy; difficultly measuring the 
social and economic impacts of chronic diseases compared with communicable diseases, and 
the separation within the Ministry of Health of curative and preventative treatment, leading to 
conflicts for resources and potential policy gaps (where there should be overlap).  
 
The existence of a comparatively low western, or ‘anti-western’, health culture also plays a 
role here.  
 
A significant number of Pacific people express a preference for using traditional herbal 
medicines only and use western drugs as a last resort.  This difference may be contributing to 
the finding under objective five, that generally CSOs, and even some government officials, 
appear to place less emphasis on protecting access to medicines than on, say, civil rights for 
health.  Here, it is important that ‘outside’, western development professionals do not assume 
that a western health philosophy is implicit in the region.  The extent to which this factor is 
contributing to the finding of a low profile of trade and access to medicines would warrant 
further research as it could be a major factor that might otherwise be overlooked if research 
into trade and access to medicines were to focus exclusively on the trade sector. 
 
This low acceptance of ‘western health culture’ is further compounded by the finding in 
objective three that most NGO’s, working within limited resources, feel hesitant to move into 
trade and IPR advocacy because of its complexity.  This has consequences for how well 
organised community groups are to lobby for protection of access to medicines.  In turn, low 
constituent awareness places less pressure on the MOH and MFAT to have it included on their 
agendas or to push for greater trade and policy coherence. However, there were early signs of 
some of these factors changing.  For example, the next phase of the non communicable 
diseases testing programme at the community level, organised by the WHO, could lead to a 
demand for public access to new technology, patented drugs after people receive their results.  
 
Affordability and availability issues are also likely to raise constituent awareness in the future. 
Although not directly related to trade factors, the government’s capacity to ensure affordable, 
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available drugs is compounded by internal limitations that are reported to result in drug ‘stock-
outs’ in public hospitals and medical centres where these drugs are normally free to the public.  
People are then expected to pay full price for drugs at private pharmacies.  Price is a 
significant barrier to access for poor people.  Affordability also becomes a barrier to 
medication compliance which can prolong recovery periods, contribute to drug resistance and 
impact on economic growth through the loss of livelihoods. Although Fijian citizens are 
probably better off than other PICs for the range of free drugs they have access to, there was 
early evidence of individuals and CSOs starting to question the efficacy and availability of 
some medicines, including access to newer, more expensive ones for treating chronic diseases.  
 
In summary, trade and access to medicines has a relatively low and inconsistent profile 
amongst national and regional stakeholders.  A substantial resource exists in the knowledge 
and work of the Chief Pharmacist, and senior staff of Fiji Pharmaceutical Services. This 
resource is providing a point of reference for other PICs when they request assistance to 
understand the trade issues relating to medicines in their own countries.  In the near future, it 
is conceivable that any one of the potential triggers identified by interview participants in 
Section 4.3.3 may puncture the ‘generics bubble’ that Fiji currently operates within, either as 
an internal push for greater access to medicines from CSOs and UN agencies, or as external 
factors play out, such as a pandemic.     
 
 
5.2.3 Which stakeholders should take responsibility for mainstreaming health into 
 trade? 
 
 
Research objective three is “to elaborate which stakeholders have a role in putting a public 
health perspective into trade and intellectual property rights law and whether the impact of 
trade obligations on access to medicines is factored into trade negotiations”. 
 
The PIFS, SPC, several health-related UN agencies, particularly WHO, UNAIDS and UNDP, 
and regional NGOs and associations, for example, clinicians and pharmacists, were identified 
as the key regional stakeholders for taking responsibility for mainstreaming health into trade 
policy by interview participants and the literature review.  The two most critical Pacific 
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regional agencies to take the lead were identified as PIFS and SPC; with the UN agency WHO 
as a third critical stakeholder.  At a national level the Ministry of Health and Fiji 
Pharmaceutical Services, the Ministry of Foreign Affairs and External Trade, Ministry of 
Justice, NGOs and national associations were identified as the main stakeholders.   
 
The research findings suggest that these stakeholders could be doing more collectively to 
proactively raise the profile of trade and access to medicines; a finding that is reinforced in 
objective two.  
 
The absence of a multi-sector approach between trade policy and health, policy misalignment 
between stakeholders, limited resources and capacity constraints, an exclusive technical focus 
rather than incorporating a strategic policy role, the division between curative and preventative 
services in the public health system, and the prioritisation of specialist resources to develop a 
traditional knowledge framework rather than intellectual property rights, appear to be factors 
contributing to this finding at both the national and regional level. 
    
Public health perspectives are not commonly taken into account in trade policymaking in most 
countries.  However it is something that is recognized as essential to protecting health 
development space in trade liberalization, with many developed countries aspiring to better 
link the two sectors.  The finding that a multi-sector approach between trade policy and health 
is lacking is therefore not unexpected.  For example, historically, health ministries have 
generally been marginalized in two ways: first excluded from foreign policy, and, secondly, 
disconnected from other policy areas within national policymaking.  Ensuring that ministries 
of health take a leadership role on trade and health policy therefore requires a reversal of long-
held practices (WHO, 2007d).  
 
Mainstreaming health into trade policymaking, and in associated governance structures, has 
many benefits.  Firstly, rather than centralised policymaking, the responsibility will be shared 
across multiple agencies.  Secondly, it reduces the potential for trade policymakers and 
negotiators from signing up to greater obligations in future trade rounds than they are required 
to under the WTO TRIPS Agreement.  This is particularly relevant in the Pacific region where 
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there is a relatively high turnover of senior trade staff, and therefore lost knowledge, and of 
foreign consultants providing trade and IPR policy advice who potentially promote a 
neoliberal mindset (Slatter, 2006). 
 
This sector-by-sector approach is exemplified at a regional level where technical assistance is 
provided to Forum Leaders on economic, trade and IPR issues by the PIFS under a separate 
agenda to health.  The PIFS have a specific mandate under the Pacific Plan, to evaluate scales 
of economy relating to health which they mandate to the Secretariat for the Pacific (SPC) 
whose role is to provide technical assistance on social and cultural issues.  SPC’s public health 
programmes appear to focus on surveillance and managing internal limitations rather than 
incorporating linkages with trade. As a result, there appears to be a gap between the policy 
agendas of the PIFS and SPC where the linkages between health (access to medicines) and 
trade could be better managed.    
 
A good example, however, of PIFS responding proactively to the impact of TRIPS-plus on 
medicines took place in early 2007 when the PIFS took the initiative to have the proposed 
draft EU EPA for the Pacific region analysed by the Geneva group associated with Dr Carlos 
Correa, the IP specialist who suggested Fiji’s current IPR law is modified. They then 
circulated this (negative) critique to Forum Leaders to make their own assessment.   
 
SPC is the other major regional organisation which could take a lead role in trade and access 
to medicines advocacy.  The absence of a strategic policy role for SPC, rather than an 
exclusive focus on technical assistance, which is what they were originally established to 
deliver, is a further limiting factor that was raised by some interview participants.  This is 
apparent from literature reviews, including a formal review in 2006 that referred to, amongst 
other things, health economics and trade policy needing ‘better reinforcement’ in SPC’s 
programmes.  Furthermore, SPC’s current focus does not appear to include the impact of 
external trade on the public heath programmes they oversee.  Providing a strategic policy role 
is also vital to other significant health-related stakeholders, including the WHO, which only 
has observer status at PIFS meetings and relies on SPC, who is an advisor, to raise strategic 
issues with the PIFS.   
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The UN is a third group of agencies that could be taking a lead role in trade and access to 
medicines advocacy. Findings were that, whereas some UN agencies such as UNDP, UNAIDS 
and WHO, are proactively involved in trade and access to medicines initiatives in some 
overseas countries, for example, Thailand, it does not appear to be on their agenda in Fiji or 
the PICs.  Furthermore, WHO WPRO seek advice on trade issues from the trade and health 
regional advisor based in Manila which may mean that strategic opportunities to advocate for 
protecting access to medicines at a local level have been overlooked.  For example, the Non 
Communicable Diseases Regional Framework has a section on trade and legislation in regard 
to physical activity, nutrition, alcohol and tobacco but not on access to medicines.  This is a 
regional document that is translated into a national document which Cabinet endorses.  It is 
multidisciplinary, in that it is so not just housed within Ministry of Health, and is in the 
process of being signed off by all PICs with implementation assisted by WHO and SPC. 
 
At a national level, interview participants acknowledged that the Ministry of Health have 
started to collaborate more frequently with the Fijian MFAT on trade and health issues. 
Instead the agenda is based on Ministry of Health’s current strategic plan, which doesn’t 
include trade, TRIPS and access to medicines.  Stakeholders are also limited by their capacity 
constraints, particularly at the civil society level.  Here, national and regional NGOs are 
hesitant to move into trade and IPR advocacy, not only because of resource constraints, but 
because of its perceived complexity.   
 
Whereas several NGOs are involved in health advocacy, relatively few are involved in trade, 
or intellectual property rights advocacy.  Consequently there is very limited capacity for any 
trade and access to medicines advocacy amongst regional NGOs even if the issue was raised 
by their constituents.  In contrast, the most effective access to medicines campaigns in other 
developing countries have often been mobilized by partnerships formed between grass roots 
NGOs and their international NGO counterparts in the north.  This finding also relates to 
research objective five, which finds limited capacity amongst NGOs for human rights 
advocacy, as well as for trade and IPR. 
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5.2.4 Is trade and access to medicines considered in regional initiatives? 
 
Research objective four is “to place findings from the secondary objective within the broader 
context of the ‘regional integration process’ led by the Pacific Islands Forum Secretariat 
(PIFS) to evaluate whether the impact of trade-related factors on access to medicines is 
considered in the review of collective medicines procurement, medicines regulation, and 
regional integration of intellectual property rights.” 
 
Key findings for this objective are consistent with several of the findings discussed under 
objectives one, two and three.  In particular, the finding that a sector-by-sector approach to 
decision making in the trade and health sector appears to affect whether trade and access to 
medicines, which ideally requires a multi sector approach, is taken into consideration under 
regional integration initiatives.  The adverse effect on the profile of trade and access to 
medicines that arises from an apparent prioritisation of resources to further develop a 
traditional knowledge framework compared with IPR is a new finding under this objective.  
 
This sector-by-sector approach is illustrated in the health sector where various regional 
initiatives are being led by the WHO and SPC and in the trade sector, where regional IPR 
initiatives are led by PIFS with assistance from WIPO, IP Australia and other international 
development agencies such as the Asia Development Bank.   
 
Several initiatives led by WHO and SPC to review collective medicines procurement are 
progressing at a halting pace and do not appear to explicitly include the impact of IPR on 
access to medicines.  Furthermore, medicines regulation (testing for quality), is not yet part of 
these regional reviews.  However, it is worth noting that if out sourcing of medicines 
regulation, for example to the Australian Therapeutic Goods Authority, was ever considered in 
the future this could provide an alternative mechanism to international trade agreements (the 
conventional instrument for introducing TRIPS-plus provisions into national and regional IPR 
law), to introduce  pharmaceutical patent law that is TRIPS-plus to the region.  These TRIPS-
plus provisions were recently introduced to Australia in the free trade agreement with the 
United States. 
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In the trade sector a contract to continue the review of regional integration of IPR has not been 
renewed by the PIFS.  In 2004, the PIFS, WIPO and IP Australia finished implementing a 
three year Regionally Focused Action Plan (PIFS/WIPO/IP Aust, 2001)which included 
investigations into the integration of IP administration under a regional office. National 
sovereignty issues are a key factor for consideration in these reviews as currently the content 
and form of national IPR law varies widely in the region and is independently managed by 
each PIC. The two foreign agencies continue to work bilaterally with different countries such 
as PNG, which is the most technically advanced IP office.   
 
Two observations are worth noting here.  Firstly, the assistance PICs receive for IPR capacity 
building, for example from WIPO, is not from independent sources.  This situation may 
introduce a neoliberal bias that is misaligned with development-friendly policy that is more 
appropriate for the Pacific region. 
 
Secondly, research findings under objective one suggest that the terms of reference for a much 
referenced report prepared for the PIFS, titled ‘A regional IPR Office for the South Pacific: 
cost benefit analysis’ (Farquhar, 2005), were perhaps not broad enough from a development 
perspective.  This report was an output from the Asia Development Bank technical assistance 
program to strengthen regional cooperation and integration in the South Pacific, funded by the 
Commonwealth Secretariat.  Here, the terms of reference of this report could have been 
broadened to include the indirect economic impacts of streamlining patent registration. 
 
The configuration of any proposed regional IP models will have a significant implication on 
national and regional development policy because it has the potential to accelerate patent 
registrations without commensurate economic benefit for PICs, who are not net IP generators.  
Three external environmental factors are of particular significance here.  The trilateral patent 
office harmonisation underway between the EU, US and Japan, the Chapter three 
harmonisation of world wide PCT offices, described by Drahos  as a ‘patent pipeline’ (Drahos, 
2007), and increasing homogeneity of patent examination criterion.  This global harmonisation 
is designed to make patent registration more seamless between countries and regional trading 
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blocs.  In theory this will increase economic growth and technology transfer.  However, these 
gains are unlikely to be captured by developing countries, such as the PICs, as the majority of 
patents being filed are by foreigners.   
 
This finding suggests that further investigation of alternative regional IPR initiatives, from a 
development-friendly perspective in particular, is timely. As noted, earlier negotiations with 
the EU EPA suggested the PICs could have to consider integrating IPR at a regional level and 
to join PCT as a regional bloc.  Under pressure to meet negotiating deadlines, it is conceivable 
these concessions could be made by trade negotiators without adequate economic and social 
impact analysis being undertaken.   
 
A prioritisation of limited resources within the PIFS to focus on further developing a regional 
traditional knowledge framework, in preference to IPR programmes, is a further significant 
finding. PICs continue to face unauthorized use of their traditional knowledge which, in the 
main, conventional IP law fails to protect.  A draft model law on ‘Traditional Biological 
Knowledge, Innovation and Practices’ was developed for the Pacific region in 2000 by the 
Secretariat of the South Pacific Environmental Programme (SPREP). At the request of Forum 
Leaders, traditional knowledge will be further developed by the Forum Secretariat in 
2008/2009. Resource constraints are likely to mean that traditional knowledge will be 
prioritised over further research into an appropriate regional or national IPR framework, 
development of an IPR policy framework for the CROPS, and assistance to individual PICs to 
ensure WTO safeguards are incorporated into national IPR law.   
 
There is an understandable preference for traditional knowledge amongst Pacific people 
because of a perception it may capture greater economic benefits for the region compared with 
IPR and because the ownership rights shared by a group under traditional knowledge are more 
culturally relevant and highly important to them than IPR, where rights are owned by 
individuals.  However, evidence from the literature reviews suggest that taking this approach 
may mean the region risks being forced to adopt an IPR model that is not development 
friendly.  Findings from objective one suggest a shift in thinking would be advantageous so 
IPR is not viewed by Pacific people from a purely economic perspective. Instead, discussions 
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about IPR might be better ‘reframed’ as an essential instrument of development policy that can 
be applied to protect Pacific islanders’ rights to public goods, to reinforce national 
sovereignty, and to achieve social, cultural and health development goals.  In a worst case 
scenario the public commons the PICs and Fiji already have access to, may be eroded away 
through international trade agreements, such as EU EPA and WTO accession packages, while 
the PIFS work programmes remain focused on developing the traditional knowledge model.   
 
5.2.5 What is the scope for using human rights? 
 
 
Research objective five is “to assess the general scope for using human rights instruments to 
protect access to medicines in Fiji.”  The findings from this objective are best discussed in the 
context of credibility issues raised following on from the recent political instability, capacity 
limitations, and human rights challenges and opportunities. 
 
In the first instance, findings suggest that any philosophical or political application of human 
rights instruments by the Fijian government (taking the moral high ground) to analyse the 
impact of trade agreements on health could lack credibility in the international arena because 
of the treatment of civilians by the military regime in the 2006 coup.  Political credibility 
could be compromised further by the temporary suspension of the Fijian Human Rights 
Commission from the United Nations.  Lack of ratification of the ICESCR, the main 
international convention used to challenge international trade agreements on the right to 
health, is a further limitation.  
 
In general terms, findings are that the capacity for human rights advocacy amongst the PIFS, 
CROPS, national governments, and NGOs appears to be limited while the greatest capacity 
exists within some UN agencies, for example UNDP and their special human rights 
programme, RRRT.  The primary focus of human rights mechanisms is generally on civil and 
political rights, with few organisations promoting the right to health, and none promoting the 
right to access to medicines.  For example, the UNDP have linked human rights into 
HIV/AIDS policy and the regional strategy.  However, here the emphasis appears to be on 
civil rights, such as non discrimination, rather than the right to access to medicines. 
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Human rights mechanisms face unique challenges in the Pacific where people are generally 
suspicious of human rights and raise concerns relating to the conflict with customary rights, 
limitations on resources, and onerous international treaty body reporting obligations as 
limitations to its implementation.  The Pacific region has the lowest ratification rates 
worldwide of the core international treaties. It has been acknowledged that a human rights 
blend with customary rights needs to be developed involving Pacific islanders.  Despite these 
challenges there is a broad infrastructure for its promotion.  
 
Interviewees expressed a wide range of views, from supporting the concept of applying human 
rights to protect access to medicines, to rejecting the concept.  This response is likely to reflect 
the underlying suspicion of human rights by Pacific people as well as the political nature of 
advocating for health rights in the wider global trading system.  However, the ‘right to health’ 
was considered easier to promote, than say civil rights, because it is less likely to offend power 
bases associated with traditional forms of decision making in the Pacific. 
 
In the short term, these challenges suggest the human rights approach to health may be better 
fostered through UN agencies and NGOs.  This view was endorsed by several interviewees 
from NGOs and RRRT, who commented the potential exists to develop access to medicines as 
a right if the need was demonstrated by the people they represent.  The absence of demand-
side factors, identified under objective two, that could galvanise UN and NGO constituents to 
raise the profile of trade and access to medicines might limit this from happening in the 
medium term 
 
The literature research and interviews highlighted several areas where human rights could 
most practically be introduced to mitigate trade obstacles to access to medicines in Fiji and at 
a regional level.  These, along with other suggested responses, are listed in Appendix 5. 
 
5.3 The significance of this research for human rights theory 
 
As discussed in Section 1.5, rather than applying human rights theory as a research lens, this 
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thesis uses human rights as one system, in a multi-system approach. The findings that are 
significant for human rights theory therefore reflect this approach by either describing the 
interface of human rights with these other systems, for example human rights and new 
regionalism, or they are specific to human rights, for example, putting the principle of 
indivisibility into practice.   
 
In this research, human rights appeared to have the least significant influence on shaping how 
Fijian and Pacific people view trade and access to medicines compared with other national and 
regional factors relating to trade, health and local culture. Of significance, from a human rights 
perspective, these other factors also appear to be shaping how Pacific people view human 
rights instruments rather than the other way around. From a human rights theory perspective it 
would be interesting to observe how, and at what point this dynamic could shift so that human 
rights, or a human rights blend with local custom, became a key driver to stimulate access to 
medicines advocacy either at government or civil society level.   
 
All of the complex challenges facing the international human rights framework, discussed in 
Chapter 2, appear to be reinforced at both the regional and national level in the Pacific.  The 
most significant of these is cultural relativism; the perceived conflict between the hegemonic 
human rights model with values and customs in the Pacific.   
 
Difficulty experienced with implementing the principle of indivisibility of human rights was 
also reinforced because often ‘development’ involves making trade offs between conflicting 
interests. The significance here for human rights theorists was that the UNDP special human 
rights programme, RRRT, found this principle relatively easy to implement.  The interview 
participant mentioned this was helped by the organisation being modeled on a rights based 
approach.  This observation might suggest the principle of indivisibility is more easily put into 
practice by organisations that focus exclusively on human rights compared with other ‘variant’ 
organisations that apply human rights in conjunction with other multidisciplinary tools, for 
example ECREA.  If this is so it would be important to acknowledge these differences and to 
encourage information exchange between these diverse organisations to help develop the new 
tools and mechanisms needed to assist with this.   
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Some of the research findings suggest that a unique set of factors associated with small island 
developing states having limited resources, together with the pressures of regionalism may be 
creating a context that is uniquely shaping the views of Pacific islanders on trade and access to 
medicines.  This raises the question for human rights theorists, while acknowledging there are 
human rights issues that are unique to small island developing states (for example, rising sea 
levels as a result of climate change) is there a unique set of human rights mechanisms, 
challenges and responses that are specific to small island developing states undergoing 
regionalism and how might these be supported.     
 
The research identified the emergence of two new challenges for human rights theory.  First, 
the concept of  collective rights of individual countries in the ‘new regionalism’ envisaged by 
the EU, particularly for regions comprised of small island developing states, such as the 
Pacific region, and second, the relationship of human rights at the interface with traditional 
knowledge.  This would warrant further research, particularly as human rights mechanisms 
currently function at the state level, whereas the proposed EU EPA envisaged dealing with 
institutions and aid distribution through new regional architecture versus individual states. An 
example of this could be the justification on human rights grounds for collective compulsory 
licensing to achieve regional health development goals, as opposed to compulsory licenses 
being raised by individual states. 
 
The interest in developing traditional knowledge model law amongst developing countries, 
including the PICs, provides a new opportunity to scope out the relationship of human rights at 
its interface.  I would expect this to be more compatible and synergistic than the relationship 
with IPR, because of the focus on socioeconomic and cultural development and collective 
distribution of the commercial benefits. 
 
In the global context, this research reinforces the significance for human rights theory to 
provide an alternative perspective to the dominant, global trading system and to counter the 
expansion of intellectual property rights, which is the main legal instrument that restricts 
access to public goods for developing countries, in particular access to essential medicines.  
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Finally, findings that refute aspects of human rights theory were less clear.  However, the 
human rights theory was a useful framework for this thesis because it offered insights into 
how socioeconomic and cultural rights are traded off civil and political rights in the neoliberal 
order, which is particularly relevant in the Pacific region where trade liberalisation is 
dominating the economic agenda. 
 
5.4 Conclusion 
 
“The world we have made, as a result of the level of thinking we have done thus far, 
creates problems we cannot solve at the same level of thinking at which we created 
them”. 
Albert Einstein 
 
The extent to which trade restricts access to medicines and has adverse effects on health and 
economic development in Fiji and the Pacific region may depend critically on how Pacific 
Island Countries cope with the forces of regionalism and the realities of joining the global 
trading system, where there are pressures to make concessions in areas such as TRIPS. Yet, 
the level of awareness of these potential trade restrictions generally appear to be low and 
inconsistent amongst most of the key health and trade stakeholders at the national and regional 
level. A central question being asked in this research is what underlying factors shape how 
Pacific islanders view trade and access to medicines, notably in the area of trade, health, local 
culture, and human rights, and what are the regional and national responses to mitigate 
potential trade impediments.  
 
By combining a public health lens with a multi-system review of population health trends, 
intellectual property rights law, trade policymaking, and human rights, this research has 
elaborated findings that are usually less evident because they are conventionally researched 
and managed in isolation, on a sector-by-sector basis.  The findings suggest human rights are 
less significant, while the challenges associated with small island developing states, together 
with local cultural preferences and the pressures of regionalism have a more direct influence.  
The combined effect of these factors may be creating a unique context that is leading the 
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Pacific region not to deal with these issues as well as some other developing countries might. 
 
In a worst case scenario, TRIPS flexibilities may be signed away by trade negotiators, 
unaware of the indirect costs to the health sector, and subsequently to economic development 
through sickness and loss of livelihoods.  Once integrated into national legislation, these 
obligations might sit, like a ‘trojan horse’, until they are triggered at a later stage and cost the 
government more with no commensurate economic benefits.   
 
Improvements to current, declining population health trends in the Pacific region are crucial to 
the region being able to sustain any future benefits from economic development, especially if 
the PICs have had to absorb significant adjustment costs and suffer the loss of national 
sovereignty under the pressures of trade liberalisation and regionalism.   
 
By not acting now to declare public good priorities in the Pacific region, opportunities are 
already being lost to limit potential trade restrictions on access to medicines which could have 
an irreversible, adverse effect on health and economic development in the region in the future.  
National and regional stakeholders in trade policy and health should therefore start to 
acknowledge trade and access to medicines in their agendas, and begin to systematically 
implement a broad range of multidisciplinary responses to mitigate these, some of which are 
suggested in this research paper. 
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Recommended websites 
 
Several recommended websites (in no particular order) providing information about the 
relationships between economic globalisation, international trade agreements, TRIPS and 
economic policy, and public health. 
 
www.cpath.org - Center for Policy Analysis on Trade and Health 
www.cptech.org – Consumer Project on Technology 
www.keionline.org – Knowledge Ecology International 
www.IP-health – Intellectual property relating to health watch 
www.IP-watch – Intellectual property watch 
http://www.ciel.org/ – Centre for International Environmental Law 
http://www.twnside.org.sg/heal.htm – Third World Network 
http://www.msf.org/ -  Médecins Sans Frontières 
www.ictsd.org - International Centre for Trade and Sustainable Development 
http://www.3dthree.org/en/ - trade, human rights, equitable economy   
http://www.southcentre.org/ an intergovernmental organisation of developing countries 
http://www.oxfam.org/en/ - Oxfam International  
http://cgkd.anu.edu.au/ - Centre for Governance of Knowledge and Development, Aust 
National University, publishers such as Peter Drahos. 
http://www.vanuatu.usp.ac.fj, - useful documents on civil society in the Pacific are available in 
the South Pacific Civil Society Library 
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Appendix 1: Human Ethics Approval Forms 
 
 
 
TO Sarah Meads 
COPY TO Professor John Overton, Supervisor 
FROM Dr Allison Kirkman, Convener, Human Ethics Committee 
 
DATE 1 October 2007 
PAGES 1 
 
SUBJECT Ethics Approval: No 129/2007, The impact of international 
trade agreements on access to essential medicines in Fiji: 
national and regional responses. 
 
 
Thank you for your application for ethical approval, which has now been considered by the 
Standing Committee of the Human Ethics Committee.  
 
Your application has been approved and this approval continues until 31 January 2008. If your 
data collection is not completed by this date you should apply to the Human Ethics Committee 
for an extension to this approval. 
 
 
 Best wishes with the research. 
 
 
 
  
 Allison Kirkman 
 Convener  
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INFORMATION SHEET 
 
Putting a Public Health Perspective into International Trade Negotiations and Trade 
Related Intellectual Property Rights in Developing Countries: A human rights-based 
approach to accessing essential medicines - Fiji as a case study 
 
Dear Project Participant, 
 
My name is Sarah Meads and I am a Masters student in Development Studies at Victoria 
University of Wellington. As part of this degree I am undertaking a thesis research project.  
The project will investigate the extent to which trade obligations, such as Trade Related 
Intellectual Property Standards (TRIPS), restrict access to essential, affordable medicines in 
Fiji.  My intention is to identify responses Fiji may use, either at a national or regional level, to 
mitigate any adverse restrictions, particularly during trade negotiations. I have obtained ethics 
approval from the University before involving human participants. 
 
I am inviting over 20 participants from several different government and non government 
organisations associated with health development and medicines procurement in particular, to 
participate in this study over a three week period.  Participants will be interviewed on an 
individual basis.  They will be asked a series of semi-structured questions prompted by a 
check list that I have prepared in advance.  Questions will not be of a personal nature and you 
have the right to refuse to answer any question at anytime. The interview is expected to take 
one hour. I will record the interview either on an audiotape recorder, or by taking notes, and 
type up the main points as a draft transcript after the interviews are complete.  You will be 
given an opportunity to modify the draft transcript of your interview before it is finalised for 
use in my thesis. 
 
Information from the interview will form the basis of my research project. It will not be 
possible for you to be personally identified, or for your organisation to be named, unless you 
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are comfortable with this and have signed an ‘Informed Consent Form’ to that effect. All 
material collected will be kept confidential. No other person besides myself and my 
Supervisor, Professor John Overton, will see the transcripts or hear any audiotape recordings 
of the interview.   
 
The thesis will be submitted for marking to the School of Geography, Environment and Earth 
Sciences and a copy kept in the University Library. It is possible that one or more articles will 
be submitted for publication in scholarly journals.  Transcripts of the interview will be 
destroyed and any audiotape recordings will be electronically wiped two years after the end of 
the project unless you indicate that you would like them returned to you. 
 
Should you feel the need to withdraw from the project, you may do so without question at any 
time before the information is analysed.  
 
If you have any questions about this project or would like to receive further information, 
please feel free to ask me now, or to contact me later on ++ 64-4-934-0081 or 
smeads@paradise.net.nz or my supervisors, Professor John Overton, at the School of 
Geography, Environment and Earth Sciences at Victoria University of Wellington, P O Box 
600, Wellington, phone ++64-4- 472-1000 and/or Dr Peggy Fairbairn-Dunlop, Associate 
Professor Va’aomanu Pasifika, at the School of Humanities and Social Sciences, Victoria 
University of Wellington, phone ++64-4-463-6867. 
 
I wish to thank you most sincerely for participating. 
 
Yours sincerely 
Sarah Meads   
(Student enrolled in Master of Development Studies, Victoria University of Wellington)
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CONSENT TO PARTICIPATION IN RESEARCH 
 
Putting a Public Health Perspective into International Trade Negotiations and Trade 
Related Intellectual Property Rights in Developing Countries: A human rights-based 
approach to accessing essential medicines - Fiji as a case study 
 
I have been given, and have understood, an explanation of this research project.  I have had an 
opportunity to ask questions and have them answered to my satisfaction.  I understand that I 
may withdraw myself (or any information I have provided) from this project (before 
information collection and analysis is complete) without having to give reasons or without 
penalty of any sort. 
 
I understand that any information I provide will be kept confidential to the researcher, the 
supervisor.  The transcript of the interview will be destroyed and audiotape recordings will be 
electronically wiped two years after the end of the project unless I indicate that I would like 
them returned to me. 
   Please cross-out which is not appropriate: 
   I agree to take part in this research 
 
   I consent to information or opinions which I have given being attributed to me in this 
research thesis and in any articles or reports related to this research 
 
   I wish to remain anonymous so that information or opinions which I have given and that 
are being used in this research thesis and in any articles or reports related to this research 
does not identify me.   
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   I understand that I will have an opportunity to check and to modify the draft transcript of 
my interview before publication. 
 
   I understand that the information I provide will not be used for any other purpose or 
released to others without this written consent. 
 
   I would like to receive a copy of the summary of this research thesis when it is 
completed. 
 
  I would like the audio tape recordings, if that was the method used to record my 
interview, to be sent to me at the conclusion of the project. 
 
 
Participant: 
 
Name:       
 
Signature:      
 
Date:         
 
Researcher: 
I certify that this form and its attached “Information Sheet” cover letter provide a complete 
and accurate description of the aims and processes of this research project. 
 
Name: Sarah Meads 
 
Signature:     
 
Date:      
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Appendix 2: Themes covered in field research interviews 
 
 
1. Elaboration of the process of medicines selection and procurement by the Fijian 
government and private sector and of how global procurement schemes, eg.Global 
Fund, function in Fiji. 
 
2. The extent to which these are influenced by regional integration, in particular, the 
review of collective medicines procurement, the review of regional intellectual 
property rights and the process of conducting regional trade negotiations, eg. EU EPA. 
 
3. Identification of any reported restrictions of trade-related factors on access to essential 
medicines in Fiji. 
 
4. Evaluation of any desirable essential medicines, or medicine groups, not currently 
procured because trade-related factors restrict their access.  
 
5. Elaboration of the mechanisms used to assess the potential impact of regional trade 
agreements on access to medicines in Fiji and how this is factored into the national and 
regional trade negotiations process.  
 
6. Identification of strategic and policy responses Fiji may use, either at a national or 
regional level, to mitigate adverse restrictions, particularly during trade negotiations 
and the process of regional integration.  
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Appendix 3: Description of the key international trade agreements 
 
 
1.0 Bilateral Trade Agreements 
 
Fiji is partied to non-reciprocal bilateral trade agreements (BTAs) with small island states of 
the Forum such as Tonga, Tuvalu and the Cook Islands, and reciprocal agreements with larger 
trading partners that have the capacity to trade with Fiji on an equal footing, for example, 
Papua New Guinea, Vanuatu, Australia and China.  Negotiations for BTAs are continuing 
with New Zealand, Solomon Islands, Kiribati, Nauru, Samoa and New Caledonia (The 
Republic of the Fiji Islands Ministry of Foreign Affairs and External Trade, 2006). 
 
2.0 Regional Trade Agreements  
 
Fiji’s regional trade agreements (RTAs) include the Melanesian Spearheads Group (MSG), 
which Fiji joined in 1998 with the founding participants: PNG, Vanuata and Solomon Islands; 
the South Pacific Regional Economic Cooperation Partnership (SPARTECA); the Pacific 
Island Countries Trade Agreement (PICTA), and the Pacific Closer Economic Relations 
(PACER).  Fiji is also a member of the African, Caribbean and Pacific (ACP) group engaged 
in negotiations for an Economic Partnership Agreement (EPA) with the EU.  The major 
regional trade agreements are described below. 
 
2.1 SPARTECA 
 
In 1981 Australia and New Zealand guaranteed 13 Pacific Island Countries (PICs) non-
reciprocal preferential access for a long list of exports under the SPARTECA. This was 
critical to the establishment of the textile and garment industry in Fiji, reinforced by the Free 
Economic Zones established under the first Rabuka Government.  By 1999 Australia was 
taking 70% of Fiji’s total textile exports (Kelsey, 2004) accounting for 26% (1997) of Fiji’s 
total domestic exports. The Australian government introduced a self fulfilling Import Credit 
Scheme (ICS) which ran foul of WTO Rules of Origin and was replaced in 2001 by the 
SPARTECA Textiles, Clothing and Footwear (TCF provisions).  The benefits have since 
 121 
reduced in the face of NZ and Australia lowering tariffs to imports from China and Asia and 
cheaper competition forcing down garment worker wages to below the poverty line. In August 
2004, Australia announced it would be extended for seven years with a review after three 
years, however the benefits for renewal of SPARTEC-TCF are diminishing as a result of these 
trends. 
 
2.2 PICTA 
 
In 1999 Pacific Island Forum Leaders endorsed, in principle, a free trade area among Forum 
Members.  In 2001, 9 PICs55 signed the Pacific Island Countries Trade Agreement (PICTA) 
which is now in place and, together with Australia and New Zealand signed the Pacific 
Agreement on Closer Economic Relations (PACER), seen as an umbrella agreement for 
PICTA.   
  
Fundamentally, PICTA is supposed to lead to a free trade area amongst ratifying PICs.  Tariff 
and non-tariff barriers to PICTA trade are to be gradually removed over the next ten years for 
products which have at least 50% of PIC value added.  If all the parties ratified it is expected 
to create a consumer base of over 7 million. Theoretically the concept is seen as a ‘training 
ground’ for lifting competitiveness and an economic ‘stepping stone’ to the eventual 
integration with multinational trading system.  
 
However, many international studies have concluded that developing countries, especially 
small island developing states, will not do as well setting up free trade areas amongst 
themselves (see for example Narsey, 2006) compared with a developed country.  This is due  
to the tendency in small markets for monopoly domination, lack of scales of economy, 
resistance to trade and likelihood of loss of jobs.  Theoretically, if PICTA succeeds in the 
medium term, and PACER also comes into effect, then investors are likely to invest in areas 
they know will have a fast turnaround of their capital before their industries eventually 
collapse under competition with Australia and New Zealand.   
                                                 
55
 Fiji, PNG, Solomon Islands, Tonga, Samoa, Cook Islands, Niue, Nauru and Kiribati have ratified. Vanuatu and 
Tuvalu have not yet signed, while the three Compact countries have been given a grace period  
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Furthermore, there has been external pressure from the EU for PICs to form a regional trading 
bloc arguing that the post-Cotonou EPAs will be facilitated if the PICs are bound by an FTA, 
which then would facilitate the WTO compatibility of the EPAs.   
 
The Pacific Plan, signed off in 2004 by Pacific Forum Leaders is a framework for coordinating 
dialogue and research on regionalism and the economic and social gains this may bring for 
Pacific Island people. 
 
2.3 PACER 
 
PACER is the agreement signed and ratified by all PICs and Australia and New Zealand.  
Negotiations are scheduled to begin eight years after the PICTA came into force (in 2013) 
unless they are triggered earlier by PICs granting significant tariff reductions to other 
developed countries, for example, the EU through the EPAs.  It has been described by Kelsey 
as a ‘reactive’ agreement, protecting the trading interests of Australia and New Zealand 
(Kelsey, 2004).  However, access to labour markets in Australia and New Zealand under the 
PACER agreement would represent a significant advantage to PICs.  
 
2.4 EPA 
 
Fiji is signatory to the Lome Convention under which the European Union (EU) grants non-
reciprocal trade preferences to countries in Africa, the Caribbean and the Pacific (ACP States).  
The EU ACP trade negotiations is a legacy of the British Empire and the incorporation of 
preferential trading arrangements in Lome Conventions since 1975 with their ex-colonies.  As 
is the present case in Fiji, the ‘rent-seeking’ governments and elites were in many cases the 
beneficiaries rather than the poor and proved an obstacle to industrial productivity (Robertson, 
2006). 
 
The economic, political and aid dimensions of the Lome Conventions reflected Europe’s 
development ideology.  By the time of Lome IV in the 90’s, aid funding through the European 
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Development Fund was used to complement the World Bank structural adjustment agenda, 
requiring ACPs to pursue neoliberal policies in the name of development (Kelsey, 2005). 
 
In 2000 a new partnership, the Cotonou Agreement, was announced requiring ACP countries 
to implement reforms and replace trade preferences with reciprocal rights for European goods 
to have access to their markets.  Aid was bound to trade, making it conditional for ACPs to 
display ‘good governance’ before being rewarded with aid. 
 
The EU ACP Partnership Agreement is the most important foreign policy instrument of the 
EU .  This is because the majority of the WTO membership involved with the EU regard the 
Agreement as an essential element in an overall strategy for the evolution of global trading 
arrangements. 
 
Economic and trade conditions under Cotonou are required to produce ‘WTO compatible’ 
outcomes, bringing non WTO members within the ACP under its rules.  Moreover the EU 
Commission secured ‘WTO-Plus’ negotiations, including the issues of competition policy and 
investment that ACP States have steadfastly resisted in the WTO.  Negotiations on services 
are designed to advance the current WTO negotiations on GATS.  For two Pacific Islands 
these requests include reducing foreign ownership restrictions on land (Kelsey, 2005). 
 
The alternatives available to ACPs that decide not to participate, the ‘Everything But Arms’ 
option for LDCs and the ‘Generalised System of Preferences’ for developing countries, carry 
fewer risks, but leave those countries at the whim of the EU, which can alter, or eliminate, 
those arrangements at will. 
 
As part of the new convention between ACP countries and the EU, there is a move towards 
Regional Economic Partnership Agreements (REPAs) whose objectives are the progressive 
removal of barriers to trade between the parties in accordance with WTO negotiations. 
 
Very little of the PICs duty revenues will be directly at risk because of reduction of duties on 
imports from the EU.  Thus while the EPAs will not pose any great danger to Pacific ACP 
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fiscal stability, their triggering of PACER will have drastic consequences, because they would 
have to offer the same concessions to New Zealand and Australia, reducing their revenue from 
import duty. Percentages of total import duty lost if duty on 90% of imports from Australia 
and New Zealand were reduced would mean none lose 38% of revenue (Narsey, 2006). The 
EU however, is not expected to make any concessions as they could set a precedent for other 
larger ACP states or developing countries. 
 
In early December 2007, under trade negotiation deadlines set by the EU, rather than a 
regional agreement being signed between the EU and the 14 PICs, both Fiji and PNG signed 
individual trade agreements.  The implications of these agreements for the countries and the 
region as a whole are still being analysed.   
 
3.0 Sugar Protocol Agreement 
 
The Lome and Cotonou supply agreements with the EU underlay Fiji’s export-led growth 
through sugar in the mid to late twentieth century.  Fiji, along with sugar producers from the 
ACP group has depended on an annual export quota to the EU, at prices aligned with the price 
of sugar within the EU itself. 
 
At the WTO, the EU recently lost a case mounted by Australia, Brazil and Thailand against its 
subsidised sugar exports, and also lost its subsequent appeal against the decision.  The EU 
therefore announced the regime would be overhauled. 
 
The EU has proposed price cuts, due to begin 2005, but extended to 2006. Negotiations are 
ongoing, however, in 2006 these cuts were predicted to result in a 23% fall in the price of 
sugar to Fiji (Narsey, 2006). 
 
The Fijian Cabinet approved in principle a reform plan for the sugar industry, which was 
prepared by Indian Experts, and commenced negotiating with the EU for aid to overhaul the 
industry.  These negotiations were stalled after the 2006 coup, when aid was withheld until 
certain conditions were met by the military, for example a date set for a democratic election.   
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4.0 Multilateral Trade Agreements 
 
Fiji acceded to the GATT in 1993, becoming a member of the WTO in 1996.  It accords at 
least Most Favoured Nation (MFN) tariff status to all its trading partners.  As part of its 
undertakings in the Uruguay Round, Fiji bound all its agricultural tariffs and some 43 per cent 
of its industrial lines.  Under the General Agreement on Trade in Services (GATS), Fiji has 
scheduled commitments to grant foreign suppliers the rights to establish a commercial 
presence and to invest in two sectors, hotels and restaurants.  
 
Fiji is working towards WTO TRIPS compliance. 
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Appendix 4: Overview of intellectual property rights in the Pacific region 
 
1.0 WIPO intellectual property treaties  
 
The Paris Convention, administered by WIPO, is the key Treaty dealing with substantive 
patent law.  Many of its provisions are incorporated by reference into the WTO TRIPS 
Agreement.  Through this web of obligations under the WIPO and WTO frameworks, PNG, 
Tonga, Fiji and Solomon Islands have international obligations regarding substantive patent 
law. WIPO has been active in the region providing technical assistance for countries to join 
and implement the various treaties that it administers. The status of PICs under the various 
Treaties is summarised in Table 3 below. 
 
The Patent Cooperation Treaty (PCT) is a registration treaty and simplifies the process of 
applying for patent protection in member countries.  A single PCT ‘international’ application 
can be used to apply simultaneously for patent protection in all PCT member countries.  This 
is in contrast to the national registration system under Treaties such as the Paris Convention 
which requires individual applications to be filed in each country where patent protection is 
sought.  At present only PNG is a member of PCT.  If other PICs join the Treaty, the currently 
low rate of patent registration in the region could escalate dramatically.  This may raise a 
barrier to some generic drugs being imported and increase the price of patented drugs for the 
PICs. 
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Table 3: Summary of Country Development Status, WTO Membership, and IP Treaty 
Membership 
 
Country 
DC/LDC 
WTO Membership Status 
And TRIPS Agreement 
(Tot. members 149) 
Paris 
Convention 
Treaty 
(Tot. mbers  
169) 
PCT Treaty 
(Tot. 
members 
128) 
WIPO 
Convention 
Membership 
(Tot. mbers 
183) 
Fiji 
DC 
Member 1996 
 (former GATT member) 
  Member1972  
PNG 
DC 
Member 1996 
(former GATT member) 
Member  
1999 
Member 
2003 
Member 1997 
Solomon 
Islands 
LDC 
Member 1996  
(former GATT member) 
   
Tonga 
DC 
Working Party on accession established 15 
Nov 1995, WTO members approved 
Tonga’s terms of accession at the 
Ministerial Meeting, Dec 2005.  Ratified by 
Govt of Tonga in July 2007, becoming 150th 
member 
Member  
2001 
 Member 2001 
Samoa 
LDC 
Working party on accession established July 
1998.  Samoa submitted initial offers in 
goods and services and informal 
consultations held 2003. Still working 
through the process of accession in 2007, 
however the Working Party terms appear to 
include harsh provisions 
  Member 1997 
Vanuatu 
LDC 
Final meeting of the Working Party held on 
Oct 2001. Vanuatu postponed forwarding to 
WTO General Council after realizing giving 
away too much in accession package. Still 
under review  
   
Source: Ey, F. (2005). pp. 14 and 15 
Key: ‘DC’ – Developing Country; ‘LDC’ – Least Developed Country (as per UN classification).  All the 
countries in the PICs are also classified by the UN as Small Island Developing States (SIDS) 
 
 128 
2.0 WTO membership 
 
WTO membership and accession, are key drivers for patent law reform in the Pacific, as they 
are in many other regions.  The current status of WTO membership is summarised in Table 3. 
 
Fiji and PNG have to provide patent protection for pharmaceutical products from 1 January 
2005, however, because it is an LDC, the Solomon Islands does not have to comply until 
2016.  The Solomon Islands also has until 2013 to implement other elements of TRIPS 
Agreement.  Under its WTO accession package, Tonga has until 1 June 2008 to implement 
TRIPS obligations.  
 
For countries seeking to accede to the WTO, these timeframes are determined by the terms of 
their accession.  Samoa and Vanuatu, both LDCs, should seek to have these extended 
timeframes included in their WTO accession packages.  However, in June 2007, the proposed 
accession package for Samoa contained tough obligations which attempt to ‘bring forward’ 
TRIPS implementation and to include TRIPS-plus provisions such as data exclusivity 56.   
 
3.0 Main features of national patent laws and patent activity 
 
Patent laws in the Pacific vary widely across the region.  They are influenced by factors such 
as WTO membership activity, donor assistance and colonial-era regimes, summarised in Table 
4 below. These differences are broadly classified under three categories: 
(i) Registration countries: only re-register United Kingdom (or other overseas) patents and 
do not have the capacity to examine and register in their own country eg.  Kiribati, 
Nauru, Solomon Islands, Tuvalu and Vanuatu; 
(ii) WTO-based reform countries: these states have joined WTO, or are in the process of 
doing so, and have revised their patent laws to be TRIPS-consistent eg. PNG, Tonga 
and Vanuatu (although Vanuata’s legislation has not yet commenced operation as law).  
In some cases the legislation is ‘TRIPS-plus’ going beyond the minimum standard 
                                                 
56
  Personal correspondence with Oxfam New Zealand re.evaluation of Samoa’s WTO accession package, July 
2007 
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required by the WTO TRIPS Agreement.  WIPO has been active in providing technical 
assistance to these countries, including drafting and providing model laws.  As a 
consequence, there are many similarities in the legislation in these countries;  
(iii) Transitional countries: in the process of reviewing and amending their patent regimes, 
either to update colonial era or early post-colonial laws to ensure TRIPS compliance.  
These reviews are undertaken in the context of either the country being a WTO 
member (as for Fiji) or seeking to accede to the WTO (as for Samoa). This is 
particularly the case for compulsory licencing where some countries do not take full 
advantage of the TRIPS flexibilities. For example, Fiji has been redrafting national 
patent law to remove some of the ‘inflexibilities’ with support from external experts 
such as Dr Carlos Correa, a prominent IPR expert advocating for developing countries.   
 
 Table 4: Patent laws in the Pacific Island Countries 
 
Category Country Patent Law 
Re-registration Kiribati 
Nauru 
Solomon Islands 
Tuvalu 
Vanuatu 
Re-registration of United Kingdom Patents Ordinance (Cap 87) 
Patents Registration Act 1973 
Registration of United Kingdom Patents Act 
Re-registration of United Kingdom Patents Ordinance (Cap 61) 
Registration of United Kingdom Patents Act (Cap 80) 
WTO-based 
reform  
Papua New Guinea 
Tonga 
Vanuatu 
Patents and Industrial Designs Act 2000 
Industrial Property Act 1994 
Patents Act 2003 (not yet in force) 
Transitional Fiji 
 
Samoa 
Patents Act (Cap 239) Patent Bill under consideration – based 
on UK and Singapore patent legislation 
Patents Act 1972 
Source: Ey, F.(2005) pp. 19 
 
Patent offices in each country are usually a small office that deals with all IP rights and in 
many countries it is combined with the company’s registry.   PNG has a patent office with the 
greatest capacity.  
 
Generally the Patent Office is responsible for three functions: (i) searching (ii) examination 
and the granting of patent applications, and (iii) administration of a register of patents that 
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have been granted, working within the context of the national patent laws. In some countries, 
their function is limited to re-registration of patents already granted in another nominated 
country., for example the United Kingdom, while in others, all patents are registered without 
scrutiny and their validity is tested in court if they are appealed. 
 
Search and examination capacity is limited and IP Australia has an arrangement to provide 
patent searches and examination for the IP offices of Tonga, Fiji and PNG (Farquhar, 2005). 
 
Patent activity is very low in the Pacific.  The vast majority of applications are made by 
foreign applicants and many are in the pharmaceutical categories.  This can be expected to 
increase rapidly, as experienced by other developing countries, if TRIPS obligations or PCT 
was introduced to more countries in the region.  This could happen as a result of three 
independent mechanisms: (i) trade agreements such as EU EPA or PACER, (ii) collective 
medicines procurement which triggers a review (and harmonisation) of IPR amongst the 
countries that take part, or (iii) a review of collective medicines regulation which results in 
joining the proposed joint Aust/NZ TGA that already incorporates TRIPS-plus patent 
obligations Australia inherited under the Australia/US free trade agreement. 
 
4.0  Doha declaration and ‘paragraph 6 decision’ application in the Pacific 
 
There are two factors that currently limit the application of the “Paragraph 6 Decision” in the 
Pacific region: (i) it only applies to PICs that are WTO members (PNG, Fiji, Solomon Islands, 
Tonga) that are bound by the WTO TRIPS Agreement (ii) the low patent activity in the region 
means that it is less likely a compulsory licence needs to be issued to overcome a patent.  
 
The Decision could be of significance to the WTO members given that their health priorities 
include combating rising levels of HIV/AIDS and many of the new and second generation 
drugs are on patent.  However, there is again an issue about whether there are patents in force 
for relevant medicines that require a compulsory licence mechanism.   
  
The “Paragraph 6 Decision” incorporates a regional mechanism for pharmaceutical 
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procurement and production.  This is based on establishing a regional exporting hub in which 
a country either manufactures and exports to other countries under a regional trade 
arrangement or imports pharmaceuticals under a compulsory licence and re-exports.     
 
The regional mechanism has a number of strict parameters however which limits its 
application in the Pacific.  Firstly it requires a pre-existing regional trade agreement rather 
than a political or economic grouping of states.  Secondly, at least half of the current 
membership must be LDCs (PICTA currently has nine member countries of which three are 
LDCs).  At the sub-regional level, Vanuatu and Solomon Islands are LDCs in the Melanesian 
Spearhead Group Trade Agreement with Fiji and PNG, however, it is far from a 
comprehensive regional mechanism. Thirdly, both the manufacturing country and the 
receiving country must share the disease in question.   
 
Lastly, this model was conceived using regional arrangements based in Africa.  These make 
assumptions about the existence of regional patents and health, political and economic 
parameters that do not apply in the Pacific.  For example, in Africa the regional models have 
their roots in regional patent laws that facilitate the re-export of pharmaceuticals whereas, in 
the Pacific there is no regional system, patent laws vary, and there is resistance to forfeit 
sovereign patent systems for a regional system. 
  
A more effective means of harnessing the benefits of a regional approach in the Pacific would 
be through a pooled procurement mechanism outside of the WTO framework.  Such a regional  
mechanism is under review by WHO, PIFS and SPC.   
 
5.0 Intellectual property rights: regional initiatives 
 
The PIFS have been facilitating IP initiatives in the region since 2000 in cooperation with 
agencies such as WIPO and IP Australia (PIFS/WIPO/IP Aust, 2001).  WIPO has been active 
in the Pacific providing technical assistance for countries to join and implement the various 
treaties that it administers.  IP Australia is the Australian government agency that administers 
patents, trade marks and designs in Australia.  The Australian government is positioning IP 
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Australia to provide services to the greater Pacific region, including some services to New 
Zealand. 
 
In 2004, PIFS, WIPO and IP Australia finished implementing a three year ‘Regionally 
Focused Action Plan’ (RFAP) in the Pacific which included work on regional IP 
administration (PIFS/WIPO/IP Aust, 2001).  Two models under review include: 
(i) stand-alone: a stand-alone regional patent administration ie. PICs undertake their 
own searching and examination using shared resources based in a joint regional 
office; 
(ii) outsourced: a regional patent administration located in a central office in the PICs, 
however, substantive searching and examination outsourced, for example to IP 
Australia. 
 
The PIFS did not renew the IPR contract with WIPO and IP Aust.  Both organisations 
continue to work with PICs bilaterally.  If further research into a regional facility is 
progressed, there will be a number of issues to be resolved, including the relationship between 
the regional facility and national offices and laws, the level of fees to be charged and possible 
loss of skills and expertise in national IP offices.  The costs and benefits of a regional IP office 
have also been considered as part of the Pacific Plan (Farquhar, 2005) and are earmarked for 
further analysis.  
 
6.0 IPR, traditional knowledge and medicines 
 
Traditional knowledge (TK) and medicines are used locally, often in preference to, or to 
complement, conventional medicines.  The principle of integrating traditional knowledge (TK) 
and medicines into the public health system is promoted by the WHO on cultural and cost 
effectiveness grounds.  The key to more effective integration lies in the standardisation of 
medicines dispensed under these systems, the training of providers and the issuance of 
guidelines on their use.  As in most other countries however, the two systems generally remain 
philosophically and scientifically separate. 
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Traditional medicines systems could also serve as a base for bio-prospecting, for example, an 
official traditional medicines research centre is operating in Kiribati and Samoa.  However, 
currently there is no international IPR Treaty for TK which leaves the PICs, and other 
developing countries, unprotected against ‘biopiracy’ (the act of foreign firms 
commercialising plant and animal extracts and genetic material that have traditionally been 
used or owned by indigenous groups without authorisation and for commercial gain).   
 
WIPO, WHO and WTO acknowledge that eventually an international Traditional Intellectual 
Property System (TIPS) will need to be developed.  This would govern bioprospector’s use of 
TK and ensure indigenous people’s authorise its use and share in any commercial benefits.   In 
its absence TK law is being developed ad hoc at a country level or between regional trading 
blocs.  For example, in New Zealand the Ministry of Economic Development has recently 
engaged with the New Zealand public and private sector on developing TK law as currently 
there are no recognised guidelines on bioprospectors’ use of TK in New Zealand.  In contrast, 
a form of TK patent law has existed in Peru and China for several years. 
 
PICs continue to face unauthorised use of their TK, innovations and practices (Mead and 
Ratuva, 2007).  While conventional IP laws exist in all PICs, to protect certain forms of IP, in 
the main they fail to protect TK from exploitation.  The model law on ‘Traditional Biological 
Knowledge, Innovation and Practices’ developed for the Pacific region both complements 
conventional IP laws and overrides them. 
 
Drafted in 2000 by the Secretariat of the South Pacific Environmental Programme (SPREP), 
the framework provides PIC officials with a starting point for dialogue at regional meetings. 
The model law requires further development which is proposed to be led by the PIFS in 
2008/2009.   
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Appendix 5: Protecting access to medicines: suggested regional and 
   national responses in the Pacific 
 
The research findings, together with suggestions made by interview participants and personal 
observations, were used to compile a range of multidisciplinary responses to help mitigate 
trade restrictions on access to medicines at the national and regional level. The responses are 
designed to assist with the mainstreaming of public health development into trade 
policymaking.  This will enable any adverse effects on the health sector to be considered 
during trade negotiations and the design of regional institutions.  The responses are 
categorised into four main areas (advice given to trade negotiators, drafting IPR law and 
regional IPR initiatives, monitoring pharmaceutical patents and, integrating health into trade 
policymaking) and presented as summarised bullet points (in no particular order) under each 
of the key health stakeholders. 
 
1.0 Technical advice given to national and regional trade negotiators  
 
Pacific Islands Forum Secretariat (PIFS): 
• Establish formal mechanisms to scrutinise international trade agreements from a public 
health perspective ( For example, previously PIFS arranged for the draft EU EPA 
agreement to be critiqued by  a group of pro-poor development IPR and health experts 
associated with Dr Carlos Correa.  Their response was then circulated to Forum Leaders 
and trade negotiators). 
• Build policy and programme coherence with SPC in the trade and health sector 
• Advocate for WTO TRIPS safeguards and exemptions in national and regional IPR law and 
in trade agreements 
• In conjunction with health stakeholders, provide capacity building relating to knowledge of 
IPR laws, implementation of WTO flexibilities and exemptions, and impact analysis of 
trade agreements on health 
Secretariat for the Pacific Community (SPC): 
• Incorporate health economics and trade into current policy and programmes 
• Shift focus from technical assistance to include strategic, policy advice on health, including 
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the impact of trade on access to medicines 
• Take the lead on trade and access to medicines in joint WHO/SPC initiatives and as an 
advisor to PIFS 
UN agencies: 
• Exchange knowledge and expertise on access to medicines from other regions in the South 
where a high profile already exists 
• WHO – undertake empirical studies of affordability and efficacy of government procured 
drugs and population health trends to build evidence based research for monitoring 
pharmaceutical patents and mitigating trade impediments to access to medicines in the 
future 
National Governments: 
• Clearly identify public (health)goods priorities that are non negotiable in trade negotiations 
• Do the minimum in terms of commitment to international IPR standards 
• Provide capacity building relating to knowledge of IPR laws and implementation of the 
WTO flexibilities and exemptions  
• Formalise regular meetings with MFAT, MOH, FPS and other stakeholders on access to 
medicines 
 
2.0 Drafting intellectual property law and regional IPR initiatives 
 
Pacific Islands Forum Secretariat (PIFS): 
• Promote a paradigm shift amongst Forum Leaders of IPR as an instrument of development 
policy that may protect national sovereignty, reinforce existing rights to public goods, and 
help to achieve social, cultural and health development goals.  In contrast, IPR currently 
appears to be viewed primarily from an economic perspective as an instrument for the PICs 
to gain commercial advantage.  However, as ‘net users’ of IPR, rather than ‘net generators’, 
the PICs appear to be investing limited resources in the development of traditional 
knowledge on the basis that this may generate financial returns in the future.  This mindset 
may inadvertently limit IPR development in the short term and lead to existing rights to 
access public goods being traded away  
• Allocate resources to develop IPR strategy guidelines as requested by the CROPS  
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• Re-commence IPR national and regional design initiatives using (independent) 
international experts and a multi-sector approach to review alternative IPR models.  The 
review should take into account key drivers influencing the global IPR agenda and its 
implications for the Pacific region, the potential indirect costs this could generate for public 
goods, such as health, as well as considering an existing ADB report on the cost/ benefit 
analysis of regional IPR mechanisms (Farquhar, 2005) which appears to have a narrower 
Terms of Reference 
UN agencies: 
•  Provide technical assistance on the use of competition law and other national exemption 
mechanisms to mitigate trade impediments to access to medicines 
National Government:  
• Evaluate national IPR law to ensure minimum WTO TRIPS safeguards are incorporated 
(see below), delay for as long as possible joining PCT 
• Do the minimum in terms of commitment to international IPR standards, including: 
 supporting parallel importation,  
 Compulsory License is subject to conditions under TRIPS Article 31 only,  
 limit the scope and duration of data exclusivity under TRIPS Article 39.3,  
 grant patents only for truly new and inventive products/processes TRIPS Art. 27.1,  
 no linkage between patents and drugs registration,  
 create national exemption mechanisms, for example, competition law  
• Develop a simple and easy to use compulsory licence system at national and regional level 
• Fijian Ministry of Justice – speed up progress of national draft IPR Bill to ensure TRIPS-
plus provisions are removed (Correa, 2003)  
 
3.0 Monitoring pharmaceutical patents 
 
Pacific Islands Forum Secretariat (PIFS): 
• Promote the monitoring of pharmaceutical patents and assist with capacity building for this 
UN agencies: 
• Share knowledge amongst the PICs relating to monitoring of pharmaceutical patents  
• Establish a ‘hotline’ to help countries ascertain pharmaceutical patent status 
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• Assist to negotiate with pharmaceutical companies not to insist on pharmaceutical patent 
protection 
National Government: 
• Establish a formal preventative mechanism where Patent Office notifies MOH of every 
pharmaceutical patent registered  
• Establish an Expert Group to monitor pharmaceutical patent examinations, for example, the 
Brazilian Model, against appropriate criterion and to oppose if necessary, during pre-grant 
phase  
• Train professionals in the field of interpreting pharmaceutical patents, including lawyers, 
pharmacists, economist, chemists, medical doctors 
• Implement methods for delaying registration, such as increased filing fees and bureaucratic 
delays, to deter patent holders from automatically filing in several countries 
 
4.0 Integrating health into trade and property rights 
 
Pacific Islands Forum Secretariat (PIFS): 
• Establish a formal working group on IPR, trade and health which includes ALL trade and 
health-related stakeholders 
• Ensure seamless policy and programmes with SPC on trade implications on health 
development 
• Include trade and access to medicines in existing and any future regional health 
development strategies signed off by the Forum Leaders, for example Regional HIV/AIDS 
Strategy 
• If a human rights desk is established in the future, include rights to access to medicines 
Secretariat for the Pacific Community (SPC): 
• Build a strategic policy role, rather than a purely technical assistance role, to fill a ‘gap’ 
between health and trade that appears to exist between SPC, and PIFS as the two major 
health stakeholders identified in this research, and with WHO, the major UN agency 
stakeholder 
CROPS: 
• Include trade, IPR and health on the agenda of the inaugural CROPS Working Group 
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attended by the Executive Directors of the various CROPS 
• Include trade, IPR and health development in University of the South Pacific academic 
research and development agenda 
UN agencies role:  
• UNAIDS - include a broader group of stakeholders in the inaugural meeting of the Pacific 
AIDS Commission attended by Commission Experts to enhance knowledge exchange.  
Example of  stakeholders include: PIFS, SPC, MFAT, Ministry of Justice, MOH, Fiji 
Pharmaceutical Services and health-related regional associations   
• Assist with sharing of drug price information amongst PICs 
• Share learning from South experiences, for example, Thailand, including knowledge 
exchange through workshops 
• Promote the concept of using human rights instruments to protect the right to access to 
medicines 
• WHO – build stronger trade and health advocacy 
• Include trade and access to medicines in existing, and in any future, regional health 
strategies, for example, WHO Regional NCD strategy, Regional HIV/AIDS strategy   
National Government: 
• Create a mechanism for monitoring the impact of new trade agreements on healthcare 
• Promote strong institutional linkages between MOH and MFAT, and include trade, IPR and 
health development on the agenda and establish an informal working group working on IP 
and health from a national perspective that interfaces with trade policymaking at the 
regional level   
• Include access to medicines in the MOH Strategic Plan  
• Increase capacity within MOH to trigger the implementation of safeguards under the 
Patents Act 
• Formalise holding two yearly workshops with all stakeholders, organised and funded by the 
WHO 
• For PICs signed up to International Human Rights Conventions whose progress is 
monitored by a Human Rights Committee, reinforce and expand the agenda of the 
Committee, for example, CEDAW to uphold women’s’ and children’s’ rights, to include 
protecting the right to access to medicines  
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Non Government Organisations: 
• Expand awareness of trade and access to medicines by including on the agenda of regional 
and national workshops for associations eg. Nurses, Pharmacists, Clinicians, Economists 
• Identify appropriate lobbying mechanisms for trade and access to medicines advocacy 
• RRRT broaden current human rights policy and training to include access to medicines.  
For example, expand talks to graduating lawyers on human rights case law to include talks 
to graduating health care workers, including medical students, on access to medicines and 
human rights advocacy 
• ECREA, build advocacy for access to essential medicines with community groups 
(including the use of human rights instruments alongside other multidisciplinary tools to do 
this).  Build information relating to affordability and efficacy of drugs provided free by the 
public health system and of desirable patented medicines, for example for treating chronic 
non communicable diseases, in the future  
• Explore the role of advocating for improving the interface between different sectors and 
structures to improve multi-sector collaboration on trade and health issues 
• NGOs that are accredited to attend Working Groups with the PIFS, for example, PCRC, use 
the ‘new observer’ status to introduce trade and health issues to the level of the Forum 
Secretariat  
 
 
 
 
 
